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Abstract 
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Abstract 
Ewing's sarcoma is the second most common bone tumour in children and 
adolescents. The prognosis is mainly influenced by the occurrence of primary 
metastasis. Although great improvement in treatment has been achieved, still 
only 2/3 of patients with localized disease can be cured. Furthermore, the 3-year 
event free survival in patients with lung metastases is only ~50%, and is less than 
20% in patients with bony metastases. Metastatic models of Ewing’s sarcoma 
developed in this study using cell lines in immunocompromised mice show a 
pattern of disease spread similar to that found in patients, providing a suitable 
system for studying the metastatic process likely occurring in the course of 
Ewing’s sarcoma. The comparison of microarray gene expression patterns 
revealed interesting candidate genes for diagnosis and identified putative 
metastasis-specific targets that might be exploited in the development of new 
treatment approaches. However, it will be necessary to additionally analyse these 
patterns in primary material. 
One gene that formerly has been shown to play a role in the metastasis to bones 
in a variety of cancer types is CXCR4, which encodes for the cytokine receptor 
of CXCL12 (SDF-1), and which plays a role in the metastasis to bones in a 
variety of other cancer types. As Ewing’s sarcoma cells express CXCR4, a 
shRNA vector was constructed, transduced and stably expressed to investigate 
the role of the CXCR4/CXCL12 axis in Ewing’s sarcoma cells via RNA 
interference. This stability provides the possibility of an in vitro and furthermore 
an in vivo use for investigations. 
In order to investigate the biology of bone malignancy and especially the 
interaction of tumour cells with cells of the microenvironment of the bone 
Abstract 
II 
directly, an orthotopic model for Ewing’s sarcoma was developed. Additionally, 
osteosarcoma as a further primary bone sarcoma and prostate carcinoma as a 
cancer type with frequent bone metastases were tested in this model. The 
previously described technique of intrafemoral transplantation was used in this 
model. Using small animal imaging techniques such as nano computed 
tomography and magnetic resonance imaging in combination with histology it 
could be shown that the transplanted cells led to the development of orthotopic 
tumours presenting a comparable picture to the clinical situation. This model will 
be further used for research projects performed in the Northern Institute for 
Cancer Research on the effectiveness of drugs targeting Ewing’s sarcoma cells. 
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Chapter 1 – Background and Introduction 
1 
1. Chapter – Background and Introduction 
Ewing’s sarcoma/Primitive neuroectodermal tumour (ES/PNET) is a rare disease 
and its diagnosis can still be fatal for patients. However, over the past decades 
outcome of patients has significantly improved. While 30 years ago more than 
90% of patients would die nowadays the long-term survival rates have improved 
to 60-70% for patients with localised disease. Regardless, relapse rates of over 
30% are still unacceptably high and these patients usually have a very poor 
prognosis (Leavey et al., 2008). Patients with systemic disease still have a poor 
prognosis (Paulussen et al., 2008). 
Improved treatment of this malignant tumour has been achieved through 
application of multimodal treatments including local management as well as the 
introduction of chemotherapeutic approaches. The lack of alternatives to 
chemotherapeutic treatment approaches shows the necessity of basic and 
translational research to discover more specific, accurate, and effective targets 
for molecular therapies and diagnosis of ES/PNET.  
 
 
1.1 Ewing’s sarcoma 
ES/PNET was first described by Lücke and Hildebrand but in 1921 the US-
American pathologist James Ewing was the first to publish an elaborate 
characterisation of the disease which he described as a “diffuse endothelioma” 
and an “endothelial myeloma”. This approach characterised the disease as being 
distinct from lymphoma and other types of cancer (Lücke, 1866; Hildebrand, 
1890; Ewing, 1921, 1924). 
Chapter 1 – Background and Introduction 
2 
1.1.1 Epidemiology 
ES/PNET is the second most common primary malignant tumour of the bone in 
Caucasian children and adolescents with a median age at diagnosis of 15 years. 
In the UK it accounts for 39% of primary malignant tumours of the bone with a 
yearly incidence of approximately three new diagnoses per one million children 
under the age of 15 years and approximately 2.4 new diagnoses per one million 
adolescents between 15 and 25 years according to the (EI)CESS studies 
(European Intergroup Cooperative Ewing’s Sarcoma Study). However, since new 
molecular tools for diagnoses have been introduced, more and more cases of 
unclassified sarcomas are identified as ES/PNET. This results in a growing 
number of diagnoses of ES/PNET in patients older than 20 years and a 
decreasing number of cases in patients aged 30 and older (Pieper et al., 2008). 
More than 50% of new diagnoses are made for children and adolescents in their 
second decade of life and men are affected with an overall ratio of 1.5:1, which 
even increases with age (see Figure 1.1) However, data for the ratio between 
male and female patients vary between different studies.  
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Figure 1.1: Age and sex distribution of patients with ES/PNET at the date of the initial 
diagnosis. Data based on 1426 patients of the (EI)CESS studies; f; female; m, male; n, number 
(Jürgens et al., 2006). 
 
 
The incidence of ES/PNET in the African or Asian populations in very low, 
suggesting a genetic predisposition, although the formal evidence for this is 
limited (Fraumeni and Glass, 1970; Li et al., 1980; Hense et al., 1999).  
 
 
1.1.2 Clinical presentation and diagnosis 
Typically, patients present with diffuse pain which very often at first is thought 
to be caused by a trauma or “growth pain”. However, there is no correlation 
between ES/PNET and traumas. Usually, the pain increases with physical 
activity but persists also in periods of recovery and during the night. This pain 
advances and results from the expansion of the periosteum caused by the 
Chapter 1 – Background and Introduction 
4 
formation of new bone which ultimately leads to a swelling of the effected 
region. This swelling is very often misinterpreted as an inflammation.  
The primary tumour is most frequently localised in the os ilium of the pelvis or 
the long bones of the extremities with the femur being affected in 20% of the 
cases (see Figure 1.2). Usually, the localisation in the long bones is diaphysial 
opposed to the metaphysical localisation of osteosarcoma (Hauben and 
Hogendoorn, 2010). 
 
 
 
Figure 1.2: Skeletal dissemination of primary ES/PNET. Data based on 1426 patients of 
(EI)CESS studies (modified from Bernstein et al., 2006). 
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Further symptoms include increased body temperature or, depending on 
localisation and size of the tumour, neurological deficits. These symptoms are 
more common in advanced and metastatic stages of the disease and can be of 
indirect prognostic value (Widhe and Widhe, 2000; Bernstein et al., 2006).  
The first tool for diagnosis of a suspected osseous lesion is imaging. Usually a 
radiograph in two planes is performed and images are investigated for tumour 
related osteolysis, Codman triangles (detachment of the periosteum from the 
bone) and formation of new bone (spiculae of calcification in the soft tissue mass 
of the tumour). To be able to more precisely evaluate the extent of the lesion and 
the location of the tumour in relation to blood vessels and nerves, magnetic 
resonance imaging (MRI) is performed (Bernstein et al., 2006). 
 
 
1.1.3 Adverse factors and prognosis 
Numerous factors are associated with poor prognosis in ES/PNET patients. The 
most unfavourable marker, which is important to clarify during initial staging, is 
the presence of metastases. Approximately, a quarter of patients present with 
metastatic disease at the time point of diagnosis (see Figure 1.3; further discussed 
in chapter 4). An additional important prognostic factor is age of the patient at 
the time of diagnosis. Patients younger than 10 years have a better outcome than 
older patients (Grier et al., 2003; Paulussen et al., 2007). A further unfavourable 
factor is a tumour volume larger than 200ml. Very often this is the case for 
tumours located in the pelvis as these are recognised and diagnosed relatively 
late. The response of the tumour to chemotherapy can be evaluated after surgical 
resection and gives evidence for prognosis as well (Paulussen et al., 2001).  
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The site of the primary tumour can also impact on prognosis. Patients with 
tumours located in the axial skeleton have a worse prognosis than patients with 
primary tumours in other sites as these are usually more difficult to treat and may 
not come into consideration for surgery (Cotterill et al., 2000a).  
Taking the evidence based importance of these adverse prognostic factors into 
account several current therapeutic approaches and regimens are stratified 
accordingly. 
 
 
 
Figure 1.3: Percentage dissemination of primary metastases to organs. Data based on 1426 
patients of (EI)CESS studies (modified from Bernstein et al., 2006). 
 
 
1.1.4 Pathology 
Macroscopically, ES cells of the bone, primitive neuroectodermal tumours 
(PNET) and Askin’s tumours of the thoracic wall are histochemically 
characterised through a monomorphic appearance of small blue round cells 
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(routine hematoxylin and eosin staining). This predominance of blue staining is 
due to the fact that the tumour cells consist predominantly of a nucleus and scant 
cytoplasm. The existing glycogen inclusions can be visualised through periodic 
acid-Schiff staining (Roessner and Jürgens, 1993). 
When characterising cells of these types of tumours immunhistochemically, 95% 
show positivity for the MIC2-antigen (CD99). However, CD99 is also expressed 
by other cell types and has a high incidence of expression in myeloid 
haematopoietic neoplasms. This limits the use of CD99 for differential diagnosis 
(Zhang et al., 2000).  
To be able to further distinguish between the different tumour types, the presence 
of neuronal markers is also tested. Tumours that lack neuronal markers are 
termed as classical ES. However, tumours with two or more neuronal markers 
such as S-100 protein, neuron-specific enolase or synaptophysin are named 
PNET (Schmidt et al., 1991). 
Today, the World Health Organisation classification no longer distinguishes 
between the three types of tumours as their biology is very similar and there is no 
evidence that the prognosis for patients with PNET and Askin’s tumours differs 
from prognosis for patients with classical ES. Therefore, the currently used term 
is Ewing’s sarcoma/primitive neuroectodermal tumours (ES/PNET; Dirksen and 
Jürgens, 2010). 
 
 
1.1.5 Genetic background 
Regardless of neuronal markers, ES/PNETs are classified as a biologic entity 
through the common chromosomal translocation they harbour. They represent 
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the first group of sarcomas for which a chromosomal translocation was 
characterized (Delattre et al., 1992, 1994). This molecular similarity is widely 
believed to play a major role in tumour pathology and biology. 
 
 
1.1.5.1 Chromosomal translocations in Ewing’s sarcoma 
CD99-positive tumours are classified as ES/PNET+ve when a translocation 
exists between the EWS gene (Ewing’s sarcoma breakpoint region 1, also known 
as EWSR1) at 22q12 and a member of the ETS (E26 transformation specific 
gene) family of transcription factors. In 85% of ES/PNET cases a translocation 
t(11;22)(q24;q12) is detected which fuses EWS to the gene FLI1 (Friend 
leukaemia virus integration 1). This results in the fully functional but aberrant 
fusion transcript EWS-FLI1 (Delattre et al., 1992; Zucman et al., 1993; Delattre 
et al., 1994). In half of such cases, this translocation results in a fusion protein 
consisting of the first 264 N-terminal amino acids of the EWS protein 
(breakpoint in intron 7) and the 233 C-terminal amino acids of FLI1 (breakpoint 
in intron 5), which is termed “type 1” fusion protein (see Figure 1.4). There are 
further EWS-FLI1 fusion proteins involving slightly different breakpoints of the 
two genes (Delattre et al., 1992; Plougastel et al., 1993; Zucman et al., 1993). 
 
 
Chapter 1 – Background and Introduction 
9 
 
Figure 1.4: Scheme of the proteins EWS and FLI1 as well as the EWS-FLI1 fusion protein 
type 1. DNA-BD, DNA-binding domain; Pro, proline-rich activation domain; PTD, pointed 
domain; RGG, arginine-glycine-glycine-rich region; RRM, RNA-recognition motif; SYQC, 
serine-tyrosine-glutamine-glycine-rich region; ZN, zinc finger (modified from (Janknecht, 2005). 
 
 
All possible EWS-FLI1 translocations create fusion proteins consisting of the 
potent transactivation domain of the EWS protein and the DNA binding and 
proline-rich transcription-advancing domains of FLI1. Thus, the aberrant fusion 
proteins are potent transcription factors that are capable of binding to DNA 
(Bailly et al., 1994; Mao et al., 1994; Lessnick et al., 1995).  
Approximately 10% of ES/PNETs harbour a t(21;22)(q22;q12) translocation 
between EWS and the ETS gene ERG (ETS-related gene). Further translocation 
partner genes of EWS include ETV1 (ETS variant gene 1), FEV (fifth Ewing’s 
sarcoma variant) and E1AF (E1A enhancer binding protein) (Jeon et al., 1995; 
Kaneko et al., 1996; Peter et al., 1997; Sorensen et al., 1994; Urano et al., 1996; 
Zucman et al., 1993). All different forms of translocations produce chimeric 
proteins that function as potent aberrant transcription factors because the 
transactivation domain of EWS is fused to a DNA-binding domain of a member 
of the ETS-family of transcription factors (Uren et al., 2004a; Janknecht, 2005).  
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Recently, it has been shown that neither the fusion partner nor the different 
breakpoints (different types of EWS/FLI) are of prognostic relevance (Le Deley 
et al., 2010; van Doorninck et al., 2010).  
 
 
1.1.5.2 Further aberrations 
In 80% of the cases there are molecular abnormalities discovered in addition to 
the characteristic translocations between EWS and members of the ETS family of 
transcription factors (Roberts et al., 2008). However, numbers vary in different 
studies. In the majority of cases these non-random chromosomal aberrations are 
chromosomal gains with number changes. Most often a trisomy of chromosome 
8, as well as chromosomes 2, 12 and 20 can be detected. Additional structural 
aberrations are less common and appear as unbalanced rearrangements involving 
chromosomes 1 and 16 with a net gain of 1q and loss of 16q (Hattinger et al., 
2002). Different studies suggest that these chromosomal gains may be of 
prognostic value or may even lead to a worse prognosis for patients (Armengol et 
al., 1997; Hattinger et al., 2002; Roberts et al., 2008). 
 
 
1.1.6 Mechanisms of fusion transcripts in tumorigenesis 
In vitro studies have proven that the EWS-ETS fusion proteins contribute to 
tumorigenesis and behave as oncoproteins. This was established using NIH3T3 
cells transformed following transfection and ectopic expression of EWS-FLI1 
(May et al., 1993a, 1993b; Lessnick et al., 1995; Thompson et al., 1999). 
Chapter 1 – Background and Introduction 
11 
Furthermore, antisense experiments in ES/PNET cells led to growth impairment, 
increased apoptosis rates and prevention of tumour formation in vivo proving that 
the fusion protein is also critically important for maintaining the ES/PNET 
phenotype (Lambert et al., 2000; Prieur et al., 2004; Siligan et al., 2005).  
Recently, development of new techniques has allowed detailed investigations of 
direct and indirect downstream target genes of chimeric fusion proteins, 
including investigations elucidating the function of EWS-FLI1 as an aberrant 
transcription activator and repressor. Amongst other functions, genes that are 
transactivated are involved in cell survival and proliferation, such as IGF1 
(Cironi et al., 2008) and Myc (Sollazzo et al., 1999), or differentiation (SOX2; 
(Riggi et al., 2010). Repressed genes include, amongst others, TGFB2 (Hahm, 
1999) and IGFBP3 (Prieur et al., 2004).  
Important cellular signalling pathways activated in ES/PNET include amongst 
others the Wnt signalling pathway and the insulin growth factor 1 (IGF1) 
mediated tyrosine kinase pathway. In ES/PNET cell lines Wnt/Frizzled-
signalling has been shown to be functional with the canonical Wnt/β-catenin 
signalling enhancing motility of cells and thus probably contributing to 
metastasis of ES/PNET (Uren et al., 2004b; Endo et al., 2008; Navarro et al., 
2010). The interplay of IGF1 and its receptor IGF1R and subsequently 
downstream targets of this pathway have been shown to be effected by EWS-
FLI1 knockdown (Herrero-Martín et al., 2009). This in turn influences growth 
and maintenance of the tumour.  
Other functions of fusion transcripts and proteins are currently further 
investigated, including RNA binding, aberrant RNA splicing and protein-protein 
interactions (Watson et al., 1997; Yang et al., 2000; Toretsky et al., 2006). 
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Although progress has been made in identifying downstream targets, it has 
become clear that the identification of the cell of origin in ES/PNET is 
immensely important. It is possible to transform the immortalised cell line 
NIH3T3 but so far transformation experiments with native murine and human 
fibroblasts has not been successful, primarily because expression of EWS-FLI1 
leads to cell cycle arrest (Lessnick et al., 2002). 
All this underlines the importance of further investigations for the cell of origin 
as the fusion transcript seems to have different effects on varying cell types. 
Furthermore, in this context the role of additional aberrations has to be kept in 
mind as well.  
 
 
1.1.7 Potential cell of origin of Ewing’s sarcoma 
As mentioned before, all ES/PNET harbour an in-frame EWS-ETS translocation. 
This translocation and the resulting fusion transcripts act on the affected cells 
with complex mechanisms of which the function as an aberrant transcription 
factor is best known. The specificity of the EWS-FLI1 and other EWS-ETS 
fusions for ES/PNET tumours suggests that the cell of origin is critical for 
EWS-FLI1-induced oncogenesis. However, despite elaborate and extensive 
investigations the cell of origin is currently still unknown (Prieur et al., 2004).  
On the one hand, historically and histologically, for a long time ES/PNET has 
been thought to be of neuroectodermal origin as early neural markers and other 
features can be detected that are typically found in primitive neuroectodermal 
cells (Cavazzana et al., 1987). Although these findings strongly suggested the 
origin to be neuroectodermal the fact that these neural markers are just found in a 
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minority of cases and the fact that EWS-FLI1 induces neuroectodermal 
differentiation and upregulation of a number of genes associated with early 
neural differentiation raise the assumption that the cell of origin might not 
necessarily be of neuroectodermal origin (Teitell et al., 1999; Hu-Lieskovan et 
al., 2005b). This is why, the finding suggest that occasional neuroectodermal 
features of ES/PNET cells are a direct result of the fusion transcrips rather than 
the cell of origin. 
On the other hand, there is evidence that ES/PNET might originate from a 
mesenchymal stem cell (MSC). As all bones of the skeleton except the cranial 
bones and the cells of the bone marrow originate from the mesenchyme and 
ES/PNET most often arise in the long bones or the pelvis it seems to be plausible 
that the cell of origin of ES/PNET is a resident of the bone. Besides, MSC from 
the bone marrow show some characteristics of neuroectodermal cells (Olsen et 
al., 2000; Takashima et al., 2007) which could explain neuroectodermal features 
of ES/PNET cells. Admittedly, the term of MSCs is not exact enough. One of the 
problems is that extraction of MSCs from bone marrow leads to a mixture of 
cells enriched from all adherent cells through selection of specific surface 
markers (Bianco et al., 2008; Lin et al., 2011). This implies that more defined 
extraction terms will have to be identified as there is evidence of more than one 
type of pluripotent non-haematopoietic cell within the bone marrow (Colter et 
al., 2001; Jiang et al., 2002). The current definition of MSC is that of multipotent 
stem cells that are able to differentiate into mature cell types, including 
osteoblasts, chondrocytes (cartilage cells) and adipocytes (fat cells) (Beyer Nardi 
and da Silva Meirelles, 2008). 
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However, approaching from the opposite side, a subpopulation of CD133+ 
tumour cells from ES/PNET has been identified and characterised. These are 
characterised through a high degree of plasticity similar to MSCs and are able to 
initiate and promote the growth of tumours in in vivo experiments with 
immunodeficient mice (Suvà et al., 2009). 
Furthermore, there is more direct evidence supporting the hypothesis of a MSC-
like cell as origin of ES/PNET. EWS-FLI1 knockdown experiments in ES/PNET 
cell lines leave the cells with the ability to differentiate into a range of 
comparable cell types as MSCs are able to differentiate into (Tirode et al., 2007). 
The identified “core” EWS-FLI1 transcriptional pattern achived through 
knockdown of the fusion transcript could be shown to resemble the one of human 
MSCs (Hancock and Lessnick, 2008; Kauer et al., 2009). 
Additionally, knock-in experiments with murine MSCs produce transformed 
cells that form sarcomas in vivo (Castillero-Trejo et al., 2005; Riggi et al., 2005). 
Transfection of human MSCs did not lead to tumour formation after 
transplantation into immunocompromised mice but the cells took on an 
ES/PNET -like morphology and CD99 expression was upregulated (Miyagawa et 
al., 2008; Riggi et al., 2008).  
It seems that due to the additional genetic changes in ES/PNET cells these cannot 
be reverted to normal MSCs by a simple knockdown of EWS-FLI1. Although a 
lot of data is suggestive that MSCs are the cell of origin for ES/PNET additional 
studies are necessary and the phenotype for extraction of MSCs needs to be 
further defined. This leads to the assumption that they cannot yet be definitely 
understood as the cell of origin (Lin et al., 2011).  
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1.1.8 Current treatment and studies 
Shortly after the first description of ES/PNET it was clear that the tumours are 
sensitive to radiotherapy (Ewing, 1939). However, only since the 1970s it was 
possible to achieve a cure of the disease and increase survival rates because 
multimodal multidisciplinary treatment was developed applying neoadjuvant 
systemic chemotherapy and local therapy consisting of surgery and/or 
radiotherapy (Stiller et al., 2001). Today, current regimens reach a 5-year 
survival of up to 75% of patients with localised disease (Paulussen et al., 2001).  
Currently, surgical therapy following initial chemotherapy is performed when the 
primary tumour is located in the extremities, the thoracic wall or the pelvis as 
long as the sacrum is not involved. Through the development of novel surgical 
techniques, including amongst others extendable endoprostheses for children and 
adolescents, nowadays, limb salvage can often be achieved (Kotz et al., 2002). 
Postoperative radiotherapy care has to be considered and the dosage depends on 
histologic response of the tumour to chemotherapy and the success of surgery. 
The combination of surgery and radiotherapy opposed to radiotherapy alone 
increases survival rates by 15-20% (Schuck et al., 2003). 
First studies in the early 1960s proved the sensitivity of ES/PNET to cytostatics 
(Sutow and Sullivan, 1962). About a decade later, first combinations of 
cytostatics were tested in clinical trials and a combination of VACD (vincristine, 
actinomycin D, cyclophosphamide, doxorubicin) soon became standard in many 
trials for non-metastatic disease. Local control and event free survival could be 
improved but at the same time increased doses of doxorubicin lead to greater 
cardiac morbidity (Nesbit et al., 1990; Burgert et al., 1990). 
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Subsequently, inclusion of ifosfamide (I) and etoposide (E) showed improvement 
of ES/PNET of patients with localised disease as well as better prognoses for 
relapsed patients (Craft et al., 1998; Grier et al., 2003).  
During the course of the EICESS-92 trial patients were divided into standard risk 
and high risk groups (tumour volume </≥ 200ml). Standard risk patients did not 
benefit from the VAID regime opposed to VACD and there was no significant 
benefit for high risk patients when treated with an EVAID regime compared to 
patients treated with VAID. Despite the insufficient power of the study, however, 
etoposide might be beneficial to those patients (Paulussen et al., 2008).  
To be able to recruit more patients the EURO-E.W.I.N.G.99 (EUROpean Ewing 
tumour Working Initiative of National Groups - Ewing tumour studies 1999) trial 
was initiated bringing together major European study groups. The aims of the 
study are to address whether further increases in treatment intensity will lead to 
further benefits for patients as well as to further improve survival of patients with 
poorer prognosis and to decrease long-term effects of toxicity. Furthermore, the 
effect of a myeloablative therapy with haematopoietic stem cell rescue in high 
risk patients will be investigated (Rodriguez-Galindo et al., 2003). 
Up to today it is not possible to make a reliable statement about the outcome of 
the study although first results are published (Ladenstein et al., 2010) and final 
results are awaited to be published.  
 
 
1.2 Bone Biology 
One of the major specialised tissues of the human body is bone, a composite 
tissue of inorganic materials, organic matrix and cells. Bone does not only have a 
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mechanical function of giving the body structural support, allowing movement 
by supporting musculature and protecting vital organs but also has biological and 
metabolic functions. These functions include maintenance of mineral 
homeostasis and acid-base balance as well as keeping a reservoir of growth 
factors and cytokines. Furthermore, bone provides within the bone marrow cavity 
an environment for haematopoiesis (Clarke, 2008). 
 
 
1.2.1 Bone structure 
There are two different types of bone structure. Trabecular bone (also referred to 
as cancellous or spongy bone) is made of characteristic irregular branches giving 
it a honey comb appearance. The emerging cavity contains the bone marrow. 
Due to its fine branches and the close proximity to the bone marrow, trabecular 
bone is more metabolically active than cortical bone. 
Trabecular bone is surrounded by cortical bone giving bones the typical smooth, 
white appearance. It makes up 80% of the dry weight of the total bone mass and 
accounts for the mechanic stability of bones due to its compactness (Safadi et al., 
2009).  
 
 
1.2.1.1 Molecular structure 
The inorganic compound makes up 60% of the try weight of bone tissue and 
consists mainly of crystalline calcium phosphate salts (hydroxyapatite, 
Ca10(PO4)6(OH)2), carbonate, fluoride, magnesium, acid phosphate and citrate. 
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To resist applied forces, calcium hydroxyapatite crystals are arranged in parallel 
to collagen fibres. This orientation maximises resistance to stretch (type I 
collagen) and compression (calcium hydroxyapatite salt) forces (Sela et al., 1987; 
Safadi et al., 2009). 
The organic matrix produces mainly type I collagen which is synthesised 
intracellularely as tropocollagen. When cells export tropocollagen, fibrils are 
formed. Proteoglycans, glycoproteins, phospholipids, phosphoproteins and 
various growth factors are part of the organic matrix as well. This means besides 
mechanical functions bone tissue also fulfils the function as a reservoir for 
inorganic ions and is involved in metabolic processes through the active 
participation in the calcium/phosphate balance and release of growth factors and 
other components resting within the bone tissue (Safadi et al., 2009).  
According to the pattern in which collagen and other proteins form the osteoid, 
there are two types of bone tissue – woven and lamellar bone. Woven bone is 
characterised by a rather high number of osteocytes and a disorganised 
appearance due to randomly orientated collagen fibres. This disorganisation 
accounts for a weaker structure. It is mainly found in sites of rapid growth such 
as the embryonic skeleton and later at sites of fractures (Price et al., 1994).  
Lamellar bone is the mature form of bone which grows slowly and in parallel 
lines of deposited bone, the collagen fibres are highly organised and run in 
opposite directions to maximise mechanical stability. Usually it is deposited on 
pre-existing bone (Khurana and Safadi, 2009).  
The secondary structure of lamellar bone accounts for the high level of 
organisation of compact bone (see Figure 1.5). 
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Figure 1.5: Scheme of the cross section of a typical human long bone (Standring and Gray, 
2008). 
 
 
The part of the bone formed by compact bone (surrounding the trabecular bone 
part in the centre of the bone) consists of closely packed osteons (also called 
Haversian systems). Each osteon consists of a Haversian canal in the centre 
through which blood and lymphatic vessels as well as nerves run. The canal is 
surrounded by 5-15 concentric layers, or lamellae, of compact bone tissue 
arranged in parallel to the long axis of the bone. Volkmann’s canals connect 
Haversian canals to each other as well as to the blood system of the body (Safadi 
et al., 2009).  
Between layers osteocytes are located in spaces termed lacunae. These are 
interconnected through canaliculi and connected to the Haversian channel to 
provide all cells equally with nutrition. The entity of tubular osteons is 
surrounded by outer circumferential lamellae that lie underneath the periosteum 
and in parallel to it. The periosteum is a fibrous layer coating the entire bone 
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except at joints where articular cartilage covers the bone surface. It consists of an 
outer connective tissue layer containing fibroblasts, nerves and blood vessels 
supplying the bone tissue and an inner cambium layer containing osteoprogenitor 
cells.  
The inner circumferential lamellae are located next to the endosteum, which is a 
membranous layer. The endosteum covers the inner surface of cortical bone, 
trabecular bone and the Haversian and Volkmann’s canals and contains blood 
vessels, osteoblasts and osteoclasts (Clarke, 2008; Safadi et al., 2009). 
The rods and plates forming the structure of trabecular bone consist of so-called 
packets (trabecular osteons). These have a semilunar shape and consist of 
concentric lamellae.  
 
 
1.2.1.2 Cellular structure 
The existence of bone and its continuous remodelling relies on the precise 
equilibrium between the different types of cells present in this tissue.  
Within the bone marrow there is a small population of MSCs which are distinct 
from the haematopoietic stem cells. These MSCs are capable of giving rise to 
various cell types one of them being osteoprogenitor cells. Osteoprogenitor cells 
differentiate to different cell types (Pittenger et al., 1999). One of those cell types 
is the osteoblast which is a bone-forming, large and mononuclear cell that 
deposits osteoid (organic bone matrix). This is why one of the characteristics of 
osteoblasts are large Golgi structures and an extensive endoplasmic reticulum. 
Subsequently, the osteoid becomes mineralised through the secretion of alkaline 
phosphatase and non-collageneous, calcium- and phosphate-binding proteins. 
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However, osteoblasts are heterogeneous in their expression of gene patterns 
which may explain different microarchitecture of skeletal sites, site-specific 
disease manifestation and regional differences in response to drug treatments 
(Harada and Rodan, 2003; Clarke, 2008).  
Another type of cell is the osteocyte which resides within the bone tissue and 
maintains the structure of it. It originates from formerly active osteoblasts and 
changes shape throughout the production of mineralised bone. When trapped in 
the lacunae between the lamellae of bone osteocytes keep in contact with each 
other via canaliculi (Safadi et al., 2009). 
Furthermore, there are protective lining cells that cover the surface and are 
thought to be quiescent osteoblasts. They form the endosteum and underlie the 
periosteum on mineralised bone. Usually, lining cells are found in close 
proximity to osteoblasts and interact with those (Clarke, 2008).  
Osteoclasts are antagonising osteoblasts. They are multinucleated and originate 
from mononuclear precursor cells of the monocyte-macrophage lineage (Boyle et 
al., 2003). Osteoclasts are able to bind to the bone surface because they express 
integrin receptors that bind collagen, fibronectin and laminin of the bone matrix 
(Ross and Teitelbaum, 2005). Upon binding to the bone matrix, the osteoclast 
becomes polarised and apical a ruffled border is formed. The cytoskeleton of the 
osteoclast forms a ring to seal in the periphery of the osteoclast’s attachment to 
the bone surface (Howship’s lacuna or resorption pit). Subsequently, acidified 
vesicles export proteins via the ruffled border into the Howship’s lacuna. 
Amongst others matrix metalloproteinases (such as MMP-1) and cathepsins 
(such as pro-cathepsin K) are secreted, the latter of which are activated through 
exocytosis within the acidic milieu of the Howship’s lacunae. The acidified 
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condition is achieved through secretion of H+ ions via H+-ATPase and chloride 
channels (Väänänen et al., 2000). While enzymes cause resorption of the organic 
part of the bone matrix, the acidic milieu leads to solubilisation of the crystalline 
calcium hydroxyapatite.  
 
 
1.2.1.3 Macroscopic structure 
The formerly mentioned macroscopic structures of cortical and trabecular bone 
are not found in all bones. In the adult human body trabecular bone can only be 
found in the metaphysis and epiphyses of long bones, the vertebral bodies and 
flat bones. This has the advantages of skeletal weight reduction without 
compromising strength (Price et al., 1994; Clarke, 2008). Consequently, ratios of 
cortical and trabecular bone structures vary between different bones; for example 
the ratio is 25:75 in vertebrae whereas it is 95:5 in the radial diaphysis. Due to 
these findings, bones are classified into four main groups: long bones (e.g. 
femurs, tibiae, humeri), short bones (e.g. carpal and tarsal bones), flat bones (e.g. 
skull, ribs) and irregular bones (e.g. vertebrae).  
Long bones consist of a diaphysis (hollow shaft), a cone-shaped metaphysis 
below growth plates and a rounded epiphysis above growth plates. While the 
metaphysis and the epiphysis are mainly made up of trabecular meshwork 
surrounded by a thin layer of cortical bone, the diaphysis is primarily composed 
of dense cortical bone (Clarke, 2008).  
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1.2.2 Bone remodelling 
Throughout life, bone tissue is constantly remodelled giving it an adaptive and 
regenerative capacity. Remodelling of bone takes place alongside the processes 
of growth and skeletal modelling taking place in childhood. This means, 
remodelling already starts before birth and continues until death. It is achieved 
through the simultaneously, and normally counterbalanced, processes of bone 
formation and resorption (Clarke, 2008; Safadi et al., 2009).  
There are different aspects of the randomness of remodelling sites in the human 
skeleton. On the one hand, to achieve one of the goals of remodelling, i.e. 
maintaining the balance of essential minerals, remodelling does not have to target 
a specific site and thus mostly occurs randomly. On the other hand, to achieve 
the goals of maintenance of stability, adaption to mechanical stress and repair of 
damage, remodelling has to be targeted (Burr, 2002).  
Studies with genetically modified mice have shown that net bone formation 
occurs when mice are deficient for normal osteoclasts. Net resorption takes place 
when mice cannot develop fully functional osteoblast. This suggests that the two 
types of cells do not require each other to function or be activated but that 
balance in bone metabolism can only be achieved with both cell types controlling 
each other (Corral et al., 1998; Kong et al., 1999). In humans defects in the fine 
equilibrium of bone remodelling leads to a variety of different bone diseases 
including osteoporosis, osteopetrosis and Paget’s disease.  
The process of remodelling not only involves osteoclasts and osteoblasts but as 
well osteocytes and lining cells. The tightly coupled cells function together as the 
basic multicellular unit and perform the four sequential phases of remodelling: 
initiation, resorption, reversal and formation. 
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However, due to the complexity of remodelling this subchapter can only 
selectively highlight some of the more important processes of remodelling (Sims 
and Gooi, 2008). 
 
 
1.2.2.1 Initiation and activation of osteoclasts 
Haematopoietic myelomonocytic osteoclast precursor cells are attracted to the 
site of remodelling, where they fuse and subsequently bind to the bone surface as 
multinucleated cells (see Figure 1.6). Cells of the osteoblasts lineage 
(pre-osteoblasts, mature osteoblasts, lining cells and osteocytes) play a critical 
role in each of those steps (Sims and Gooi, 2008).F 
One the one hand, chemoattractants released by the osteoblast-lineage are 
responsible for the control of the movement of osteoclast-precursors towards 
each other and the bone surface. These factors might be directly released by 
osteoblasts and/or lining cells, bone matrix-derived (osteocalcin, 
α2 HS-glycoprotein, collagen I fragments, aging of bone resulting in 
isomerisation of collagen I) or set free through apoptosis of osteocytes (see 
further below). In more detail, factors released by osteoblast-lineage cells include 
CXCL12 (chemokine (C-X-C motif) ligand 12; also referred to as SDF-1, 
stromal-derived factor 1), CCL3, CCL5 and CCL7 (chemokine (C-C motif) 
ligands 3, 5 and 7). In addition to promotion of osteoclast formation these factors 
increase chemotaxis of osteoclast-precursors in vitro (Yu et al., 2003, 2004). It 
could also be shown that some of these factors play a role in osteoclast-precursor 
attraction in pathological conditions such as multiple myeloma or bone 
metastases caused by breast and prostate cancer, but their role in 
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non-pathological remodelling remains to the greatest extend unclear (Aggarwal 
et al., 2006; Guise et al., 2006). 
 
 
 
Figure 1.6: Initiation of osteoclast formation (osteoclast-lineage cells shown in red shades, 
osteoblast-lineage cells shown in blue shades). Proliferation of osteoclast precursors (light red 
cells) and expression of RANK is stimulated through CSF-1 produced by osteoblasts. Locally 
acting factors such as IL-11, OSM, PGE2 and PTHrP (grey arrow) and microdamage-induced 
osteocyte apoptosis (lightning) induce RANKL (receptor activator of NF-κB ligand) expression 
on osteoblasts. chemoattractants (blue arrows) released from osteoblast-lineage cells and bone 
matrix attract osteoclast precursors. Resulting interaction between RANKL and RANK leads to 
expression of fusion proteins (green blocks). Lining cells (light blue) prepare the bone surface 
(collagenases) and lift off to form the bone remodelling compartment, in which osteoclast 
precursors enter. They attach to the bone surface as resorbing osteoclasts (red cell) (Sims and 
Gooi, 2008). 
 
 
A lot of cytokine receptors that stimulate bone resorption through initiation of 
osteoclast formation are expressed in cells of the osteoblast-lineage. This proves 
Chapter 1 – Background and Introduction 
26 
that at least to parts osteoblast-lineage cells are required for the formation and 
activation of osteoclasts (Suda et al., 1999). Subsequent to osteoblasts binding, 
indirectly acting osteoclast-activating factors like IL-11 (interleukin 11), PGE2 
(prostaglandin E2), OSM (oncostatin M) and PTHrP (parathyroid hormone-
related protein), intracellular signalling is activated. In most cases intracellular 
signalling results in osteoclast-activation mediated through RANKL (receptor 
activator of NF-κB ligand) which is presented on the osteoblast cell surface. A 
further important factor produced by osteoblasts is the soluble TNF receptor 
superfamily member OPG (osteoprotegerin), which inhibits osteoclast formation 
(Yasuda et al., 1998; Horwood et al., 1998; Liu et al., 1998; Palmqvist et al., 
2002). The very complex interactions leading to the activation of osteoclasts are 
only described to parts in Figure 1.6. 
Further to released factors, the interruption of a physiological link between 
osteocytes and existing osteoclasts, as well as the release of certain factors such 
as cytokines and prostaglandins through apoptosis of osteocytes, might trigger 
the osteoclast formation (Sims and Gooi, 2008). 
 
 
1.2.2.2 Attachment of osteoclasts to and resorption of bone material 
Attachment of osteoclasts to the bone surface depends on the activity of 
terminally differentiated lining cells deriving from the osteoblast-lineage. These 
lining cells are thought to prepare the bone surface for resorption by releasing 
collagenase to destroy the fine layer of non-mineralised matrix on which they are 
located (Chambers and Fuller, 1985). This causes the lift off of lining cells from 
the bone surface and formation of a cover underneath which a space is created. 
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This space serves as a temporary bone remodelling compartment where the bone 
surface is exposed to osteoclasts for resorption as well as to osteoblasts for 
subsequent bone formation, but it still remains unclear, how both cell types enter 
the bone remodelling compartment. It has to be mentioned that the bone 
remodelling compartment is highly supplied with blood vessels indicating that 
stromal derived osteoblasts might be able to arrive via the blood stream (Parfitt, 
2001; Sims and Gooi, 2008).  
The attachment itself occurs when osteoclast-expressed integrins bind to an 
arginine-glycine-aspartic acid sequence of bone matrix proteins such as 
osteopontin and bone sialoprotein which have been laid down within the matrix 
by osteoclasts in previous cycles of remodelling (Ross and Teitelbaum, 2005). 
Polarisation of the osteoclast attached to the bone surface and sealing of the 
resorptive pit allows directed and selective resorption (see chapter 1.2.1.2). 
When resorption and recycling of matrix components is completed, osteoclasts 
die through apoptosis and detach from the bone surface. Currently, it is unknown 
whether the apoptotic process is initiated by the osteoclast itself or whether the 
osteoblast-lineage cells are involved. 
 
 
1.2.2.3 Reversal 
The process of reversal is still not known entirely. After apoptosis of osteoclasts 
mononuclear cells of unknown origin enter the resorptive pit. These are thought 
to be haematopoietic phagocytes as well as osteoblast-lineage cells that might 
complete the process of resorption through release of MMPs and serine proteases 
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as well as prepare the bone surface by formation of a “reversal line” (Tran Van et 
al., 1982; Everts et al., 2002).  
Amongst several influences that activate osteoblasts, osteoclast-secreted factors 
play a role in this activation (Matsuo and Irie, 2008) as well as factors released 
from the bone matrix during resorption (see Figure 1.7). These factors include 
IGF-1 and -2 (insulin-like growth factor 1 and 2), BMPs (bone morphogenic 
proteins) (Schmid et al., 1992; Harris et al., 1994).  
The process of reversal requires more detailed research to be entirely understood.  
 
 
1.2.2.4 Formation of new bone material 
To achieve bone formation osteoblasts have to mature from progenitors. 
Osteoblastogenesis has been shown to be influenced by a number of different 
pathways. One of the more prominent ones is the Wnt/β-catenin pathway (also 
referred to as canonical wnt (wingless) signalling) which mediates cell fate 
determination, proliferation and survival through increase of β-catenin levels. 
Furthermore, alteration of the expression pattern of genes occurs due to the 
transcription factor Lef/Tcf (Lymphoid enhancer factor/T cell factor) binding β-
catenin (Westendorf et al., 2004). As a consequence of downstream signalling, β-
catenin accumulates in the cytoplasm, translocates to the nucleus, and alters gene 
expression (Krishnan et al., 2006).  
Further promoters of osteoblastogenesis are BMPs which belong to the large 
superfamily of TGFβ. In vitro BMPs are capable of causing differentiation of 
myoblastic cell lines into osteoblast-lineage cells. Besides, induction of 
osteoblast specific proteins such as alkaline phosphatase, osteocalcin and 
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transcription factor Runx2/Cfba1 (member of the Runt-related family of 
transcription factors) could be achieved through a SMAD-dependent downstream 
signalling (Katagiri et al., 1994). Intracellular SMAD proteins are transduce 
extracellular signals mediated through transforming growth factor beta ligands to 
the nucleus where they activate downstream TGF-β gene transcription. 
Following osteoblast differentiation formation of new bone is achieved by the 
secretion of collagen I and other proteins and factors through osteoblasts. This 
organic part of the bone material gets mineralised most probably through alkaline 
phosphatase (Wennberg et al., 2000).  
Further factors from different other cell types seem to be required to initiate bone 
formation (see Figure 1.7). A direct contact-dependent mechanism between 
osteoclasts and osteoblasts seems to play a role although direct contact of 
osteoclasts and osteoblasts can usually not be observed in histology (Zhao et al., 
2006).  
Furthermore, osteoblasts use contact-dependent mechanisms (e.g. gap-junctions) 
as well as expression of membrane-bound and secreted factors to “communicate” 
with each other. Factors like ephrines, PTHrP and sclerostine for example are 
expressed at all stages of differentiation (Sims and Gooi, 2008).  
At the end of the remodelling cycle, osteoblasts become quiescent and cover the 
bone surface as lining cells or become osteocytes when they remain within the 
bone tissue. 
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Figure 1.7: Control of bone formation in remodelling (osteoclast shown in red, osteoblast 
shown in blue). Osteoclastic bone resorption releases factors previously embedded by osteoblasts 
in the bone (green), including IGFs, BMPs, TGFβ, PDGF and FGF. These and factors produced 
and released by osteoclasts including cardiotrophin-1 (CT-1), stimulate osteoblast differentiation 
and bone formation. Lining cells prepare the bone surface for osteoid deposition (blue cell 
releasing red substance). EphB4, expressed by both osteoclasts and osteoblasts, interacts with 
ephrinB2, expressed by the osteoblast lineage to stimulate bone formation. This is further 
enhanced by PTHrP. Osteoblasts also sense the resorption pit (double arrows) and communicate 
with each other (boxed double arrows) to determine the quantity of new bone required. Negative 
feedback from osteocytes within the bone matrix through sclerostin production inhibits the 
process of bone formation. At the completion of matrix deposition, osteoblasts differentiate into 
osteocytes or lining cells (Sims and Gooi, 2008). 
 
 
1.2.3 Cancer metastasis to the bone 
The concept of organ-specific metastasis dates back to the pioneering work of 
Dr. Steven Paget. More than 120 years ago he described his “seed and soil” 
hypothesis for metastasis which claims that a metastasising cancer cell (seed) 
needs a congenial local microenvironment (soil) to grow a metastasis (Paget, 
1889). More than 80 years later this hypothesis was proven with advanced 
methods showing that although cancer cells reached the blood stream 
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development of metastasis could only be observed in specific organs (Fidler and 
Kripke, 1977; Hart and Fidler, 1980). 
 
 
1.2.3.1 Clinical picture of bone metastases 
After lung and liver, bone tissue is the third most common site for metastatic 
tumours and metastatic carcinoma is the most frequent malignancy occurring in 
the skeleton of humans. Preferred sites of metastasis are spine, pelvis, femur and 
ribs (Berrettoni and Carter, 1986; Hauben and Hogendoorn, 2010). Bone 
metastases may lead to complications in many malignancies. Bone tissue 
involvement can worsen the clinical picture and impair the quality of life 
immensely and increases morbidity significantly. Amongst the most common 
skeletal complications are pain, hypercalcemia, spinal cord compression and 
pathological fractures (Coleman, 2006). 
 
 
1.2.3.2 General mechanisms of metastasis  
It has been suggested that the complex mechanism of metastasis can be separated 
into two phases. The first phase, the physical translocation of a cancer cell, 
involves intravasation and extravasiation. Intravasation includes the invasion of 
the surrounding tissue of the primary tumour and entry to the lymph and blood 
system. Extravasation takes place, when the cell survives and translocates via the 
blood stream to microvessels of distant tissues and enters this tissue from the 
blood stream. 
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The second phase describes the colonisation, involving survival in the new 
microenvironment, adaption and finally proliferation to form a secondary 
tumour. The complexity and many different aspects of the second phase of 
metastasis still remain to be investigated to a greater extent (Chaffer and 
Weinberg, 2011).  
One aspect of the first phase that has been investigated during the last decades is 
the epithelial-to-mesenchymal transition (EMT) that mainly plays an important 
role as cell-biological program in early embryonic morphogenesis (Thiery et al., 
2009). EMT involves dedifferentiation of cells and improvement of their motility 
by reduction of cell-cell-contacts and thus adhesion. However, recently it could 
be shown for breast cancer that non-CSCs can transform into CS-like cells due to 
EMT. This might be a key mechanism by which dissemination of cancer takes 
place (Mani et al., 2008; Morel et al., 2008; Thiery et al., 2009).  
In carcinoma, the activation of this EMT-program in tumourigenesis calls for 
signalling between cancer cells and their neighboring stromal cells so that a 
variety of different cell types are attracted to the surrounding stroma. These cells 
lead to the formation of a “reactive” stroma leading to an inflammation and 
finally in the release of EMT-inducing molecules. This triggers the expression of 
certain EMT transcription factors by the carcinoma cells resulting in the EMT 
programm (Yang and Weinberg, 2008; Chaffer and Weinberg, 2011).  
However, the concept of EMT as a mediator of dissemination and subsequently 
metastasis as well as the mechanisms of colonisation as the second phase of 
metastasis still have to be investigated in other types of cancers and sarcomas as 
such.  
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1.2.3.3 Mechanisms of metastasis to the bone 
Regarding the site of bone metastases of different types of cancers, it is obvious 
that these are mainly affecting bone regions which contain red bone marrow, 
which consists mainly of haematopoietic tissue. This might play a role in the 
process of metastasis to the bone (marrow) because properties of circulation, 
cells and extracellular matrix in the bone might support homing and growth of 
metastasised cancer cells. Furthermore, post-mortem studies in animals and 
humans have shown that venous blood from breast and pelvis does not only flow 
into the vena cava but also into a vertebral-venous plexus. This might, to a 
certain extent, explain the tendency of breast, prostate and other cancer types to 
metastasise to bones at certain anatomical sites (Batson, 1940; Coleman, 2006).  
Disseminating tumour cells become attracted to certain regions and are 
physically trapped in the capillary beds of a variety of tissues. However, the 
tumour cells have to interact with the local tissue and this is only possible in 
tissues that offer the appropriate microenvironment for survival and growth to 
which the disseminating cell has to adapt. This process of communication plays a 
critical role in homing and establishment of metastatic disease. In more detail 
this involves degradation of extracellular matrix, secretion of appropriate growth 
factors, chemokines and cytokines, and expression of receptors on tumour cells 
(Nannuru and Singh, 2010). 
Furthermore, it is thought that bone metastasis can be described as a vicious 
circle in which tumour cells get attracted by growth factors released from bone 
tissue through normal osteoclastic resorption during bone remodelling. This leads 
to enrichment of the microenvironment and leads to increased tumour cell 
growth and alteration of tumour cell phenotypes. This, in turn, influences the 
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cells of the bone microenvironment and disturbs the fine equilibrium between 
osteoblasts and osteoclasts (Bussard et al., 2008).  
 
 
1.2.3.4 Metastasis in Ewing’s sarcoma 
Metastatic disease is one of the most important factors influencing prognosis, 
disease and the choice of treatment in ES/PNET (for more details see chapter 4). 
ES/PNET is known to be a systemic disease with patients most commonly dying 
from lung metastases (Cotterill et al., 2000; Grier et al., 2003; Paulussen et al., 
2008).  
Until today, the process of detatchment form the primary tumour has been 
investigated in ES/PNET. It is known that activation of certain downstream 
signalling pathways is important for anchorage-independent survival and growth, 
such as PI3K/Akt. Furthermore, the activation of tyrosin-kinase receptors 
involving IGF-1R (insulin-like growth factor 1 receptor) may not only be 
important in the survival of detached ES/PNET cells but as well in maintenance 
of a malignant phenotype (Strauss et al., 2010).  
As a further mechanism promoting tumour development, growth and a metastatic 
phenotype chromatin modifications are increasingly recognized in different 
cancer types and as well ES/PNET. EZH2 (histone methyltransferase Enhancer 
of Zeste, Drosophila, Homolog 2), the enzymatic subunit of the polycomb PRC2 
complex has been shown to methylate histone H3K27. This ultimately leads to 
gene silencing.  
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EWS-FLI1 was found to be bound to the promoter of EZH2 in vivo and its 
downregulation suppressed tumour development and metastasis in vivo (Burdach 
et al., 2009).  
The exact mechanisms of metastasis in ES/PNET as such still remain unclear. 
With micrometastases in many cases being resistant to chemotherapy and 
responsible for a high risk of relapse and a worse outcome for patients 
(Schleiermacher et al., 2003; Strauss et al., 2010) it is crucial to investigate the 
development of metastasis in order to improve treatment strategies and patient 
outcome. 
 
 
1.2.3.5 Degradation of extracellular matrix 
Proteases are released by tumour cells metastasising to the bone as well as by 
bone cells themselves to degrade extracellular matrix. Tumour cells require these 
to invade into bone tissue.  
MMPs are zinc-dependent endoproteases employed for this purpose. Breast 
cancer cells and other cells of further malignancies can express different MMPs 
at high levels and this correlates with a poor prognosis (Leppä et al., 2004). 
Additionally, TIMPs (tissue inhibitor of metalloproteinases) are often inhibited in 
malignant and non-malignant cells during the metastatic process. In vitro 
inhibition of MMPs and addition of TIMP1 and TIMP2 to cultures of breast 
cancer cell lines lead to reduced adherence and migration (Zhao et al., 1999; 
Saad et al., 2000).  
More recently, the role of MMP-7 and MMP-9 has been investigated. Both 
proteases seem to contribute to osteolytic metastatic lesions. While MMP-7 
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solubilises RANKL (presented on the osteoblast cell surface, usually leads to 
osteoclast-activation; see chapter 1.2.2.2) in prostate cancer models of bone 
metastases, MMP-9 is thought to be involved in osteoclast recruitment (Dong et 
al., 2005; Lynch et al., 2005). 
Cathepsins have been shown to be vital for differentiation and activation of 
osteoclasts. Cathepsin G has been shown to mediate activation of MMP-9 and 
thus promote bone destruction. Targeting cathepsin G inhibits tumour 
vascularisation through reduced levels of VEGF (vascular endothelial growth 
factor) and chemoattractant protein-1 (Ishikawa et al., 2001; Wilson et al., 2009, 
2010). 
 
 
1.2.3.6 Growth factors and cytokines 
The bidirectional interaction between tumour cells and stromal cells of the bone 
microenvironment has been investigated extensively. On both sides this interplay 
induces production of growth factors and cytokines leading to complex signalling 
cascades. These factors can be categorised into bone-resorbing and bone-forming 
factors (Mundy, 2002).  
Amongst many factors that promote resorption the role of different cytokines and 
growth-factors in metastasis of cancer to the bone has been investigated and they 
often act in a RANKL-dependent way. Thus, differentiation of newly recruited 
osteoclast precursors to active osteoclasts is triggered (Thomas et al., 1999; 
Bendre et al., 2005). The limiting step in this interaction is the direct cell-to-cell 
contact between RANKL-expressing osteoblasts and RANK-expressing 
osteoclasts.  
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However, promotion of RANK-RANKL interaction can be achieved through 
cleavage of the membrane bound form of RANKL into a fully functional soluble 
RANKL. MMP-7 and cathepsin G are able to cleave the membrane bound form 
of RANKL. Their expression and thus promotion of osteoclast activation could 
be shown in different types of cancers metastasising to the bone (Lynch et al., 
2005; Thiolloy et al., 2009).  
A form of promotion of osteoblastic metastases of the bone could be achieved 
through endothelins. Osteoblasts produce ETA and ETB receptors (endothilin A 
and B receptors) and thus bind ET-1 (endothelin 1) which triggers mitogenesis 
and consequently proliferation of osteoblasts via the Wnt/β-catenin signalling 
pathway (Clines et al., 2007).  
Thus, tumour cell derived ET-1 might stimulate osteoblasts as well as promote 
tumour cells themselves in an autocrine fashion (Takuwa et al., 1990; Chiao et 
al., 2000; Guise and Chirgwin, 2003). 
As mentioned before, the bone matrix is rich in a range of growth factors such as 
IGF-1 and -2, TGF-β, BMPs, FGF (fibroblast growth factor) and PDGF released 
during osteolysis. These additionally promote proliferation and survival of 
tumour cells in the bone microenvironment which closes the “vicious cycle” of 
metastasis to the bone. 
 
 
1.2.3.7 Chemokines and their receptors 
Chemokines and their G-protein-coupled receptors play an important role in the 
interaction of tumour cells and the bone microenvironment. Chemokines, 
secreted by tumour cells or through degradation of the extracellular matrix, 
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provide a chemotactic signal to cells expressing the appropriate receptors. This 
attraction is likely to be responsible, at least in part, for distant organ-specific 
metastasis (Nannuru and Singh, 2010). 
The first two chemokine receptors, which initiated the idea of chemokine driven 
metastasis to bone, were CCR7 and CXCR4. These are highly expressed in 
breast cancer cells while the associated ligands CCL21 and CXCL12 are 
expressed in bone as well as lung and lymph nodes (Müller et al., 2001). 
Furthermore, evidence for expression of CXCR4 could also be found in prostate 
cancer cells where interaction of CXCR4 with CXCL12 has amongst others the 
effect of increasing MMP-9 expression which subsequently promotes 
invasiveness of tumour cells (Chinni et al., 2006). There are many more effects 
of the CXCR4/CXCL12-axis but it can be reasoned in general that this leads to 
the establishment of the cancer stem-like cell niche where high levels of 
CXCL12 recruit a population of highly tumorigenic cells promoting cell survival, 
proliferation, angiogenesis, and further metastasis (Wennberg et al., 2000; Chinni 
et al., 2008). 
The CCL22/CCR4-axis attracts lung cancer cells to the bone marrow (Nakamura 
et al., 2006). Conversely, CCL2 expression seems to inhibit the metastasis of 
breast cancer cells to bone and lung (Takahashi et al., 2009). 
 
 
1.3 The CXCL12/CXCR4-axis 
Chemokines are a subgroup of cytokines with the ability to chemically attract 
cells expressing the appropriate chemokine receptor. Thus, chemokines are major 
regulators of cell trafficking and adhesion.  
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Chemokine receptors are seven-span transmembrane proteins which are coupled 
to G proteins. All chemokines present the N-terminus at the cell surface and the 
C-terminus to the cytoplasm with three extra- and three intracellular loops. One 
of the latter interacts with heterotrimeric G proteins. As mentioned before, this 
initiates a signalling cascade (Sun et al., 2010). 
 
 
1.3.1 Role of the CXCL12/CXCR4 axis 
For years, the interaction between CXCL12 and CXCR4 was thought to be 
exclusive. Just recently the picture of CXCL12 changed when it became clear 
that CXCR4 is not its only receptor. A new receptor was identified on murine 
fetal liver cells which was still able to bind CXCL12 after CXCR4 knockout 
(Burns et al., 2006). However, the work at hand will focus on the interaction of 
CXCL12 with the receptor CXCR4. 
So far, there is a variety of tasks known which the axis of CXCL12/CXCR4 
fulfils: it is primarily thought to regulate the migration of haematopoietic stem 
cells into and out of the bone marrow, and facilitates the cells transmigration 
through endothelial cell barriers (Möhle et al., 1997; McGrath et al., 1999). 
Furthermore, it is a key regulator of B cell lymphopoiesis and leukocyte 
migration (Nagasawa et al., 1996). 
Additionally to those functions in the adult body, in mice genetically deleted of 
CXCL12, early stage embryos exhibit profound defects in the formation of large 
vessels, septal malformation during cardiac development and abnormal brain 
development (Nagasawa et al., 1996). Eventually, between days 15 and 18 of 
gestation embryonic lethality is observed. Other investigations demonstrated that 
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CXCL12 can induce angiogenesis ex vivo and in vivo (Tachibana et al., 1998; 
Salcedo et al., 1999). 
CXCL12 has two major isoforms due to alternative splicing. The predominant 
α-isoform is involved in many local tissue-specific physiological processes and is 
expressed in nearly all organs. In blood it rapidly undergoes proteolysis. 
CXCL12β is more resistant to proteolysis and is mainly found in highly 
vascularised organs such as liver, spleen and kidneys (Janowski, 2009). There are 
four more isoforms of CXCL12 which, however, have to be further investigated 
(Yu et al., 2006). 
In the bone marrow, CXCL12 is mainly produced by osteoblast-derived lining 
cells and regulates the migration of CD34+ cells. The homology of the human 
and the murine variants of CXCL12 contribute amongst other factors to human 
CD34+ cells being able to repopulate the bone marrow of NOD/Scid mice 
(Ponomaryov et al., 2000; Jung et al., 2006; Janowski, 2009).  
CXCR4 is highly conserved and binds CXCL12 as a ligand. It is mainly 
expressed during development but later on it mediates migration of resting 
leukocytes and haematopoietic progenitors and plays a role in the immune 
system (Zou et al., 1998; Aiuti et al., 1999).  
The interaction of ligand and receptor leads to intracellular binding of a 
G protein complex to CXCR4. This causes the dissociation of the subunits of the 
G protein complex resulting in the activation of multiple downstream effectors of 
ERK1/2 (extracellular-signal-regulated kinase 1 and 2), different MAPKs 
(mitogen-activated protein kinases), and AKTs (v-akt murine thymoma viral 
oncogene homologs) (Lee et al., 2007; Lu et al., 2009).  
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The role of the CXCL12 and CXCR4 as mediators of migration and initiator of 
angiogenesis offers a high possibility for this axis to play a role in cancer as well.  
 
 
1.3.2 The CXCL12/CXCR4 axis in cancer metastasis 
Lapidot and co-workers suggested the concept of cancer stem cells by studying 
on leukaemia (Bode et al., 1992; Lapidot et al., 1994). Further investigations on 
different cancer types suggest indeed, that there is evidence for specific cancers 
arising from quiescent tissue-committed stem cells (cell of origin) acquiring 
several mutations over time. Furthermore, during the development of the specific 
tumours some cells remain in a quiescent, stem cell-like state allowing metastasis 
and relapse (cancer maintaining stem cell). This is due to their relative resistance 
to chemotherapeutics which target rapidly dividing cells. Recently, research has 
shown that these cancer stem cells play a pivotal role in many cancer types such 
as breast, prostate and brain cancers (Dontu et al., 2003; Singh et al., 2004; 
Collins and Maitland, 2006) and seem to share molecular mechanisms with 
normal stem cell trafficking as displayed in Figure 1.8 (Kucia et al., 2005). 
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Figure 1.8: Hypothetical role of the CXCL12/CXCR4 axis in migration of normal stem cells 
(SC) and metastasis of malignant stem cells (cancer SC). Cells (I) leave their stem cell niches 
(SC) or primary tumour (cancer SC) and enter circulation, (II) arrive at the site of homing (SC) 
or metastasis (cancer SC) via the peripheral blood or lymph, (III) adhere to the endothelium, (IV) 
invade tissues, and (V) proliferate and expand at a location that provides a supportive 
environment (Furusato et al., 2010).  
 
 
As CXCR4 is expressed on stem cells of various organs as well as on many 
tumour cells themselves, researchers suggest that these tumour types arise from 
CXCR4+ stem cells (Furusato et al., 2010). So far, some cancers that are positive 
for CXCR4 have been shown to metastasise and home to bone via the blood 
stream in a CXCL12-dependent way (Geminder et al., 2001; Müller et al., 2001; 
Sun et al., 2003). Therefore, metastases of breast and prostate tumours can be 
found in tissues excreting high levels of CXCL12 such as lymph nodes, lung, 
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liver and bone marrow (Allinen et al., 2004; Gladson and Welch, 2008). The 
hypothesis of the CXCL12/CXCR4-dependent homing is supported by findings 
of in vivo studies where neutralising antibodies against CXCR4 inhibited 
metastasis (Du et al., 2008). 
CXCR4 is overexpressed in a variety of different cancer types, and cancer cell 
lines such as for example breast cancer, prostate cancer, and melanoma. 
However, it is conspicuous that in all cases the originating tissue does not 
express CXCR4 (Müller et al., 2001; Scotton et al., 2001; Sun et al., 2003). 
Therefore, CXCR4 expression of cancer cells might not be due to transformation 
of a CXCR4-positive mesenchymal stem cell but a consequence of the malignant 
programme that drives the metastatic phenotype.  
The up-regulation might be caused by different mechanisms. One of those might 
be the induction of CXCR4 expression through VGEF, which in turn can be up-
regulated itself through the transcription factor HIF-1 (hypoxia-inducible 
factor 1) under hypoxic conditions. This has been shown to be the case for 
glioblastoma (Zagzag et al., 2006).  
The interesting and important role CXCL12/CXCR4 seems to play in different 
types of cancers suggests a potential role of this axis in ES/PNET as well. This, 
however, still needs to be investigated. 
 
 
1.3.3 Potential role of CXCL12/CXCR4 axis in Ewing’s sarcoma 
Until today, no research results have been published that had the direct aim to 
investigate on the role of CXCL12/CXCR4 in ES/PNET. However, different 
projects revealed interesting results that involved CXCL12/CXCR4.  
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Recently, data was published describing a novel method of gene expression 
analysis called intercohort gene expression co-analysis. This study shows that 
higher CXCR4 expression correlates with metastatic behaviour of ES/PNET. 
Furthermore, the patient group with ES/PNET cells highly expressing CXCR4 
and CXCR7 had the worst survival rates (Bennani-Baiti et al., 2010). 
Knockdown experiments targeting the fusion transcript EWS/FLI1 revealed that 
CXCR4 expression seems to be directly or indirectly regulated through the 
aberrant transcription factor EWS/FLI1 (Chansky et al., 2004; Bennani-Baiti et 
al., 2010).  
Additionally to this, HIF-1 might be responsible for the expression of CXCR4 in 
ES/PNET. As mentioned previously, HIF-1 can up-regulate VEGF expression, 
which in turn can up-regulate CXCR4 expression. In ES/PNET HIF-1α 
influences the expression of EWS/FLI1 and may also be responsible for up-
regulation of CXCR4 via VEGF. This, however, needs to be investigated further 
(Aryee et al., 2010). 
To date, there is still a need for a direct experimental proof of a role of the 
CXCL12/CXCR4-axis in the metastasis of ES/PNET. But taking its high 
expression in nearly all ES cell lines and many primary tumours as well as the 
role of this axis in other cancers into account there is strong indication for 
CXCR4 involvement in the organ-specific metastasis of ES/PNET. 
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2. Chapter – Hypothesis and aims  
The main aim of this thesis was to investigate different aspects of the cellular 
mechanisms of organ-specific metastasis in ES/PNET. In different studies on 
ES/PNET it has been observed that the occurrence and location of primary 
metastases in ES/PNET plays an important role for the outcome of patients. 
These studies revealed as well that metastasis to distinct organs leads to different 
survival rates in patients. Thus, the overall hypothesis of this thesis was that cells 
metastasising to different organs would be distinct from each other. Especially, it 
was thought that this would be manifested in the expression of genes, in vitro and 
in vivo behaviour. 
As CXCR4 has been shown to play a role in the metastasis of other cancer types 
and has been shown to be expressed in ES/PNET it was hypothesised to have a 
potential role in the metastatic behaviour of this sarcoma type as well.  
 
 
More specifically the aims were as follows: 
 
 to isolate organ-specific ES/PNET subclones employing the established 
i. v. metastasis model for ES/PNET. 
 
 on-going from this to identify organ-specific gene expression signatures 
using microarray analyses. 
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 to create a stable knockdown vector against CXCR4 for further 
investigations on its role in the metastasis of ES/PNET. 
 
 to develop and characterise an orthotopic model for ES/PNET to 
investigate the interaction of ES/PNET cells in the appropriate 
microenvironment. 
 
 
The development of an orthotopic model for ES/PNET is justified by the need of 
investigation of the interaction of the tumour cells in the microenvironment of 
the bone. Employment of such an orthotopic preclinical model would facilitate 
fundamental research on the biology of ES/PNET. Furthermore, it would provide 
an improved tool for drug development as compared with current subcutaneous 
(s. c.) models.  
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3. Chapter – Materials and Methods 
3.1 General devices and materials 
If not stated otherwise or directly in the correlating chapter the following 
equipment and materials were used: 
 
 
3.1.1 Equipment 
ABI 7000 Real Time detection system, Applied Biosystems, Warrington, UK 
ABI 7500 Fast Real-Time PCR system, Applied Biosystems 
ABI 7000 SDS program, Applied Biosystems 
ABI 7900HT Sequence detection system, Applied Biosystems 
ABI SDS 2.2, Applied Biosystems 
Agarose gel electrophoresis unit, BIO-Rad, Hemel-Hempsted, UK 
FACSCalibur, Becton Dickinson, Oxford, UK 
FACSCanto, Becton Dickinson 
MINI-PROTEAN II electrophoresis cell, BIO-Rad 
ND-1000 spectrophotometer, Nanodrop Technologies Ltd., Wilmington, USA 
Spectramax 250 multiwell plate reader, Molecular devices, Crawley, UK 
Centrifuge 5415C, Eppendorf AG, Germany 
Centrifuge 5415R, Eppendorf AG 
L870M Ultracentrifuge, Beckman Coulter, UK 
Allegra® X-12 benchtop centrifuge, Beckman Coulter, High Wycombe, UK 
Bio Mat2 Class II Microbiological Safety Cabinet, Medical Air Technology Ltd., 
Oldham, UK 
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CO2 Incubator, Sanyo E&E Europe, Loughborough, UK 
Sub-Cell® GT gel-electrophoresis chamber, BIO-Rad 
ChemiDoc XRS+ system, BIO-Rad 
GeneAmp® PCR System 2700, Applied Biosystems 
Thermomixer comfort, Eppendorf AG 
 
 
3.1.2 Material 
Costar® Cell culture flask, different sizes, Corning Incorporated, USA 
CryoTubes, Nunc A/S, Denmark 
Costar® cell culture plates, different sizes, Corning Incorporated, USA 
FACS tubes, BD Bioscience, Oxford, UK 
 
 
3.1.3 Kits 
Maxiprep Endofree Plasmid Isolation Kit, Qiagen, Crawley, UK 
QIAprep Spin MiniPrep Kit, Qiagen 
RNeasy kit, Qiagen 
QIAShredder spin colums, Qiagen 
 
 
3.1.4 Chemicals 
If not stated otherwise, chemicals were purchased from Sigma-Aldrich (Poole, 
UK) or Fisher Scientific (Loughborough, UK). 
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3.2 Microbiological work 
 
3.2.1 Bacteria  
Escherichia coli K12 JM109 
A suspension of Escherichia coli (E. coli) K12 JM109 grown in minimal media 
and cryopreserved in 50 % glycerol was purchased from Promega 
(Southhampton, UK). Competent bacteria were produced from this stock. 
Genotype: F´ traD36 proA+B+ lacIq Δ(lacZ)M15/ Δ(lac-proAB) glnV44 e14- 
gyrA96 recA1 relA1 endA1 thi hsdR17 
 
Escherichia coli K12 ER2925 
A suspension of E. coli ER2925 grown in Lysogeny broth (LB) and 
cryopreserved in 50 % glycerol was purchased from New England BioLabs 
(Hitchin, UK). This strain is dam- and dcm- and was used for the production of 
plasmids in which the restriction site XbaI was used. 
Genotype: ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 galK2 galT22 mcrA dcm-6 
hisG4 rfbD1 R(zgb210::Tn10)TetS endA1 rpsL136 dam13::Tn9 xylA-5 mtl-1 thi-
1 mcrB1 hsdR2 
 
 
3.2.2 Plasmids  
Table 3.1 lists all plasmids purchased, used and constructed for the projects of 
this work. 
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Table 3.1: List of purchased and constructed vectors. 
Plasmid Antibiotic 
resistance 
Manufacturer/Co-operator 
pSUPER Ampicillin Oligoengine, Seattle, USA 
pSUPERshMA6Mut1 Ampicillin Dr. Frida Ponthan 
pSUPERshCXCR4 Ampicillin Henrike Knizia 
pEPI-EGFP Kanamycin Prof. Lipps, University of 
Witten/Herdecke, Germany 
pEPI shCXCR4 Kanamycin Henrike Knizia 
pEPI shMA6Mut1 Kanamycin Henrike Knizia 
 
For the selection of bacteria carrying the designated plasmid the adequate 
antibiotic was added to the culture medium. 
 
 
3.2.3 Media, additives and growth conditions 
Table 3.2 and 3.3 describe the medium and additives used to cultivate and select 
bacteria. Medium was sterilised before use for 20 minutes at 121°C and 
2×105 Pa. To create selection pressure antibiotics were added after cooling down 
the media. Cultures were incubated at 37°C in a shaking incubator either 
overnight or until the designated density was obtained. To produce agar plates 
1.8% (w/v) agar was added to the medium prior to autoclaving.  
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Table 3.2: Recipe for Lysogeny broth (LB).  
LB medium 
Bacto-tryptone 1% w/v
Yeast extract 0,5%w/v
NaCl 1%w/v
ddH2O ad 1000ml
pH 7.5
 
 
Table 3.3: Antibiotics and used concentrations. 
Antibiotic Stock solution End concentration 
Ampicillin 50mg/ml 50μg/ml 
Kanamycin  50mg/ml 50μg/ml 
 
 
3.2.4 Strain conservation  
For short term conservation strains were maintained on LB agar plates with the 
appropriate antibiotics. These plates were sealed with Parafilm® M (American 
National Can Company, Chicago, USA) and stored inverted at 4°C in a 
designated refrigerator.  
For long term conservation E. coli strains were stored as glycerine-suspensions. 
Therefore, bacteria were cultivated overnight in liquid LB medium with the 
appropriate antibiotics. Aliquots of the bacteria solution were brought to an end 
concentration of 20% (v/v) with sterile glycerine and stored in a screw cap glass 
tube at -80°C. 
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To reactivate the frozen bacteria a sterilised inoculation loop was used to pick up 
the frozen stock and inoculate a LB culture with the adequate antibiotics. 
 
 
3.2.5 Preparation of competent Escherichia coli 
A 5ml culture of bacteria was incubated overnight at 37°C in LB medium. The 
culture was transferred into a sterilised 200ml conical flask and 25-50ml of fresh 
LB medium was added (the dilution should at least be 1/100). The diluted culture 
was grown to an optical density at 600nm (OD600) of 0.2-0.5, which was 
examined every 30 minutes. After the required OD600 was reached the culture 
was split and transferred into 50ml tubes and incubated on ice for 10 minutes. 
The bacteria were centrifuged for 10 minutes at 1000g at 4°C and the supernatant 
discarded. The required number of 1.5ml reaction tubes were pre-chilled on ice 
and the pellet was resuspended in ice-cold TSS buffer (see Table 3.4; 10% of the 
former culture volume). The solution was mixed gently, to dissolve all 
aggregates. From this solution 100µl aliquots were added to the chilled 1.5ml 
reaction tubes and these were immediately transferred from ice to a -80°C 
freezer.  
For each batch of competent bacteria a positive control was performed and the 
transformation efficiency calculated. 
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Table 3.4: Recipe for TSS buffer. 
TSS buffer End concentration
Polyethylene glucol 8000 (PEG) 10% (v/v)
DMSO (Dimethyl sulfoxid) 5% (v/v)
MgCl2  30mM
LB medium ad 50ml
 
The solution was filter sterilised (0.22µm filter) and stored at 4 or -20°C. 
 
 
3.2.6 Transformation of plasmids into competent Escherichia coli 
The method is based on a heat shock treatment of competent E. coli with the 
purpose to transfer plasmid-DNA. Subsequent, the plasmid amplified occurs 
following the incubation and growth of the bacteria.  
The competent bacteria (in 100μl aliquots), were thawed on ice prior to the 
addition of 0.1-50ng of purified plasmid and 2μl of a ligation mix. The mix was 
incubated on ice for 30 minutes to allow the plasmids to bind to the surface of the 
bacteria. The heat shock was performed at 42°C in a water bath for 45 seconds, 
followed by incubation on ice for 2 minutes. Next, 450μl of ice cold 
SOC-Medium was added (see Table 3.5), and the transformed E. coli were 
incubated for 1 h at 37°C to facilitate recovery. 
The transformed bacteria were centrifuged in a 1.5ml reaction tube at full speed 
using a benchtop microcentrifuge at 1200g, the supernatant was discarded and 
the bacteria were resuspended in the remaining liquid on the pellet and placed on 
a pre-warmed LB agar plate (containing the appropriate antibiotic as a selection 
Chapter 3 - Materials and Methods 
54 
marker if required). The bacteria were spread on the agar plate with a 
Drigalski-applicator and incubated overnight at 37°C in an inverted position.  
 
 
Table 3.5: SOC-Medium. 
SOC-Medium 
Tryptone (pancreatic digest of casein) 2% (w/v)
Yeast extract 0.5% (w/v)
NaCl  10mM
KCl 2.5mM
MgSO4 20mM
Glucose 200mM
 
The glucose solution had to be sterilised before adding it to the recipe. Adjust to 
pH 7.0. 
 
 
3.3 Nucleic acid methods  
 
3.3.1 Isolation of plasmid DNA from bacteria  
A QIAprep Spin MiniPrep Kit (Qiagen) was used to extract plasmid DNA from 
cultured bacteria according to the manufacturer’s instructions, as follows: 
Bacteria carrying the plasmid were cultivated overnight at 37°C with shaking and 
2ml of this culture was centrifuged for 5 minutes at 8000g in a microcentrifuge. 
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The bacterial pellet was re-suspended in 250µl of buffer P1 (Qiagen) and 
bacteria were lysed by adding 250µl of buffer P2 (Qiagen) and incubated for 
5 minutes at room temperature. Lysis was terminated by adding 350µl of 
neutralising buffer N3 (Qiagen) and inverting the reaction tubes cautiously. To 
sediment the resulting precipitates the solution was centrifuged for 10 minutes at 
full speed in a benchtop microcentrifuge. The supernatant was transferred to a 
QIAprep spin column, centrifuged at full speed for 1 minute and the flow-
through was discarded. Column-bound DNA was washed with 500µl PB buffer 
(Qiagen), and then washed with 750µl of PE buffer (Qiagen). The flow-through 
was discarded following each wash step. To ensure complete removal of residual 
ethanol, the spin column was transferred into a new 2ml reaction tube and 
centrifuged again for 1 minute at full speed to dry the column. To elute the 
column-bound DNA 50µl of EB buffer (Qiagen) were added to the column, the 
column incubated for 5 minutes and the resuspended DNA centrifuged for 
5 minutes at full speed. 
Plasmids were stored at -20°C until further use. 
 
 
3.3.2 Isolation of plasmid DNA from bacteria under endotoxin-free conditions 
Plasmids used for work carried out on mammalian cells samples must be 
endotoxin-free. Endotoxins produced by bacteria are harmful for mammalian 
cells and therefore have to be removed. This was achieved using the Maxiprep 
Endofree Plasmid Isolation Kit (Qiagen). 
To isolate a plasmid in larger quantities, 2ml of a pre-culture were used to 
inoculate a 100-150 ml overnight-culture in LB-medium with the require 
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antibiotic that was incubated at 37°C on a shaking platform. The next day, the 
bacteria were harvested by centrifugation at 6000g for 15 minutes at 4°C. The 
pellet was re-suspended in 10ml buffer P1 (Qiagen) and lysed by the addition of 
10ml buffer P2 (Qiagen). To ensure a complete lysis, the sealed tube was 
inverted and subsequently the mixture was incubated for 5 minutes at room 
temperature. During the incubation the QIAfilter cartridge was prepared. 
The lysis was neutralised by the addition of 10ml pre-chilled buffer P3 (Qiagen), 
vigorous inversion and incubation on ice for 20 minutes. The mixture was 
applied to the barrel of the filter cartridge, incubated for an additional 10 minutes 
and filtered into a new 50ml tube. Where required an endotoxin removal step was 
performed by adding 2.5ml of buffer ER (Qiagen) to the filtered lysate and 
incubation for 30 minutes on ice. During the incubation, the QIAGEN-tip 500 
columns were equilibrated by applying buffer QBT (Qiagen). Subsequently, the 
mixture was centrifuged for 30 minutes with 20,000g at 4°C. The supernatant 
was applied to the equilibrated QIAGEN-tip 500, allowed to enter the resin by 
gravity flow and washed twice with 30ml of buffer QC (Qiagen). Plasmid DNA 
was eluted with buffer QF (Qiagen). 
 
 
3.3.3 Isolation of genomic DNA from mammalian cells  
To be able to investigate genetic features such as fusion genes it was necessary to 
isolate the genomic DNA of cells. To acquire genomic DNA the QIAamp DNA 
Mini Kit (Qiagen) was used.  
Five million cells were centrifuged at 300g for 5 minutes. Cells were 
re-suspended in 200µl of phosphate-buffered saline (PBS; GIBCO, Invitrogen) 
Chapter 3 - Materials and Methods 
57 
and 4µl of DNase-free RNase (100mg/ml) were added. The suspension was 
incubated for 2 minutes at room temperature. Cells were lysed by adding 200µl 
buffer AL (room temperature, Qiagen) and 20µl Proteinase K. The samples were 
mixed by vortexing, briefly microcentrifuged and incubated for 10 minutes at 
70°C. Then 200µl of absolute ethanol was added and the solution was transferred 
to a QIAamp DNA spin column placed in a 2ml collection tube. By 
centrifugation at 6000g for 1 minute the DNA bound to the column matrix. The 
flow-through was discarded and the column was washed once with 500µl buffer 
AW1 (Qiagen) and subsequently with 500µl buffer AW2 (Qiagen) by 
centrifugation at 6000g. Again, the flow-through was discarded. To avoid a 
possible negative effect of remaining ethanol on subsequent reactions, the 
column was centrifuged once again at full speed for 3 minutes. To elute bound 
DNA from the column it was transferred into a 1.5ml reaction tube, incubated 
with 100µl of buffer AE (Qiagen) for 1 minute and centrifuged for 1 minute at 
full speed. 
DNA was stored at -20°C if not used immediately. 
 
 
3.3.4 Isolation of RNA from mammalian cells  
RNA from mammalian cells was isolated using the RNeasy kit and QIAShredder 
spin columns (both Qiagen). Therefore, cells were harvested and counted as 
usual. One x106 cells were pelleted at 300g. The cell pellet was resuspended in 
350µl of RLT buffer (Qiagen). Additionally, the cells were disrupted 
mechanically using QIAShredder columns.  
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One volume of 70% ethanol was added to the homogenized lysate. Up to 700μl 
of the sample were transferred to an RNeasy spin column placed in a 2ml 
collection tube and centrifuged for 15 seconds at 8000g. The flow-through was 
discarded. 
To wash the spin column, 700μl of buffer RW1 (Qiagen) and twice 500μl buffer 
RPE (Qiagen) were added to the spin column. With both buffers the column was 
centrifuge for 15 seconds (for 2 minutes during the last wash step) at 8000g and 
the flow-through discarded. The spin column was placed in a new 1.5ml 
collection tube and 30-50μl RNase-free water was applied directly to the spin 
column membrane. To elute the RNA, the sample was centrifuged for 1 minute 
at 8000g. 
RNA was quantified and stored at -20°C until further use. 
 
 
3.3.5 Determination of the concentration of DNA and RNA samples 
A NanoDrop® ND-1000 spectrophotometer was used to determine the 
concentration of DNA and RNA samples after isolation.  
Briefly, 1.2μl was applied onto the pedestal of the spectrophotometer and 
measured at 260nm and given in ng/μl. Additionally, by calculation of the ratio 
of the absorbance at 260 and 280nm the purity of the DNA sample was checked. 
DNA absorbs maximally at 260nm while proteins absorb maximally at 280nm. 
An OD260/280 ratio of 1.8 would indicate highest purity. However, values above 
1.4 are considered as sufficient. 
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3.3.6 Polymerase chain reaction  
To amplify specific genes the technique of polymerase chain reaction (PCR) was 
used. If required for genomic DNA, a prolonged denaturation step prior to 
addition of the polymerase and start of the PCR has been applied to avoid 
problems.  
After pipetting the PCR reaction-mix (see Tables 3.6, 3.8 and 3.9) into a 200µl 
PCR tube, 5-25 µl of DNA-sample (200ng-1µg DNA) was added and the 
mixture was overlaid with 20µl of mineral oil (PCR-grade). A negative control 
containing water instead of sample was included. 
If a hot-start PCR was performed, the samples were put into the thermal cycler 
and denatured for 10 minutes at 95°C, before adding the Taq (Thermus 
aquaticus) polymerase and starting the actual PCR programme described in 
Table 3.7. 
 
 
Table 3.6: Recipe for PCR master mix. 
PCR master mix 50 µl
10x Brady buffer 1x
3’ primer 0,2µM
5’ primer 0,2µM
dNTPs 0,2mM
Taq-Polymerase (GibcoBRL Taq-Polymerase) 0,2U
ddH2O ad 50µl
 
 
Chapter 3 - Materials and Methods 
60 
Table 3.7: PCR cycling conditions. 
Temperature Time cycles
95°C 10 minutes 1
95°C 1 minute 
3556-68°C 50 seconds 
72°C 1 minute 
10°C  hold 1
 
 
dNTPs 
The different 100mM dNTP stocks (25µmol in 250µl; Boehringer, Mannheim, 
Germany) were combined and diluted to 1:50 in distilled, deionised water 
(ddH2O).  
 
 
Table 3.8: Recipe for 10x Brady buffer.  
10x Brady buffer 50 µl
Tris/HCl pH8,3 100mM
KCl 500mM
MgCl2 15-50mM
BSA 1mg/ml
Triton X-100 0,5% (v/v)
ddH2O ad 1000µl
 
 
Chapter 3 - Materials and Methods 
61 
Table 3.9: PCR primers for ES fusion transcript EWS-FLI1 (embedded PCR). 
Gene 5’ sense 3’ antisense 
 EWS FLI-1 
1. PCR CCACTAGTTACCCACCCCAAAC AACTCCCCGTTGGTSCCYTCC 
 EWS FLI1 
2. PCR TCCTACAGCCAAGCTCCAAGTC GAATTGCCACAGCTGGATCTG 
 
 
3.3.7 Digestion of DNA using restriction endonucleases 
The sequence-specific hydrolysis of the DNA backbone was achieved by using 
restriction endonucleases of the type II (Fermentas, York, UK). These are able to 
recognise sequences that are palindromic and produce single strand cohesive 
ends or blunt ends. 
For a typical restriction digest a reaction volume of 20μl was used and the mix 
was prepared with ddH2O (see Table 3.10): 
 
 
Table 3.10: Recipe for restriction reactions. 
Restriction reaction 
dsDNA 0.7pmol
Buffer (10x) 1x
Restriction enzyme 5U
 
The volume of the restriction enzyme should not exceed 10% of the total volume 
as the glycerol supplied with the enzyme will inhibit the reaction. Thus, only 
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0.5μl of enzyme, typically 10Units/μl (U/μl) were used when carrying out double 
digests. 
The reaction mixture was incubated in a water bath or heating block at 37°C for 
1 hour and heat inactivated at 65°C or 80°C according to manufacturer’s 
information. 
 
 
3.3.8 Hybridisation of DNA-oligo single strands  
Lyophilised sense and antisense oligonucleotides were re-suspended in 
hybridisation buffer (see Table 3.11 and 3.12), adjusting the stock to a 
concentration of 100µM each. Both stocks were combined to a final 
concentration of 10µM in 10x buffer O+ (Fermentas) and ddH2O. To denature 
possible secondary structures the mix was heated for 30 seconds at 95°C. 
Subsequently, the thermomixer (Eppendorf) was switched off and the 
hybridisation mix was allowed to slowly cool down to room temperature within 
the heat block. During the cooling down process hybridisation could occur 
during which the complimentary strands annealed. The generated duplexes were 
stored at -20°C until further use.  
 
 
 
 
 
Chapter 3 - Materials and Methods 
63 
Table 3.11: Hybridisation buffer used for DNA oligos. 
Hybridisation buffer 
NaCl 100mM
Tris 25mM
 pH 7.5
 
 
Table 3.12: Oligonucleotides for cloning of shRNA-plasmids, 5' - 3' (Purimex, Grebenstein, 
Germany). 
Gene Orientation  Sequence  
CXCR4 Sense GATCCCCCACCCTGTTTCCGTGAAGAATTCAAGAGAT
TCTTCACGGAAACAGGGTTTTTCTAGAAAG 
 Antisense TCGACTTTATAGAAAAACCCTGTTTCCGTGAAGAATC
TCTTGAATTCTTCACGGAAACAGGGTGGGG 
MLL/AF4 Sense GATCCCCGAGAAAAGCAGACCTACTCCATTCAAGAG
ATGGAGTAGGTCTGCTTTTCTCTTTTTG 
 Antisense TCGACAAAAAGAGAAAAGCAGACCTACTCCATCTCT
TGAATGGAGTAGGTCTGCTTTTCTCGGG 
 
 
3.3.9 Isolation of DNA-fragments from agarose gels 
Following restriction digestion of plasmid DNA and agarose gel electrophoresis, 
linearised DNA fragments of interest were isolated from the agarose gel. DNA 
band is illuminated using a UV light source and the specific band is excised 
using a sterile scalpel blade. The DNA was extracted from the gel using the 
QIAquick Gelextraction Kit (Qiagen).  
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The excised agarose gel piece containing the DNA was put into a 2ml reaction 
tube and weighed on a balance. Three volumes of QG buffer (Qiagen; 100µl 
buffer equivalent to 100mg agarose gel) were added to and the mixture was 
incubated for 10-15 minutes at 50°C until complete dissolution of the gel piece. 
One volume of isopropanol was added to the reaction mixture, up to 700µl were 
applied onto a QIAquick spin column and the DNA bound to the matrix by 
centrifugation for 1 minute at full speed in an microcentrifuge. Subsequently, the 
flow-through was discarded and the column was washed with 500µl of QG 
buffer and again centrifuged for 1 minute at full speed to remove any residual 
agarose or QG buffer. Flow-through was thrown away and the column was 
washed with 750µl of PE buffer (Qiagen). The column was transferred to a new 
2ml collection tube and dried by centrifugation at full speed for 1 minute. DNA 
was eluted from the column by incubation with 30µl of pre-warmed EB buffer 
(Qiagen) and centrifugation for 5 minutes at full speed.  
 
 
3.3.10 Ligation of DNA-fragments  
DNA-fragments that were obtained from gel extraction, restriction digests or 
hybridisation were ligated to obtain the required complete circular plasmid with 
insert suitable for subsequent transformation.  
Therefore, a ligation reaction consisting of the plasmid DNA and insert DNA 
was carried out using T4 DNA ligase (Fermentas). This enzyme catalyses the 
ligation between the phosphate group of one strand of DNA with the hydroxyl 
group of the other. The amount of plasmid to insert used in this work was 1:3 and 
1:6 ratio of vector to insert respectively. Typically, 1U of T4 DNA ligase per μg 
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DNA, 1μl T4 ligase buffer (Fermentas), vector and insert mixture was made up 
to 10-15μl with ddH2O and incubated overnight at 14°C.  
Transformation of competent E. coli was subsequently carried out using 1-2μl of 
the ligation mixture and the rest was stored for short term storage at -20°C. 
 
 
3.3.11 Agarose gel electrophoresis for separation of DNA-fragments 
Agarose gel electrophoresis allows the separation of DNA fragments according 
to their size and possible secondary structures (for example intact plasmids). To 
achieve separation DNA samples were loaded onto a 0.8-2% agarose gel 
according to their expected size, in which a higher concentration of agarose is 
used to separate smaller fragments. Due to the negative charge of the sugar-
phosphate backbone of the DNA, it migrates towards the positive electrode once 
an electrical current is applied. 
Loading dye buffers and DNA ladders were applied to be able to monitor the 
degree of migration in the agarose gel and to size fragments. Loading buffer 
consisted of bromophenol blue, glycerol and Tris (Fermentas). Four μl of this 
loading buffer was mixed with 16μl of DNA sample for loading onto the gel. 
The appropriate amount of agarose powder (Invitrogen) was completely 
resuspended in 1x Tris/boric acid/EDTA (ethylediaminetetraacetic acid) (TBE; 
see Table 3.13) buffer by heating in a microwave and poured into a casting stand 
(Agarose gel electrophoresis unit, BIO-Rad). A comb was placed into the stand 
and the gel was allowed to set for 30 minutes. The gel was transferred to an 
electrophoresis tank filled with TBE, and DNA samples mixed with loading dye 
were loaded into the pockets formed by the comb. To allow band size 
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approximation 5μl of DNA ladder (Fermentas) was loaded alongside the DNA 
samples. The type of ladder was chosen before to match the sizes of the DNA 
samples. A voltage of 80V was impressed for approximately 45 minutes. 
The gel was transferred into a tank containing water and ethidium bromide and 
allowed to stain for 10-15 minutes. Ethidium bromide intercalates the DNA, 
which then can be visualised by using the fluorescence of ethidium bromide 
when visualised by ultraviolet light. The DNA was visualised and recorded using 
a BIO-Rad system. 
 
 
Table 3.13: Recipe for TBE buffer. 
TBE buffer 1x
Tris base 89mM
Boric acid 89mM
EDTA-Na2 2mM
ddH2O ad 1000ml
 pH 8.0
 
 
3.3.12 Reverse transcription polymerase chain reaction  
Total RNA isolated from cells was used to synthesis cDNA with the Revert Aid 
H Minus First Strand cDNA Synthesis kit (Fermentas) in a reverse transcription 
polymerase chain reaction (RT-PCR) using the recipe described in Table 3.14. 
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Table 3.14: Recipe for the reaction mix for RT-PCR. 
Reaction mix 12µl
RNA 500ng - 1µg
Random hexamers (100 µM) 8,3µM
ddH2O ad 12µl
 
 
The PCR programme starts with 5 minutes at 70°C. Afterwards it is paused at 
4°C. During the pause 8µl master mix (see Table 3.15) are added to the samples 
on ice. 
 
 
Table 3.15: Recipe for RT-PCR reaction master mix. 
Reaction master mix 8µl
buffer (5x) 1x
dNTP mix (10 mM) 2,5mM
RiboLock inhibitor 20Ul
MuMLV RT Pol 200U
 
 
The samples were put back into the PCR machine and the program was 
continued with 10 minutes at 25°C, 60 minutes at 42°C and 10 minutes at 70°C. 
On ice 30µl ddH2O were added and the samples were store at -20°C until further 
use. 
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3.3.13 Quantitative real time polymerase chain reaction  
To detect and simultaneously quantify the expression of specific targeted genes, 
cDNA (can range from 200ng transcribed RNA to up to 5µg RNA, standard 
condition is 1µg transcribed RNA) derived from total RNA was used in a 
quantitative real time polymerase chain reaction (qRT-PCR) using the reaction 
mix described in Table 3.16. For detection of the amplicon SYBR® Green QCR 
Supermix w/ROX (Invitrogen, Paisley, UK) was used, which intercalates with 
dsDNA and on doing so emits a fluorescent signal of specific wave-length. ROX 
was used as a reference dye. The ABI 7500 Fast Real-Time PCR system 
(Applied Biosystems) was used. 
 
 
Table 3.16: Recipe for the qRT-PCR reaction mix. 
Reaction mix 10µl
Primer (10µM fw+rev mix) 300nM
SyBr-Green master mix (2x) 1x
cDNA 200ng - 5µg
ddH20 ad 10µl
 
 
The master reaction mix was prepared without the sample cDNA and 8µl were 
added per well required of 384-well plate. The template cDNA was added to the 
appropriate wells to reach 10µl total reaction volume. The plate was sealed and 
briefly centrifuged. 
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The qRT-PCR was performed with the following temperature profile 
(Table 3.17). The signal was recorded at the 60°C-amplification step. 
 
 
Table 3.17: qRT-PCR cycling conditions. 
 cycles temperature time
Dissociation  (1x) 50°C 2 minutes
 95°C 10 minutes
Amplification  (40x) 95°C 15 seconds
 60°C 1 minute
Amplicon-dissociation  (1x) 95°C 15 seconds
 60°C 1 minute
 
 
All samples were performed in triplicate and water was used as a negative 
control to look for eventual primer dimers. Glycerinaldehyd-3-phosphat-
dehydrogenase was used for normalisation and all primers were checked for 
quality by loading the qRT-PCR sample onto a DNA-polyacrylamide (PAA) gel 
and performing a polyacrylamide gel electrophoresis (PAGE) to check amplicon 
length and possible side products. 
Analysis of the data was performed using ABI SDS 2.2 System software and by 
using the ∆∆Ct method. Here, SYBR-Green was used as a reporter dye for 
accumulating amplification products. The intensity of the emitted SYBR Green 
signal can be assumed as being proportional to the amount of amplified DNA. 
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3.3.14 DNA polyacrylamide gel electrophoresis 
The method of PAGE is especially performed for small amplicons typically 
generated by qRT-PCR primers as a vertical PAA gel in a TBE buffer system is 
used (see Table 3.13). This produces smaller mesh pore sizes and so leads to a 
higher resolution of the small amplicons. Typically, for an expected product size 
smaller than 50bp a 10%-TBE-PAA gel, for a product size of 50bp-300bp an 
8%-TBE-PAA gel and for product sizes of 300bp-500bp a 6%-TBE-PAA gel 
would be performed.  
To produce two TBE-PAA-gels the recipe described in Table 3.18 was used. 
 
 
Table 3.18: Example for the recipe for an 8% TBE-PAGE gel. 
8%-TBE-PAGE (example) 
40% Acrylamide/Bisacrylamide solution 
(37.5:1) 
8% (v/v)
5x TBE buffer 1x
ddH2O ad 10ml
Ammonium persulfate, APS (10%)  0,1% (v/v)
Tetramethylethylenediamine, TEMED 0,17% (v/v)
 
 
If samples of a qRT-PCR had to be analysed the seal of the 348-well plate was 
punctured, 2µl 6x DNA loading buffer were added to the sample and 5µl of 
this/well were loaded on a gel.  
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3.3.15 DNA sequencing  
Constructed plasmids were sequenced by Eurofins MWG Operon's sequencing 
service (Ebersberg, Germany). Primers were provided (see Table 3.19) as 
required and purchased before sequencing through Sigma. 
Eurofins MWG Operon uses the Cycle Sequencing Technology (dideoxy chain 
termination/cycle sequencing), which is modified from the traditional Sanger 
sequencing method. The components are DNS, primer, heat-resistant DNA-
polymerase, four dNTP’s, four ddNTP’s (dideoxy terminator nucleotides), which 
are labelled with four different fluorescent markers as well as buffer containing 
Mg2+ and K+ ions. The single primer binds to the DNA and is elongated in a 
linear manner until a ddNTP is bound. The polymerase is not able to elongate the 
fragment due to the dideoxy-characteristic of the nucleotide and the process is 
aborted. 
An ABI 3730XL Sequencer (Applied Biosystems) was used. 
 
 
Table 3.19: Sequencing primers. 
Plasmid  Primer sequence
pSUPER T7 primer AATACGACTCACTATAG 
pEPI Fwd pEPI CTGAAAGAGATTGTAGAA 
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3.4 Mammalian cell culture 
 
3.4.1 Cell lines 
For in vitro and in vivo studies ES/PNET cell lines CADO-ES1, RD-ES, RM-82, 
TC-71, VH-64 and WE-68 were used. These 6 cell lines represent Ewing’s 
sarcoma cells with different fusion transcrips and thus were chosen for the 
experiments (see Table 3.20).  
The prostate carcinoma cell lines PC3M and LNCaP (both cell lines behave in 
vivo in a metastatic manner) and the OS cell line SaOS-2 (chosen as cells were 
isolated from primary site and have been shown to grow in vivo, see chapter 
6.1.2.1) were used as an addition for the mouse model on bone malignancies (see 
Table 3.20). 
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Table 3.20: Type and origin of cell lines. 
Cell line Type ES 
translocations 
Origin Co-operator 
CADO-ES1 ES t(21;22)(q22;q12) pleural effusion Dr. van Valen 
RD-ES ES t(11;22)(q24;q12) humerus Dr. van Valen 
RM-82 ES t(21;22)(q22;q12 femur Dr. van Valen 
TC-71 ES t(11;22)(q24;q12) humerus 
(relapse) 
T. J. Triche 
VH-64 ES t(11;22)(q24;q12) pleural effusion Dr. van Valen 
WE-68 ES t(21;22)(q22;q12 Fibula Dr. van Valen 
SaOS-2 OS  Primary site Prof. Lunec 
LNCaP CaP  Lymph node 
metastasis 
Prof. Robson 
PC3M CaP  Transplant from 
mouse (PC3) 
Prof. Robson 
 
 
3.4.2 Culture media and supplements 
To produce growth medium, Roswell Park Memorial Institute (RPMI) 1640 
medium, a modification of McCoy′s 5A Medium, containing 1000mg glucose/L 
pyridoxine HCL and NaHCO3 was routinely supplemented with 10% (v/v) foetal 
calf serum (FCS) and 2mM L-glutamine. If necessary, 100IU/ml Penicillin and 
100μg/ml Streptomycin were added to the medium. 
To obtain cryopreservation medium, growth medium was additionally 
supplemented with 10% (v/v) DMSO and further 10% (v/v) of FCS to obtain a 
final concentration of 20% (v/v) FCS. DMSO prevents ice crystal formation 
within the cells during storage. 
All media was stored at 4°C and pre-warmed to 37°C in a water bath before use. 
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3.4.3 Collagen coating of tissue culture plastic 
To provide suitable conditions for ES/PNET derived cell lines all tissue culture 
plasticware had to be coated with collagen I. Rat collagen I (BD Bioscience) was 
diluted in a 0.1N HAc solution to a final concentration of 0.2mg/ml. 
Cell culture flasks (25cm2 and 75cm2) with filter-lid (Corning Incorporated) were 
coated with 1.5ml/flask or 4.5ml/flask, respectively. The collagen I-solution was 
left in the flasks for 2 days with the lid closed. After discarding the solution from 
the flasks these were left to dry with open lids in an activated safety cabinet 
overnight. 
Tissue culture well plates (Corning Incorporated) were coated with the same 
collagen I-solution. 96-well plates were coated with 50µl/well of the solution and 
from this the amount of solution required was scaled up according to the size of 
the well plate (6-, 24-, 48-well). 
 
 
3.4.4 General cell culture and cell harvesting 
All mammalian cells were grown in 5% CO2 humidified atmosphere in a 37°C 
incubator. The cells were passaged on a regular basis in a safety cabinet every 
2-3 days at a ratio of 1:5 to 1:6 once a confluence of 80-90% was achieved.  
Cells were detached from the coated cell culture plastic ware by washing off 
residual medium with PBS (see Table 3.21) before incubation at 37°C with pre-
warmed 1:10 Trypsin/EDTA 10x (see Table 3.22) in PBS solution for 
approximately 1-2 minutes inside an incubator. The digestion of surface proteins 
was stopped by adding FCS-supplemented medium. The cells were centrifuged 
for 5 minutes at 300g to pellet them and the supernatant was discarded. The 
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remaining cell pellet was re-suspended in an appropriate volume of pre-warmed 
media to be used for further culturing or experiments. 
 
 
Table 3.21: Recipe for PBS buffer. 
PBS 
NaCl 137mM
KCl 2.7mM
Na2HPO4  4.3mM
 pH 7.4
 
PBS was prepared using PBS tablets resuspended in deionised water. The 
solution was autoclaved in house at >120°C for sterility. 
 
 
Table 3.22: Recipe for Trypsin/EDTA solution. 
Trypsin/EDTA solution 10x
Trypsin 0.5% (v/v)
EDTA 0.2% (w/v)
NaCl 0.9% (w/v)
 pH 7.4
 
If experiments were performed involving attachment abilities of the cells, a less 
drastic detachment method using cell dissociation buffer was performed (see 
Table 3.23): 
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Table 3.23: Recipe for cell dissociation buffer. 
Cell dissociation buffer 
TrisHCl 0.04mM
EDTA 1mM
NaCl 0.15M
 pH 7.4
 
 
The buffer was sterilised by using a steam autoclave or sterile filters.  
An appropriate amount of cell dissociation buffer was added to the previously 
washed cells and the cells were incubated for 10 minutes at 37oC. Dissociated 
cells were collected in a tube, centrifuged at 300g and washed with pre-warmed 
PBS. Subsequently, cells could be used for experiments as required. 
 
 
3.4.5 Cell counting 
After harvesting, cells were routinely counted using an Improved Neubauer 
counting chamber (Hawksley, Lancing, UK). The particles of a trypan blue 
solution given to the cells get into the cells. Only viable cells are able to export 
these again and thus viable cells can be distinguished from dead cells and 
counted. 
Briefly, cells were harvested as described before and 45µl of the cell solution 
were mixed with 5µl of a 0.4% Trypan blue solution. This mix was allowed to 
diffuse beneath the cover slip of the haemocytometer. Cells in 4x4 squares of the 
grid were counted under a light microscope using x20 magnification. The 
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average was divided by 4 (squares) and 10 (dilution) to obtain the number of 
cells in million per millilitre of the cell solution. Viable cells were distinguished 
by their ability to exclude the Trypan blue. Therefore, dead cells appeared blue 
while viable ones appeared bright and lighter. 
 
 
3.4.6 Cell cryopreservation 
All cells were routinely cryopreserved for long term storage at, ideally, an early 
passage number. After harvesting and counting of cells these were centrifuged 
and the pellet was re-suspended in an appropriate volume of cryopreservation 
medium to obtain an approximate density of 1x106 cells/ml (see Table 3.24). One 
ml of the solution of cells was transferred into a cryo-tube (Nunc) and placed in 
an isopropanol filled container. Transferring the cells from room temperature to 
-80°C in an isopropanol filled container allows a gradual cooling of cells at a rate 
of 1°C per minute. For long-term storage cells were transferred to liquid nitrogen 
(-196°C). 
 
 
Table 3.24: Recipe for cryopreservation medium. 
Cryopreservation medium 
FCS 20% (v/v)
DMSO 10% (v/v)
RPMI ad 50ml
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3.5 In vitro assays on mammalian cells 
 
3.5.1 Cytospin  
Cells were harvested and counted as described before and 2x105 cells in 200µl 
were pipetted into the cytofunnel placed on a glass slide. Cytospins were 
performed for 6 minutes at 115g using a Shandon CytoSpin III Cytocentrifuge 
(Thermo Fisher Scientific, Schwerte, Germany). Afterwards, the glass slides 
were dried for 10 minutes at the air and stained for 30 seconds in May-Grünwald 
and 4.5 minutes in Giemsa.  
 
 
3.5.2 Cell viability assay using MTT 
This assay is used to measure the proliferation of cells. To quantify living cells 
mitochondria are stained (indirect quantification) with 3-([4,5-Dimethylthiazol-
2-yl]-2,5-dimethyltetrazoliumbromide (MTT). MTT is a yellow tetrazolium-salt 
that is soluble in water and taken up by mitochondria. Within the mitochondria 
this salt is reduced to a non-soluble blue formazan by mitochondrial 
dehydrogenases.  
Usually this test was used to either determine the growth rate of cells or to 
quantify cells and their growth subsequent to a test (e.g. adhesion test).  
Cells were either simply cultivated in 96-well plates or according to specific test 
conditions (see growth and adhesion assays).  
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Ten µl MTT (5mg/ml in PBS) was given into each well onto the cells using a 
Multipette plus (Eppendorf AG) and plates were incubated for 3 to 4 hours in an 
incubator at 37°C.  
Afterwards the MTT-containing supernatant was aspirated and 100µl of lysis-
buffer were pipetted onto the cells and plates were moved carefully back and 
forth to insure that the resulting solution is equally mixed (see Table 3.25).  
The optical density of the solution was measured using an ELISA-reader 
(FLx800, BioTek, Winooski, USA) at 550nm, using a reference measurement at 
630nm. Values measured at 630nm were subtracted from values measured at 
550nm.  
 
 
Table 3.25: Recipe for lysis buffer for mammalian cells. 
Lysis buffer 
Dimethylformamid 50% (v/v)
ddH2O 50% (v/v)
Sodium dodecyl sulfate  69.3mM
 
To remove all remaining solids the buffer was filtered after complete solution. 
 
 
3.5.3 Adhesion assay  
To test whether specific agents influence the adhesion of cells to collagen-coated 
cell culture flasks an adhesion assay was performed. It was essential to use a 
PBS2+ solution for collagen-coating of 96-well plates that was supplemented with 
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calcium and magnesium because a lot of adhesion molecules and their ligands 
require bivalent cations to function (see Table 3.26).  
Cells were cultivated so they were 90% confluent at the time point of the 
experiment. The T25-culture was washed with PBS twice and cells were 
detached with 2ml cell dissociation buffer (see Table 3.23). The detaching of 
cells was stopped after 10 minutes by tapping the flask and adding 3ml of 
adhesion medium (see Table 3.27). Cells were centrifuged at 300g for 5 minutes 
and the supernatant was discarded. The pellet was resuspended in 2ml adhesion 
buffer and cells were counted using a haemocytometer.  
Therefore, solutions were prepared containing 4x105 cells/ml and different 
concentrations of the factor that was to be investigated. These solutions were 
incubated for 30 minutes at 37°C. Subsequently, 100µl/well were pipetted in 
triplicate into collagen-coated 96-well plates. Plates were incubated a 37°C for 
30 minutes to allow cells to adhere to the collagen.  
Afterwards, the plates were tilted cautiously to loosen non-adhered cells and the 
solution was aspirated. The cells were covered with 100µl adhesion medium and 
allowed to consolidate for 1 hour at 37°C. 
To analyse the cell amounts a MTT assay was performed. 
 
 
Table 3.26: Recipe for PBS2+ solution.  
PBS2+ solution 
CaCl2 1mM
MgCl2 0.5mM
PBS ad 500ml
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The solution was sterile filtered. 
 
 
Table 3.27: Recipe for adhesion medium. 
Adhesion medium 
Bovine serum albumin  0.2%
Glutamine 1%
Penecillin/streptomycin 1%
RPMI ad 500ml
 
Adhesion medium was filter sterilised. 
 
 
3.5.4 Cell cycle analysis 
This method measures the relative DNA-content of cells using a propidium 
iodide staining. Afterwards, cells are analysed by flow cytometry.  
Cells were detached using Trypsin/EDTA, and counted. Two x105 up to 1x106 
cells were given into a FACS tube (BD Biosciences). After 5 minutes of 
centrifugation at 300g and room temperature cells were washed with PBS 
containing 2% FCS once and centrifuged again. The supernatant was discarded.  
To fix cells and make them permeable, the cell pellet was drop-wise carefully 
resuspended in cold 70% ethanol (4-8°C) and incubated for 30 minutes at 4-8°C. 
Occasionally the cell solution was mixed by flicking the tube. After the 
incubation cells were pelleted by centrifugation for 5 minutes at 300g at room 
temperature and the supernatant was discarded.  
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Subsequently the pellet was resuspended in 500µl PBS containing 2% FCS, 20µl 
RNAse A stock solution (see Table 3.28; end concentration of 400µg/ml) and 
100µl propidium iodide stock solution (end concentration of 10µg/ml; Carl Roth 
GmbH & Co. KG, Karlsruhe, Germany) and incubated for 1 hour in the dark. 
After the incubation the solution was topped up with 2ml of PBS, centrifuged at 
300g for 5 minutes at room temperature. The supernatant was discarded and the 
pellet resuspended in 100µl PBS. 
Cells were analysed using a FACS Canto or flow cytometer (BD Biosciences). 
 
 
Table 3.28: Recipe for RNAse A-solution. 
RNAse A-solution 
RNAse A  10mg/ml
TrisHCl 10mM
NaCl 15mM
 pH7.5 
 
 
3.5.5 Colony-forming assay 
To investigate the potential to grow in colonies under non-adherent conditions 
colony-forming assays were performed. These give information about the ability 
of cells or cell lines to grow under substrate independent conditions. 
Stocks of methylcellulose, 2% (v/v) BSA in RPMI medium and FCS were sterile 
filtered and used for the experiment. Each colony assay was performed in 
duplicate in 30mm petri dishes (Nunc). 
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Cells were detached using cell-dissociation buffer, counted and then diluted to 
achieve the required cell suspensions. The cell suspension was mixed with the 
serum-containing colony-forming assay medium using a 1.2 Gauge (G) needle 
and a 5ml-syringe (see Table 3.29).  
 
 
Table 3.29: Recipe for serum-containing colony-forming assay medium. 
Colony-forming assay medium 5ml
Methylcellulose 45% (v/v)
FCS 15% (v/v)
RPMI 16% (v/v)
Cell suspension in RPMI 24% (v/v)
 
 
The cells were plated carefully into the dishes avoiding the development of air 
bubbles. Per cell line two dishes with 500 cells/ml and two dishes with 
1000 cells/ml were prepared. Colonies were counted after 14 days under a light 
microscope and photographs were taken for documentation. The entire 
experiment was carried out twice.  
 
 
3.5.6 Transfection of mammalian cells using LipofectaminTM 
On the day before transfection of cells, these were plated in 1000μl of growth 
medium in 12-well format so that the cells would be 50–80% confluent at the 
time of transfection. 
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The next day complexes were prepared for each transfection sample as follows 
(according to supplier’s manual, Invitrogen): 
1. One μg of plasmid DNA was diluted in 200μl Opti-MEM® I Reduced Serum 
Medium and mixed thoroughly.  
2. PLUS™ Reagent was mixed gently before use and added directly to the 
diluted DNA from step 1. The solution was gently mixed by inversion and 
incubated for 5 minutes at room temperature. 
3. The Lipofectamine™ LTX solution was mixed by inversion and 2.5μl were 
added to the DNA solution. The DNA-lipid complex was incubated for 30 
minutes at room temperature.  
After incubation approximately 200μl of the complex was added drop-wise to the 
well containing the previously seeded cells. To dispense the complex evenly over 
the cells the plates were rocked gently back and forth. 
The cells were incubated at 37°C in a CO2 incubator for 18-48 hours prior to 
testing for transgene expression and the medium was exchanged after 12 hours 
post lipofection. As soon as the wells were around 90% confluent, cells were 
transferred to collagen-coated T25 cell culture flasks. 
If necessary, it was possible to scale the lipofection mix down by using 24- or 
48-well plates and amending the amounts of reagents and DNA used in the 
experiment. 
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3.5.7 Flow cytometry 
Flow cytometry using fluorescently labelled antibodies offers the opportunity to 
characterise cell populations by specific markers. In this work only cell surface 
markers were analysed.  
Cells were harvested, counted and 2x105 to 1x106 cells were re-suspended in 
100μl PBS. Samples were treated with 5μl of fluorescently conjugated antibodies 
to markers of interest and incubated for 20 minutes in the dark. Afterwards the 
samples were washed twice with 1ml of PBS and centrifuged at 300g for 
5 minutes. Following this, cells were re-suspended in 200μl PBS and were ready 
to be analysed on the FACS Canto or FACS Calibur (BD Bioscience). At least 
100,000 events were acquired. An unstained sample was used as a negative 
control. 
FITC-Mouse Anti-Human CD99 and APC-Mouse Anti-Human CD184 (also 
called CXCR4, clone 12G5) were both purchased from BD Bioscience. 
 
 
3.5.8 Fluorescence activated cell sorting (FACS) 
Where necessary, cells were prepared as described previously (3.5.7). Cells that 
harboured a plasmid containing an eGFP-gene were auto-fluorescing and thus 
did not have to be labelled. 
Cells were harvested, counted and the solution was adjusted to a cell 
concentration of approximately 5x106 cells per 100μl with the total volume of 
solution not exceeding 300μl in growth medium. The FCS contained within the 
medium was filtered using a 0.2μm Minisart syringe filter (Sartorius Stedim 
Biotech S.A., Aubagne Cedex, France) prior to being added to media. Prior to 
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cell sorting, the FACS Vantage SE cell sorter (BD Biosciences) was sterilised 
with 70% ethanol solution and washed with water and growth medium. Cells 
were acquired at a moderate event rate, typically 0.8-1.3x103 cells per second, 
and sorted fractions were collected in growth medium. 
After sorting, at least 300-500 sorted cells were re-acquired to assess purity of 
the desired population.  
Depending on the amount of sorted cells, these were taken back into culture in 
96-well or 6-well plates or directly in T25-tissue culture flasks. 
 
 
3.6 In vivo assays on mammalian cells  
 
3.6.1 Keeping of animals 
In vivo experiments performed at Newcastle University were done under Home 
Office license number PPL 60/3846 and ethical approval with the 
ERC Project ID 203. Experiments performed in Münster were approved by the 
district government licence number G54/2005. All care and experiments were 
carried out according to individual personal license and project license 
regulations. If necessary, advice or treatment was given from the on-site 
veterinary surgeon. 
Animals selected for experiments in at the University Hospital in Münster were 
NOD/LtSz-Prkdcscid/J mice (hereafter referred to as NOD/Scid, The Jackson 
Laboratory, Maine, USA) and at the Northern Institute for Cancer Research in 
Newcastle upon Tyne NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ mice (hereafter referred 
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to as NSG, The Jackson Laboratory, Maine, USA). The reasons for choosing 
these specific strains will be further discussed in chapter 3 and 5, respectively. 
Due to the immunodeficiency of these mouse strains housing, handling 
and general care of these mice was carried out using aseptic techniques such as a 
laminar flow hood (Faster Ultrasafe Class II Microbiological safety cabinet, 
Wolf laboratories Ltd, Yorkshire, UK). It was not possible to image mice under 
sterile conditions but all possible safety precautions were taken such as wiping of 
surfaces with ethanol, wearing of gloves, disposable paper lab coats and face 
masks to avoid extensive exposure of mice to pathogens. 
In Münster, as well as in Newcastle upon Tyne, mice were bred on site and 
maintained in single sex groups not exceeding five mice per cage. Bubble style 
isolators or individually ventilated cages were used for housing of mice, bedding 
and irradiated diet were exchanged once a week in a changing station. Water was 
provided in sterile disposable water packs or water bottles with autoclaved 
nozzles. 
Handling was only performed when wearing disposable paper lab coats or clean 
surgical gowns and nitrile gloves. These were sprayed down with disinfectant 
between handling individual cages. 
Once mice showed signs of tumour formation or generally appeared unwell 
(inactivity, breathing problems, hunched back, and untended fur), they were 
euthanized by high cervical dislocation.  
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3.6.2 Preparation of animals for surgical procedures 
The induction of the anaesthesia of experimental animals was carried out in a 
small chamber connected to an Isofluorane vaporiser and oxygen supply (Mie 
Cavendish 500 anaesthetic machine, fitted with an Ohmeda Isotec 400 volatile 
anaesthetic vaporiser and Fluovac scavenge system, Key Health Solutions Ltd, 
Wiltshire, UK). Excess anaesthetic was scavenged for safety. Typically 4-5% 
Isofluorane (IsoFlo, Abbott Laboratories, Maidenhead, UK) was supplied in 
1500cc/min oxygen. To determine suitable depth of anaesthesia the chamber was 
cautiously tilted to check if mice still had a righting reflex. Furthermore, the foot 
withdrawal in response to mild pain was used to determine suitable depth of 
anaesthesia. 
Anaesthetised mice were afterwards transferred to a face mask supplying 
Isofluorane in oxygen and maintained at a suitable depth of anaesthesia. Usually, 
this required between 2.5-4% Isofluorane in oxygen dependent on the mice 
weight. To assure that mice would not suffer after the procedure, 10μl of 
Carprofen (Rimadyl, Pfizer, Kent, UK) per 10g body weight was injected 
subcutaneously (s. c.) into the skin over the back of the mouse. 
All required anaesthetics and veterinary medicine were sourced through the 
responsible veterinarian of the Comparative Biology Centre, Newcastle 
University. 
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3.6.3 Intravenous transplantation 
To obtain a systemic spread of disease and model late stages of ES/PNET with 
cells spreading and homing to different organs mice were transplanted 
intravenously (i. v.).  
NOD/Scid mice were irradiated with 3.5Gy 24 hours in a 60Co unit before 
planned transplantation of cells. The next day, mice were transferred into a 
laminar flow hood within their cage and an infrared heat-lamp was placed above 
the open cage for 5-10 minutes. This increased the circulation to the surface 
blood vessels (as the mouse regulates its body temperature) and led to expanding 
of the diameter of veins in the tail. Hereafter, mice were trapped in a restraining 
device, which was made of a 60ml syringe. The top which usually is attached to 
the needle was cut off and closed with a rubber plug that was slotted dent to 
allow the tail of the mouse to hang out of the device. The plunge was used to 
restrain the mouse in space. 
Immediately, 5x106 cells in 100-200µl growth medium were transplanted into the 
tail vein of these mice using a very small diameter needle with 27G. The mouse 
was marked and released back into the cage and observed for a while to ensure it 
recovered and calmed down after the procedure. 
 
 
3.6.4 Intrafemoral transplantation 
Orthotopic preclinical models are the gold standard for the characterisation of 
tumour cell interaction with the microenvironment. Therefore, an intrafemoral 
(i. f.) model for ES /PNET was developed within this thesis.  
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Male NSG mice where prepared for the procedure as described before and placed 
supine breathing further anaesthesia. Subsequently, the right knee of the mouse 
was shaved and disinfected.  
The knee was flexed and grasped with the left hand to be able to puncture the 
femur with a 25G needle. The position of the drill needle was checked carefully 
to ensure, that the sample would be placed into the bone marrow cavity of the 
femur. Sample volumes of up to 30μl with 1x106 cells were subsequently 
injected with a 30G insulin syringe through the previously drilled hole. Upon 
needle withdrawal the leg was straightened to close the femoral puncture site and 
minimise backflow of the cell suspension. Additionally, control transplantations 
with medium injected into the right femur were performed. 
 
 
3.6.5 Positron emission tomography tracer preparation 
18F-2-Fluor-2-deoxy-D-glucose (FDG) for positron emission tomography (PET) 
experiments was purchased from Iba Molecular UK Ltd. (Sheffield, UK). Where 
possible, spare FDG originally delivered for patients was used. The tracer was 
diluted with sterile saline if required, to obtain a solution of which an appropriate 
amount could be used to inject 10MBq into mice. 
The isotope 18F emits positrons with a half-life of 109.8 minutes, which can be 
detected with a positron-emission tomography system. 18F is not found naturally 
and has to be produced with the help of a cyclotron for example through positron 
bombardment of the oxygen-isotope 18O. 
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3.6.6 Positron emission tomography  
To be able to determine metastatic spread of ES/PNET and to characterise local 
tumours that arose after i. f. transplantation of cells, PET scans of previously 
injected mice were performed. 
In Newcastle, all in vivo imaging experiments were performed in cooperation 
with the group “Drug Discovery and Imaging” (Northern Institute for Cancer 
Research, group leader Ross Maxwell).  
PET scans were performed with the high-resolution Philips Mosaic HP (Philips 
Medical Systems, Eindhoven, The Netherlands) with a field of view (FOV) of 
128 x 120mm. The first PET scan in each mouse was performed approximately 
two weeks after i. f. transplantation of tumour cells. Follow-up PET scans were 
performed in different intervals.  
Before tracer injection, mice were anaesthetised by Isoflurane/oxygen inhalation 
for the entire experimental procedure or by an intraperitoneal (i. p.) injection of 
Ketamin/Medetomidine (75mg/kg and 1mg/kg, respectively). Rectal temperature 
was maintained at physiological values by use of a heating pad between the start 
of the anesthesia and the experimental procedures. Scans were performed 1 hour 
after i. v. injection of 10MBq FDG. Mice anaesthetised with Isoflurane/oxygen 
were kept under anesthesia during the experimental procedure using a Minerve 
Animal Anesthesia System (Equipement Vétérinaire Minerve, Esternay, France). 
Within the machine the body temperature was maintained by air flow through the 
animal bed. Once imaging had taken place, mice that had been anaesthetised with 
Ketamin/Medetomidine were recovered through i. p. injection of 0.5-1mg/kg 
Atipamezole. All mice were observed for 30 minutes after recovery from 
anaesthesia. 
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Reconstruction of PET images was performed using the 3D-RAMLA algorithm 
with no attenuation correction (Browne and de Pierro, 1996). 
 
 
3.6.7 X-ray computed tomography 
The technique of X-ray based computed tomography (CT) was used to visualise 
and characterise eventual changes to bones that could occur through the injection 
of tumour cells into the femur of mice. In this case NanoCT scans were carried 
out using the Bioscan NanoCT (Bioscan, Paris, France), which is able to produce 
data with resolution that is high enough to visualise the relatively fine bones of 
mice.  
The FOV for the scans performed was 150 x 75mm. Parameters of whole-body 
images were: standard resolution, 180 projections, 55kVp, 1000ms exposure time 
and 10-12 minutes acquisition time, leading to a dose of ~150Sv. The parameters 
for scans of a higher resolution taken from just the lower limbs: ultra-fine 
resolution, 360 projections, 45kVp, 400ms exposure time, 2-3.5 minutes 
acquisition time, leading to a radiation dose of ~105Sv. The images were 
reconstructed using the Exact Cone Beam FBP (Filtered Back Projection) with 
the SheppLogan filter. The resulting voxel/pixel size is 0.10/0.096mm. 
Mice were anaesthetised by Isoflurane/oxygen inhalation for the entire 
experimental procedure using a Minerve Animal Anesthesia System 
(Equipement Vétérinaire Minerve, Esternay, France) and a physiological body 
temperature was ensured by air flow through the animal bed. 
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If PET scans were performed the same day as CT scans these were performed 
before each PET scan using the same animal bed so that mice were kept in the 
same position and a fusion of PET and CT images was possible afterwards. 
 
 
3.6.8 Magnetic resonance imaging  
MRI was used to describe the soft tissue component of tumours.  
One week after the last PET and CT scans transplanted mice underwent a final 
MRI scan. MRI scans were performed with a high-resolution 7T Varian MR 
system (Varian Inc., Palo Alto, USA) using a Coil-Rapid 72mm quadrature 
volume coil (RAPID Biomedical GmbH, Rimpar, Germany). Mice were 
anaesthetised for the entire experimental procedure by Isoflurane/oxygen 
inhalation and physiological temperatures were assured by the use of a rectal 
thermometer and a heating pad on which mice were placed through the whole 
procedure.  
Parameters for the lung scans were: fast spin echo sequence with respiratory 
gating, repetition time (TR) 2439ms, effective echo time (TE) 39ms, FOV 
30 x 35mm, in plane resolution 0.13mm and slice thickness 2mm. 
Parameters for the leg scans were: spin echo sequence, TR 500, TE 17, FOV 
30 x 35mm, in plane resolution 0.13mm and slice thickness 2mm. 
For analysis of tumour volumes the software Vnmr J (Varian) Version 2.3 Rev. 
A was used. 
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3.6.9 Dissection of mice  
In order to provide terminal analysis of tumour and metastasis development and 
to recover organs for pathology mice were dissected subsequent to euthanasia. 
Protocol limits were either a high tumour burden or a generally poor condition of 
a mouse. Mice used as controls were euthanized once all experimental mice had 
culled. 
Intravenously injected mice were dissected and lungs, liver, kidneys and spleen 
were taken for pathology. At this stage of the experimental work (Münster) it 
was not possible to recover bone tissue for pathology. Thus, bone tissue was only 
taken from mice when there was a clear sign of tumour development. 
Additionally, the bone marrow of both femurae was recovered. Therefore, a 
small section from each end of both femurs was clipped and bone marrow was 
extracted by flushing the lumen with transplant media repeatedly using an insulin 
syringe. Metastases from organs that were visible by eye and bone marrow 
flushes were taken into culture in RPMI growth medium containing 
Penicillin/Streptomycin. Using a sterile blade, tissues were disintegrated into fine 
pieces and incubated for 1 hour in trypsin/EDTA to ensure that tissue would 
break up. Following the enzymatic digest the tissue was pipetted up and down to 
apply shearing force to further separate the cells. To obtain a single cell solution 
for cultivation cells were forced through a fine mesh using a FACS tube with a 
Cell Strainer Cap (BD Biosciences).  
Lungs, liver, kidneys and spleen were collected from all i. f. transplanted mice. 
Instead of collecting bone marrow from the hind limbs these were stripped of 
skin and separated from the rest of the body by transection of the spin just above 
the pelvis and the tail. Organs and hind limbs were fixed in formalin and 
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preserved in 70% ethanol. The hind limbs were decalcified to make them suitable 
for pathological sectioning (see chapter 3.7.1). 
 
 
3.7 Pathology 
 
3.7.1 Immunohistochemistry 
Samples of organs and metastases were fixed in 10% neutral buffered formalin 
(4% formaldehyde in phosphate buffered saline), embedded in paraffin, and cut 
into 4–5 μm thick sections. These were stained with hematoxylin and eosin or 
used for immunohistochemistry to detect expression of huCD99 (commonly used 
as an ES/PNET marker). Typically, lung, liver, kidneys and spleen were screened 
for tumour cells also if no sign of metastases could be seen during dissection.  
Staining for antigens was carried out as follows: slides were de-paraffinised, re-
hydrated and neutralised in hydrogen peroxide solution. Antigen retrieval was 
performed by heating the slides twice for 5 minutes in 0.01M citrate buffer (pH 
6.0) using a microwave. The slides were cooled down in the buffer and then 
rinsed under tap water. Slides were then washed twice for 5 minutes in 50mM 
Tris-buffered saline with a pH 7.6. A couple of drops Tween-20 were added to 
break the surface tension. 
Immunohistochemical staining was carried out manually using the Menapath Kit 
(Menarini Diagnostics, Florence, Italy). Primary antibodies included monoclonal 
rat anti-human anti-CD99 (Dako, Carpinteria, CA, USA) diluted 1:50 and 
monoclonal rat anti-human anti-CD45 (Dako, Carpinteria, CA, USA) diluted 
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1:50. Diluted antibodies were dropped on the slides and incubated for 30-60 
minutes. Slides were incubated for 10-20 minutes with the universal probe 
(Manapath Kit) then incubated for 20-30 minutes with HPR polymer, 30 minutes 
with VectaStain ABC reagent (Vector Laboratories, Peterborough, UK) and 
washed under tap water for 5 minutes. Slides were 10 seconds counter-stained 
with Harris’s hematoxylin (BDH, VWR International, Lutterworth, UK), rinsed 
for 5 minutes under tap water, dehydrated, and cover-slipped. If not indicated 
differently, rinses were performed using Tris-buffered saline wash buffer. 
 
 
3.7.2 Haematoxylin and Eosin staining 
This method gives consistent results and is very simple to perform. 
Hematoxylin is used because it produces a stained section with clearly defined 
nuclei in blue while the background stays completely colourless. The cytoplasm 
stains in various shades of pink which helps to identify different tissues. 
Sections were prepared as described before (see section 3.7.1). Subsequent, the 
sections were stained for 15 minutes in hematoxylin solution and then wash in 
running tap water for 20 minutes. Sections were counterstain with eosin (Leica, 
Peterborough, UK) from 15 seconds up to 2 minutes depending on the age of the 
eosin, and the desired depth of counterstain.  
Finally, for dehydration sections were transferred to 95% and absolute alcohol 
twice for 2 minutes each or until excess eosin was removed. Sections were 
cleared in xylene twice for 2 minutes each and mounted. 
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4. Chapter – Metastasis model for Ewing’s sarcoma in Non-
obese diabetic/Severe combined immunodeficient mice 
(NOD/Scid) 
4.1 Introduction 
In the first half of the 19th century clinicians realised that there were common 
features in the histology of ES/PNET and other sarcomas such as PNET, and 
Askin tumour of the thoracic wall (see Chapter 1). The development of new 
diagnostic techniques such as PCR has made it possible for these tumours to be 
grouped as one entity due to the characterisation of the first chromosomal 
translocation in this disease subtype. Thus, the Ewing’s family of tumours serve 
as a model for understanding the biology of human sarcomas (Delattre et al., 
1992, 1994). 
Despite this similarity the group of sarcomas is heterogeneous in clinical and 
histochemical features and the exact cell or tissue of origin still remains unknown 
(see chapter 1). ES of the bone alone shows differences in course of disease and 
this heterogeneity reflects in treatment difficulties still present. 
 
 
4.1.1 Metastasis in Ewing’s sarcoma and patient outcomes 
It has been known for many years that ES/PNET is radiosensitive (Ewing, 1939). 
Thus, for a long time radiotherapy combined with surgery was the gold standard 
for treatment of this sarcoma. Nevertheless, more than 90% of patients receiving 
immediate local radiotherapy died of systemic metastasis within two years of 
Chapter 4 – Metastasis model for Ewing’s sarcoma in NOD/Scid mice 
98 
diagnosis. This demonstrates that micrometastases establish early on in the 
course of this disease. Over the last 30 years, treatment protocols have combined 
radiotherapy, chemotherapy and surgery leading to an improved prognosis for 
ES/PNET patients and cure is achievable (see chapter 1). 
Today, using modern multimodality therapy, one of the most important 
prognostic factors is the occurrence of primary metastasis (see Figure 4.1). The 
majority of tumours are primarily located in bony sites and while two thirds of 
ES/PNET patients with localized disease can be cured, the 5-year event free 
survival in patients presenting with osseous metastases or bone marrow 
infiltration is less than one fifth (accounting for approximately 10% of patients), 
while only 30% of patients with lung metastases survive (Paulussen et al., 1998a, 
1998b, 2001). 
 
 
 
Figure 4.1: Event free survival of ES/PNET patients in correlation with existence and 
localisation of metastases. Localised disease (blue line), lung metastases (red line), bone 
(marrow) metastases (green line). (EI)CESS 81-92 study (modified from (Jürgens et al., 2006). 
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Metastatic disease is one of the most important factors influencing prognosis, 
and thus the intensity of treatment. The mechanisms of metastasis in ES/PNET 
remain unclear; therefore it is crucial to investigate the development of 
metastasis in order to improve treatment strategies and patient outcome. 
 
 
4.1.2 Mouse model systems in cancer research 
For more than 50 years it has been possible to use in vivo models to investigate 
complex correlations of cancerous diseases (Gellhorn and Hirschberg, 1955; 
Oettel and Wilhelm, 1955). The first studies were mainly performed by the 
National Cancer Institute (Bethesda, USA) with the three murine cell lines 
sarcoma 180, L1210 leukemia, and carcinoma 755. However, concerns arose due 
to the fact that the majority of studies were initially based on the murine L1210 
leukemia model. Although relevant for some leukaemias, this model could have 
potentially selected for anti-cancer drugs only effective against rapidly growing 
tumours (Venditti et al., 1984).  
During subsequent years, treatment of human leukaemia and lymphoma 
improved as a result of preclinical work on combinations of different 
chemotherapeutics in murine models of these malignancies (Zubrod, 1965; Frei 
et al., 1965; DeVita and Schein, 1973). In contrast, no significant improvements 
for human solid tumours were achieved (Suggitt and Bibby, 2005).  
In 1966 a revolutionary publication describing a nude athymic (nu/nu) mouse 
strain (Flanagan, 1966) enabled the establishment of different human solid 
tumour xenografts, including breast, colon and lung tumours (Rygaard and 
Povlsen, 1969; Geran et al., 1972). 
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Many more mouse strains have since been developed and preclinical models 
have played a crucial role in medical research. They did not only help to improve 
the understanding of diseases but led to the development and improvement of 
therapy strategies and new drugs. Traditionally, these studies still are often 
carried out as s. c. experiments, which offer an easy approach and lead to 
tumours that are easily visible and palpable. Despite these advantages s. c. 
experimental protocols can be criticised as they simplify tumour formation due to 
the vigorous supply of blood from the skin. This leads to a quick vascularisation 
of the implant and subsequently to faster growth of the tumour. Furthermore it is 
usually only cell lines that engraft which may be due to the unnatural 
microenvironment they have to grow in.  
In order to investigate metastasis intravenous models are also often used, which 
better reflect the late steps of metastasis that occur via dissemination in the blood 
stream, including organ-specific homing, extravasation, trans-endothelial 
migration, invasion into tissue, clonal expansion of tumour cells and tumour 
angiogenesis (Vormoor et al., 2001). Equally important to the choice of the 
method of transplantation is the selection of the most appropriate mouse strain. 
Mice have to be immunodeficient in order to allow human tumour cells to 
engraft in host tissues and to prevent the rejection of the xenograft by the host’s 
immune system. 
 
 
4.1.2.1 Nude Mice  
The first immunodeficient mouse strain used in preclinical investigations was the 
Nude (nu/nu) strain discovered by Flanagan in the 1960s. Investigations showed 
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that the spontaneous mutation leading to nude mice is caused by a genetic change 
in the gene forkhead box N1 (Foxn1) on chromosome 11. Amongst others, one 
result of this pleiotropic mutation is the abnormal development of the thymic 
epithelium. These athymic mice lack functional T lymphocytes, which normally 
develop in the thymus from progenitors derived from haematopoietic stem cells 
of the bone marrow. Under normal circumstances haematopoietic progenitors are 
able to populate the thymus and expand by cell division to generate a large 
population of immature thymocytes subsequently resulting the generation of 
mature T cells (Pantelouris, 1968; Schwarz and Bhandoola, 2006). This lack of 
functional T cells in Nude mice results in an absent T cell-mediated immune 
response. As a direct result, Nude mice also carry a T cell-dependent defect in 
B cell maturation, function and immune response (Kaushik et al., 1995).  
For a long time researchers used xenograft models of human solid tumours 
including ES/PNET characterised by s. c. transplantation into the flanks of Nude 
mice (Scotlandi et al., 1998). However, this model does not mirror the typical 
clinical occurrence and growth pattern. Additionally, it is not possible to grow all 
cell lines or even primary material in Nude mice as they have a residual immune 
function that prevents engraftment, tumour development and metastasis.  
This fact and the observation that under suitable conditions even aging Nude 
mice can develop mature T cells deriving from haematopoietic progenitors 
(leakiness) made it necessary to develop mouse strains with less residual immune 
function. Nevertheless, although such profoundly immunodeficient strains were 
developed and used, Nude mice are still important in the preclinical evaluation of 
potential therapeutics in s. c. tumour models. 
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4.1.2.2 Scid Mice 
In the early 1980s the discovery and promotion of another spontaneous mutation 
led to the development of a mouse strain termed “severe combined 
immunodeficient” (Scid), which was of great use in the studies of xenograft 
implantation (Bosma et al., 1983). In comparison to Nude mice, these have a 
more severe immunodeficiency and are thus less likely to reject implanted 
xenografts. This immune defect occurs as a result of a homozygous recessive 
mutation in the gene protein-kinase, DNA activated, catalytic polypeptide 
(Prkdc) on chromosome 16. This gene encodes for the DNA-dependent protein 
kinase catalytic subunit, which is a subunit of the DNA-dependent protein kinase 
(DNA-PK). The mutation in Prkdc hinders the interaction between the 
DNA-dependent protein kinase catalytic subunit and its ligands leading to a 
defect both in immunoglobulin and T cell receptor rearrangements. This results 
in the humoral and cellular immune systems failing to mature and Scid mice, 
therefore, present with impaired ability to produce mature T and B lymphocytes. 
This renders the mice ineffective at fighting infections, and unable to raise an 
adaptive immune response against any foreign antigen, including implanted 
tumour cells (Custer et al., 1985; Bosma et al., 1988b; Lieber et al., 1988).  
The inability of the mutated Prkdc to bind the other components of the 
DNA-PK-complex additionally leads to a defect in DNA repair function of the 
complex. Thus, Scid mice are hypersensitive to ionising radiation (Fulop and 
Phillips, 1990). This effect is often used to further enhance the immune defect in 
Scid mice as ionising radiation removes all cells of the bone marrow. 
One major disadvantage of the Scid mouse strain is the possibility that few Scid 
lymphocytes can have productive rearrangements at the appropriate Ig 
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(immunoglobulin) or T cell receptor loci and thus survive and express an antigen 
receptor despite the defect. When these “leaking” lymphocytes expand, mice are 
not sufficiently immunocompromised anymore. This effect may occur due to 
immune stimulus caused by housing animals in an environment that is not 
pathogen-free (Bosma et al., 1983, 1988a; Nonoyama et al., 1993).  
However, Scid mice remain an important milestone in the research of xenograft 
models for human solid tumours (Phillips et al., 1989) but knowledge could be 
further advanced by the use of different strains of mice combining the Scid 
background. 
 
 
4.1.2.3 NOD/Scid Mice  
An important step in the development of immunodeficient mouse strains was the 
creation of the NOD/Scid mouse strain. By backcrossing the previously 
described spontaneously occurred Scid mutation (Prkdc mutation) onto the 
NOD/Lt strain background, a mouse strain with defective lymphoid function 
accompanied by reduced non adaptive immunologic function was created (Shultz 
et al., 1995). NOD/Lt mice harbour less functional NK cells (natural killer cells) 
(Kataoka et al., 1983; Serreze and Leiter, 1988), lack the complement system 
(Baxter and Cooke, 1993), and have defects in differentiation and function of 
antigen-presenting cells (Serreze et al., 1993). NOD/Lt mice show a high 
incidence of Type I insulin-dependent diabetes mellitus (IDDM), which is 
mediated by T cells. Backcrossing the Scid mutation onto this background, 
however, results in NOD/LtSz-Prkdcscid/J (NOD/Scid mice, Jackson Laboratory) 
that do not develop IDDM (Christianson et al., 1993) but carry a complex 
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immunodeficiency which is characterised through the absence of T and 
B lymphocytes, macrophages, and the complement system as well as less 
efficient NK cells. This results in an almost complete inability to reject human 
xenotransplants, as the strain provides a more permissive environment for human 
cells than traditional Nude or Scid mice. However, remaining NK cell activity 
should be erased through immune depletion (e.g. ionising radiation) to minimise 
the remaining chances of rejection of transplants (Vormoor et al., 2001). 
 
 
4.1.2.3 The established intravenous NOD/Scid mouse model 
In the early 2000s, Vormoor et al. published a novel preclinical model for 
ES/PNET in immunocompromised mice (Vormoor et al., 2001) shortly after first 
models for other types of solid tumours in NOD/Scid mice had been introduced 
(Bogenmann, 1996; Klein et al., 1997). The aim of this study was to engraft 
ES/PNET cell lines and primary material in vivo via i. v. transplantation of single 
cell suspensions into NOD/Scid mice.  
The motivation for the development of this model was the need to investigate the 
clonogenic frequency of ES/PNET cell lines and the proliferative ability of 
primary material in vivo as opposed to its often impaired growth in vitro. The 
NOD/Scid mice showed a pattern of disease spread similar to that found in 
patients with metastases in lung, kidney, ovary, bone, and s. c. tumours as well as 
involvement of bone marrow. Additionally, the time of tumour development of 
1-6 months for cell lines and 4-9 month for primary material in mice was 
comparable to the occurrence of relapse in patients.  
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It can be assumed that the result of this study was a potential model for 
investigations not only for the clonogenic frequency of ES/PNET but also for its 
hematogenic spread. The fact that pattern of and time to metastasise were very 
similar to the clinical situation showed that the late and very complex stages of 
metastasis of ES/PNET seem to be reproducible in this mouse model. These 
include spread via the blood stream, organ-specific homing, adhesion to the 
endothelial wall, transendothelial migration and tissue invasion through 
chemotaxis as well as proliferation and the potential of self-renewal, and 
induction of angiogenesis. This proves as well that the interaction between 
human tumour cells and the specific microenvironment of the different organs of 
the mouse is sufficiently conserved. 
Until now this model has been used successfully for different investigations on 
treatment opportunities and biological mechanisms of metastasis (Hotfilder et al., 
2002; Staege et al., 2004; Hu-Lieskovan et al., 2005a). 
Taking the advantages of this model into account, NOD/scid mice were chosen 
for studies of the metastasis of ES/PNET and to obtain different organ-specific 
tumours for further investigations. Since the development of this model the even 
more immunodeficient mouse strains NSG has been developed which were not 
available at the time (Shultz et al., 2005). NSG mice were used for the 
development of an orthotopic model for bone malignancies and are described in 
chapter 5.  
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4.1.3 The principles of expression profiling 
Sequencing of the human genome has been a major breakthrough for biomedical 
research (McPherson et al., 2001; International Human Genome Sequencing 
Consortium, 2004). Together with new techniques of functional genomics it is 
now possible to perform global analyses of the expression of thousands of genes 
(Eisen and Brown, 1999) and to understand complex molecular processes 
involved in the development and progression of diseases such as cancer. During 
the years that expression profiling was available and got more and more 
important, microarray analysis has become the preferably used technique as it is 
a straightforward approach which does not require the sequencing of DNA. An 
alternative which offers the advantage of faster results is RNA-Seq (RNA 
sequencing). However, this method is a lot more expensive than microarrays at a 
comparable resolution of accuracy.  
Thus, research could be performed to investigate gene profiles that correlate with 
a metastatic phenotype of tumour cells (Hynes, 2003). These profiles did not 
only discover genes responsible for the general ability of metastasis in specific 
tumours (van ’t Veer et al., 2002), but furthermore identified clones within 
tumours and tumour cell lines that prefer specific organs as a site of metastasis 
(Kang et al., 2003). It may well be that solid tumours are maintained from rare 
cells within the tumour that have tumour initialising abilities. This is also the 
case in hematologic malignancies and may be accountable for metastasis of other 
malagnancies as well (Tu et al., 2002). 
The analysis of different tumour systems, such as non-small cell lung cancer 
(Diederichs et al., 2004), breast cancer (Kang et al., 2003) and melanoma (Clark 
et al., 2000) has proven that there are organ-specific features driving metastasis 
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and this may give hints on the cellular mechanisms of organ-specific metastasis 
in general.  
Gene microarrays represent a high throughput technology, which allows for the 
identification and quantification of thousands of genes from multiple samples in 
parallel that have pre-defined characteristics such as treatment versus no 
treatment (Mocellin and Rossi, 2007). The important advantages of this 
technique are 
 
 the possibility to discover new genes and further investigate their 
functions. 
 the opportunity to clarify gene regulation and regulatory networks. 
 the chance to facilitate and improve diagnosis and prognosis by 
identification of disease- and stage-specific gene expression profiles. 
 
Southern blotting is the technique, which led to the development of microarrays. 
This method requires the attachment of fragmented sample-DNA to a substrate. 
The DNA of the known gene of interest is then given onto the prepared substrate. 
This tests, whether the gene of interest is contained within the sample.  
The underlying concept of microarray technique using GeneChips® is 
straightforward (see Figure 4.2). Briefly, RNA is isolated from cells or tissue, 
cDNA is synthesised, and biotin-labelled cRNA is generated in an IVT (in vitro 
transcription) reaction to obtain the target. This is fragmented and hybridised to 
the probes attached to the solid matrix of the microarray. The microarray with the 
hybridised sample is stained with PE-conjugated (phycoerythrin) streptavidin 
and scanned by the laser scanner of the system unit used. GeneChips® contain 
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several different 25-mer oligonucleotides matching one gene. Additionally, every 
oligonucleotide comes with a negative control containing a mismatch. From 
these match- and mismatch-oligonucleotide sets expression of the gene of 
interest can be derived and expression values of the different samples can 
subsequently be compared and analysed to obtain biological information (Staal et 
al., 2003). 
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Figure 4.2: Scheme for the workflow of expression analysis using an Affymetrix 
GeneChip®. RNA is extracted from cells or tissue, cDNA is produced and in an IVT reaction 
cRNA is created and biotinylated (target). After fragmentation the template is hybridised to the 
probes on the GeneChip®, the chip is stained and finally scanned using a laser scanner. 
 
 
Although, the human genome has been sequenced it still remains un-interpreted 
to a great extent and even the exact number of genes encoded is still unknown. 
Thus, analysis of expression profiling can only be an approximation and there 
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will always be unknown transcripts appearing in expression profiles that cannot 
yet give any biological information without further investigations on the function 
of that very gene.  
 
 
4.1.3.1 Variations of gene expression data 
 Affymetrix oligonucleotide arrays have several advantages. The most important 
one is that several probes are used for one transcript. This leads to more reliable 
data with less variation. However, one of the major problems examining global 
gene expression is the reliability of resulting data at the lower end of the 
confidence scale. This is the case when the signal for a probe is extremely weak, 
or to the other extreme very saturated. It also has to be taken into account that 
fold changes in expression of transcribed genes compared between different 
samples (in this case parental cell line and mouse-derived organ-specific 
subclones) might not reflect the importance and emphasis of a down-stream 
occurring effect in biological pathways. For example, small changes on transcript 
level can be amplified through intracellular signalling pathways but may not be 
detected by the analysis of the expression arrays due to the set threshold of fold 
change (in this study 2-fold). However, it is likely that high fold changes 
detected in gene expression experiments have an impact in the cell and thus are 
important for the undertaken investigations. 
Another drawback is that the sensitivity of oligonucleotide arrays has been found 
to differ between single arrays and the different platforms. This might be 
responsible for the mismatch between collected gene expression data from 
various studies handicapping meta-analysis of in theory comparable data.  
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4.1.3.2 Statistical and biological significance 
Two types of replicates for gene expression microarray experiments ensure that 
collected data is statistically and biologically significant; these are technical and 
biological replicates. On the one hand, technical replicates are applied to 
determine variation of preparation of RNA samples, handling and its 
hybridisation onto the microarray GeneChip. On the other hand, biological 
replicates are achieved through testing of different samples derived from 
repeated experiments.  
The Affymetrix platform is very well standardised leading to the biological 
variation outweighing any technically caused variation. Thus, only biological 
replicates had to be used in this set of experiments  
 
 
4.2 Aims 
The principle aim of this component of the project was to investigate cellular 
mechanisms of organ-specific metastasis in ES/PNET. 
The working hypothesis was that patients with pulmonary metastases and 
patients with osseous metastases have different prognosis because the cells 
initiating the metastases have a different biological properties. The heterogeneity 
of ES/PNET cell lines and the resulting subclones with organ-specific metastasis 
could correlate with differences in expression of genes leading to organ-specific 
expression patterns. The identification and characterisation of these genes could 
potentially give insight about mechanisms pertaining to organ-specific metastasis 
and thus facilitate a better understanding of clinical differences between 
pulmonary and osseous metastasis. Furthermore, new targets for molecular 
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therapy strategies could be identified to improve diagnosis, treatment and 
prognosis of ES/PNET. 
 
Concluding, the specific aims were: 
 to isolate ES/PNET subclones with preferential tendency to metastasise to 
specific organs. 
 to identify organ-specific gene expression signatures (lung versus bone 
versus bone marrow). 
 
 
4.3 Materials and Methods 
Most work for this part of the thesis in hand was performed at the Westfälische 
Wilhelms-University and University Hospital Münster, Germany. 
 
4.3.1 Tracer preparation and positron emission tomography (Münster) 
Tracer preparation [18F]fluoride was performed using an RDS 111e cyclotron 
(CTI, Knoxville, USA) according to Wieland et al. (Wieland et al., 1989). 
Subsequently, FDG was synthesised as previously described (Hamacher et al., 
1986).  
PET scans were performed as previously described (Franzius et al., 2006). The 
scanning was performed by a service unit of the research department of the 
University Hospital Münster which uses the high-resolution multi-wire chamber 
animal PET camera quadHIDAC (Oxford Positron Systems Ltd, Oxford, UK).  
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Mice were starved overnight, anaesthetised and handled as described before 
(3.6.1 and 3.6.3). One hour after i. v. injection of approximately 10MBq 
18F-FDG mice were scanned for 15 minutes. The FOV was 28cm axially and 
17cm in diameter. The volumetric spatial resolution was 1.09mm3 (using filtered 
back projection reconstruction) and constant over the whole FOV. The absolute 
sensitivity in the centre of the FOV was 18 cps/kBq. Whole-body emission 
images were reconstructed by the iterative OPL-EM algorithm, which offers an 
even higher spatial resolution of 0.7 mm full-width at half-maximum (FWHM). 
 
 
4.3.2 Isolation of organ-specific subclones from metastases 
Metastases were either localised by PET scanning or during dissection of mice. 
To achieve isolation of organ-specific metastases, mice were euthanized, 
dissected and metastases of the lung and bones as well as bone marrow flushes 
were collected in pre-warmed medium within a 50ml reaction tube and further 
treated as described before (see section 3.6.9).  
Subsequently, subclones were cultivated along with the routine cell culture. 
Remaining mouse cells in the cultures died very rapidly so that subclone-cells 
could be frozen down as soon as the small culture flask was confluent. Therefore, 
cell pellets of 5x106 cells were aliquoted in 1.5ml reaction tubes and frozen in 
liquid nitrogen. Cells were stored at -80°C until RNA was isolated for microarray 
analysis (see chapter 3.3.4). For the validation of the quality of RNA see chapter 
4.3.3. 
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4.3.3 Expression arrays 
Microarrays were performed by the IZKF (Interdisziplinäres Zentrum für 
Klinische Forschung, Münster, an institutional research facility of the Medical 
Faculty of the Westfälische Wilhelms-University, Münster). 
The IZKF is an Affymetrix Core Laboratory using the Agilent Bioanalyzer 2100 
to control the quality of the sample RNA. The unit separates the sample using 
capillary electrophoresis. The Agilent Software offers an electropherogram 
(fluorescence against time), a "gel-like image" and is able to automatically judge 
about the quality. Therefore a database for RNA-analysis is used that offers 3000 
electropherograms that were judged “by hand”.  
The Affymetrix GeneChip System® 3000 is used for the entire workflow of 
expression analysis. 
 
 
4.3.3.1 Affymetrix U133 plus 2.0 array 
For the analysis of gene expression the Affymetrix GeneChip® Human Genome 
U133 Plus 2.0 Array from Affymetrix (Affymetrix Inc., Santa Clara, USA) was 
used. This GeneChip® covers 1,300,000 unique oligonucleotide features which 
account for over 47,000 transcripts and variants representing approximately 
39,000 of the best characterized human genes. 
Transcripts were derived and selected from GenBank®, dbEST, and RefSeq and 
sequence clusters were created from the UniGene database (Build 133, April 20, 
2001). The selection was then refined by analysis and comparison with a number 
of other publicly available databases. Further information is available on the 
Affymetrix Inc. homepage, www.affymetrix.com. 
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4.3.3.2 Probe sets on the GeneChip 
In situ synthesised probes on the GeneChip are 25 nucleotides long. This ensures 
the specificity. For each transcript a probe set is created. This set consist of 11-16 
probe pairs to allow multiple and independent measurements. A probe pair is 
made up of a perfect match and a mismatch, which contains a single mismatched 
base. The mismatch probe functions as an internal control to quantify levels of 
non-specific hybridisations of perfect match. The intensity of hybridised 
mismatch is subtracted from the intensity of the hybridised perfect match probe 
to be able to control and correct for the noise in the array results. 
 
 
4.3.3.3 Planning the experiment and replicates 
To be able to analyse the expression of ES/PNET derived from different organs, 
mice were transplanted with cells of different ES/PNET cell lines as mentioned 
before (see Figure 4.3 and chapter 3.6.3). Mice developed different tumours, 
which were isolated during dissection. Due to the isolation of tumours from the 
comparable organ in multiple mice it was possible to perform the experiment 
with biological replicates. Technical replicates (determining the variation in 
handling and hybridisation onto the GeneChip) were not necessary as the 
microarray platform used is very well standardised and validated. This means 
that the biological variation of samples outweighs the technical variations. 
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Figure 4.3: Scheme of transplantations and acquired metastases from primary and 
secondary mice.  
 
Figure 4.3 shows the experimental plan with transplantation of cells, aseptic 
removal and isolation of metastases, re-cultivation of cells and secondary 
transplantation into further experimental animals with subsequent removal of 
metastases from secondary mice. 
 
 
4.3.3.4 Sample preparation 
RNA was isolated using the Qiagen kit as described before (3.3.4 and 3.3.5). 
Ideally, the amount of 5-15µg RNA of the different samples was sent in. The 
RNA had to be resuspended in ddH2O and delivered to the IZKF at 4°C. Further 
steps were carried out by this institution as described in 4.3.3. 
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In total, 19 microarrays were performed with each two replicates of the parental 
cell lines VH-64 and TC-71 from which the subclones were derived.  
 
 
4.3.4 Analysis of expression arrays 
Raw data acquired directly from the microarray-chips was analysed using 
GeneSpring GX 11 (Agilent Technologies Inc., Santa Clara, USA) and 
BioConductor (Gentleman et al., 2004). Analysis was completed in cooperation 
with the bioinformatics department of Newcastle University. 
Data was imported from the CEL files (raw data from chip scanning) and 
normalised with RMA (Robust Multi-array Average). Therefore, raw intensity 
values were background corrected, log2-transformed and then quantile 
normalized (Wu and Irizarry, 2005).  
Data were filtered using MAS5 P/M/A calls (Microarray suite 5). Probe sets 
were discarded if they did not have present or marginal calls in all samples in any 
given experimental condition. 
Finally, gene lists were filtered due to fold change. Transcripts whose abundance 
were significantly altered (p<0.05) after 100 permutation tests on the class labels 
and an absolute fold change greater than 2-fold were defined as differentially 
expressed and were therefore further analysed.  
Where applicable, differences between experimental groups were determined 
using Rank Products (Breitling et al., 2004) and further analysed in GeneSpring.  
Rank Products analysis provides a straightforward and statistically stringent way 
to determine the significance level for each transcript. It allows for a flexible 
control of the false-detection rate and family-wise error rate in the multiple 
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testing situation of a microarray experiment. This technique has been shown to 
reliably identify differentially expressed transcripts that do not originate from a 
sophisticated statistical model but rather from an analysis of biological 
reasoning. 
 
 
4.3.5 Further biological analysis 
For further, biological analysis of the normalised and processed data these were 
exported into EXEL (Microsoft Corp., Redmond, USA). Resulting gene list were 
then analysed through the use of Ingenuity Pathway Analysis 8.0 (IPA; Ingenuity 
Systems Inc., Redwood City, USA; www.ingenuity.com). IPA is a web-based 
software application, which allows the analysis and understanding of expression 
data in a biological context. It is backed by the Ingenuity Knowledge Base of 
highly structured, detail-rich biological and chemical findings. It is the largest 
knowledge base of its kind, with millions of findings generated from the full text 
literature and is updated on a weekly basis. 
In more detail, IPA Core Analyses were performed on the comparison lists 
generated in GeneSpring containing the differentially regulated transcripts. This 
delivers a rapid assessment of the signalling and metabolic pathways, molecular 
networks, and biological processes that are most significantly perturbed in a 
dataset of interest. 
IPA Core Analysis standard settings were used, including direct and indirect 
relationships with a maximum of 35 molecules per network and 25 networks per 
analysis.  
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IPA uses computational algorithms to identify local networks that are particularly 
enriched for the input genes, which are called focus genes by the IPA software. 
Furthermore, IPA uses a Fisher's exact test to determine which pathways 
(canonical pathways, toxicity pathways and biological functions) are 
significantly linked to the input gene set compared with the whole Ingenuity 
Knowledge Base. 
 
 
4.3.6 Microarray validation experiment using qRT-PCR 
Genes selected for validation of the microarray experiments via qRT-PCR are 
listed in Table 4.1. 
 
 
Table 4.1: Details of qRT-PCR primers from Sigma.  
Gene Forward primer (5’ – 3’) Reverse Primer(5’ – 3’) 
ALDH1A1 AGCTCTGCCAGGTAGAAGAAGGA ATCCAATCTGAAAAGCCTGTCTTG 
APOC1 GGACAAGGCTCGGGAACTC TGAAAACCACTCCCGCATCT 
CXCR4 CTGAGAAGCATGACGGACAA TGGAGTGTGACAGCTTGGAG 
MEG3 ATCCCGGACCCAAGTCTTCT CACGTAGGCATCCAGGTGATG 
NRG1 GTCCACTGCGCCATCCTT (exon 1) 
CCCCGATTGAAAGAGATGAAAA 
(exons 2/3) 
TTGTCCCAGTGGTGGATGTAGA 
VCAN CCGGTGCTTAGGAAATGGAA TTCATAGAATAAGTCCTTTGGTATGCA 
 
The exact method for designing of qRT-PCR primers and the qRT-PCR itself are 
described in chapter 3.3.13. 
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4.4 Results 
 
4.4.1 Intravenous transplantations and re-transplantation of subclones 
To be able to isolate organ-specific metastases from immunocompromised mice, 
the mouse model previously established by Vormoor and co-workers was 
employed (Vormoor et al., 2001). Mice were scanned on a regular basis using the 
PET-technique. To get a full and reliable picture of metastasis and to isolate 
occurring metastases, mice were dissected and screened macroscopically. For 
this project, FDG-PET did not prove to be the technique of choice as a lot of 
metastases were not detected in sequential PET imaging but were discovered 
when mice were finally euthanized and dissected due to their poor general 
condition. In some cases, metastases were visible when the sections of the PET 
scan were not summed up but rather examinated individually (see Figure 4.4). 
Accumulation of FDG in the heart muscle continued to prevent the appearance of 
lung metastases on PET images.  
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Figure 4.4: Representative PET images of a mouse transplanted intravenously with the cell 
line VH-64. A, image of all sections overlaid, accumulation of FDG in the heart (black arrow) 
prevents the appearance of lung metastases; B, one section alone allows visibility of lung 
metastases.  
 
 
Mice that died due to transplantation-related toxicity within 3 weeks of 
transplantation (n=3) or due to unexpected circumstances, for example during 
PET scanning (n=13), were excluded from the analysis. The high number of 
unexpected deaths of experimental animals seems to result from disadvantageous 
housing conditions due to building activity on site. This might as well have 
accounted for decreased breeding success and resulting small transplantation 
numbers. 
The remaining mice are listed in Table 4.2. Due to resulting small numbers there 
was insufficient statistical power to analyse tumour formation.  
After i. v. transplantation of VH-64 and TC-71 into NOD/Scid mice metastases 
from lung, bone and bone marrow could be removed. From these metastases 
subclones were isolated and cultivated and subsequently re-transplanted into 
NOD/Scid mice.  
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Table 4.2: Ewing tumour formation in intravenously transplanted NOD/Scid mice. VH-64, 
TC-71 are ES/PNET cell lines; KM006, bone marrow derived subclone from mouse 006; K006, 
bone derived subclone from mouse 006; L006, lung derived subclone from mouse 006; BD-99, 
patient derived cell line. Mouse numbers in brackets had to be excluded from the study. 
Cell lines Mouse numbers Number of transpl. 
cells 
Tumour 
formation 
VH-64 (001), (002), 003, 004, (005), 
006 
5 x 106 2/3 
TC-71 (107), (108), 109, (128), (129), 
130, 131, 132, (133) 
2 x 106 3/4 
KM006 r034, (r035), (r036) 5 x 106 1/1 
K006 (r040), (r041), (r042), r052, 
(r053), r054 
5 x 106 2/2 
L006 r043, (r044), r045, (r049), 
r050, r051 
4.5-5 x 106 2/4 
BD-99 455, 456 7 x 105 0/2 
 
 
Re-transplanted organ-specific subclones developed in different organs (see 
Table 4.3). Although only relatively small numbers of transplantations were 
analysed it was obvious that the pattern of metastasis correlated very well with 
results reported previously (Vormoor et al., 2001). Specifically, all mice showed 
metastasis to the lung. Involvement of the bone only occurred after 
transplantation of VH-64 and re-transplantation of the bone-derived subclone 
K006. In total, nine out of ten mice developed bone marrow metastases. Cells of 
the re-transplanted lung metastases L006 were further able to establish a 
subcutaneous and an intraperitoneal metastasis.  
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Table 4.3: Pattern of metatstasis in tumour baring NOD/Scid mice. SC, subcutaneous 
tumour; IP, intraperitoneal tumour. 
Cell 
lines 
Mice with 
tumours 
Lung Bone Bone 
marrow 
Kidney SC IP 
VH-64 004, 006 2/2 2/2 2/2 0/2 0/2 0/2 
TC-71 130, 131, 132 3/3 0/3 2/3 0/3 0/3 0/3 
KM006 r034 1/1 0/1 1/1 0/1 0/1 0/1 
K006 r052, r054 2/2 1/2 2/2 1/2 0/2 0/2 
L006 r043, r051 2/2 0/2 2/2 0/2 1/2 1/2 
 
 
Analysis of the pattern of metastasis as well as the time to occurrence of clinical 
symptoms suggested that re-transplanted subclones derived from the lung or the 
bone marrow led to tumours in a shorter period of time. The difference in growth 
comparing lung-derived subclone to the parental cell line was statistically 
significant. In contrast, bone-derived subclones led to metastases in a comparable 
time to cell lines (see Figure 4.5). Analysis of the pattern of metastases for 
subclones shows additionally to the classically occurring lung, bone and bone 
marrow metastases subcutaneous and intraperitoneal as well as kidney 
involvement (see Table 4.3). 
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Figure 4.5: Mean time in days from transplantation to reaching of limits of the protocol. 
Asterisk marks P <0.050 in the comparison of cell line VH-64 to the deriving subclones (one way 
ANOVA, Bonferroni); L006, lung metastasis derived from mouse 006; KM006, bone marrow 
metastasis derived from mouse 006; K006, bone metastasis derived from mouse 006.  
 
 
Therefore, these data suggest that the growth pattern as well as the shortened 
time to metastasis marks a more aggressive growth of subclones. However, 
taking the small transplantation numbers into account (due to breading problems 
on site and thus very low numbers of animals for the experiment) these data are 
not statistically robust and can only suggest a trend (see Table 4.3 and 
Figure 4.5). 
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4.4.2 In vitro characterisation of tissue specific subclones 
The isolated subclones were validated as arising from the transplanted cell lines 
as well as further examined in vitro to characterise them and compare them to the 
parental cell lines. 
 
 
4.4.2.1 Validation of clones – flow cytometry and PCR of fusion transcripts 
All isolated secondary and tertiary subclones could be validated as human 
ES/PNET cells and therefore derived from the initially transplanted human cell 
line.  
Therefore, the well-established ES/PNET marker CD99 was used in flow 
cytometry. All isolated metastases were positive for the surface-marker (see 
Figures 4.6 and 4.7). 
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Figure 4.6: CD99 staining and flow-cytometric control of subclones derived from VH-64 
transplanted mice. Additionally to the unstained and CD99-stained cells of the cell line VH-64 
analysis of one representative subclone (Lr034) is shown. The first row shows forward and side 
scatter dot plots. Cells in P1 were analysed for their CD99-positivity which is shown in 
histograms in the second row. All subclones were positively tested for CD99 with more than 90% 
of cells being positive (above 103).  
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Figure 4.7: CD99 staining and flow-cytometric control of subclones derived from TC-71 
transplanted mice. Additionally to the unstained and CD99-stained cells of the cell line TC-71 
analysis of one representative subclone (L130) is shown. The first row shows forward and side 
scatter dot plots. Cells in P1 were analysed for their CD99-positivity which is shown in 
histograms in the second row. All subclones were positively tested for CD99 with more than 90% 
of cells being positive (above 103). 
 
 
Additionally, all subclones were positively tested for the corresponding fusion 
transcripts by RT-PCR. Cells of the parental cell line TC-71 and subclones 
derived from this cell line harboured the EWS-FLI1 type 1 transcript, which 
results from the fusion of EWS exon 7 in frame with FLI1 exon 6. VH-64 cells 
and deriving subclones harboured the EWS-FLI1 type 2 transcript occurring 
through fusion of EWS exon 7 in frame with FLI1 exon 5. The resulting size 
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difference of the PCR products was distinguishable after agarose gel 
electrophoresis.  
 
 
4.4.2.2 Colony assay 
Colonies of the two cell lines VH-64 and TC-71 showed a slight difference in 
size. VH-64 colonies were smaller, which might be due to their smaller cell size 
(Figure 4.8; see also chapter 4.4.2.3). There was no difference visible between 
the parental cell lines and their derived subclones. 
 
 
 
Figure 4.8: Appearance of colonies. A cell line VH-64, B cell line TC-71. Micrographs show 
the appearance of colonies in methylcellulose gels at x20 magnification. 
 
 
No difference in clonogenicity of the parental cell lines VH-64 and TC-71 could 
be observed (data not shown). 
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4.4.2.3 Cytospins 
Representative subclones were brought onto glass slides using the technique of 
cytospins to be able to analyse cells microscopically (Figure 4.9). Comparing 
cells of the cell lines VH-64 and TC-71 against each other, it is obvious that 
TC-71 cells and cells derived from this cell line are slightly bigger than VH-64 
cells and its subclones.  
However, all cells showed a relative high number and percentage of vacuoles 
also indicating a high metabolic activity and rate of replication. 
 
 
 
Figure 4.9: Microscopic examination of cytospins. A cell line VH-64, B cells of bone-derived 
subclone K006 after VH-64 transplantation, C cell line TC-71, D lung-derived subclone L131 
after TC-71 transplantation. Magnification x64. 
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4.4.2.4 Further in vitro investigations 
No differences in the proliferation of cell lines and their subclones could be 
observed in vitro in a MTT viability assay (data not shown).  
Cell cycle analysis also did not reveal any changes comparing the organ-specific 
subclones against the parental cell lines (data not shown).  
 
 
4.4.3 Expression profiling 
Expression profiling was performed on selected subclones in comparison to the 
parental cell line. Microarrays were performed on cell lines VH-64 and TC-71 
and 17 derived subclones. The project focussed on VH-64 and derived subclones 
and these could be analysed with statistical significance (see Tables 4.4 and 4.8). 
Due to small numbers of experimental mice and thus resulting small numbers of 
subclones it was not possible to include the second cell line TC-71 and derived 
subclones into the analysis.  
 
 
4.4.3.1 Analysis of comparisons between organ-subclones directly 
The analysis of microarrays of the different organ-specific subclones against 
each other was performed using the RankProd approach and subsequently 
GeneSpring and IPA (see also chapter 4.3.4) to be able to identify gene profiles 
that result from a more biological reasonable background. The performed 
comparisons are listed in Table 4.4. 
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Table 4.4: Comparisons of gene expression between the different VH-64-derived 
organ-specific subclones. 
Name of comparison 1. group 2. group 
Lung vs. bone  K004, K006, Kr054 L004, L006, L062, Lr034, 
Lr043, Lr051, Lr052, Lr054 
 
Bone marrow vs. bone K004, K006, Kr054 KM006, KM062, KMr043, 
KMr052, Kr054 
 
Lung vs. bone marrow KM006, KM062, KMr043, 
KMr052, Kr054 
L004, L006, L062, Lr034, 
Lr043, Lr051, Lr052, Lr054 
 
 
A comparison of “Lung vs. bone” metastases revealed that 314 genes were 
significantly higher expressed in lung than in bone while only three genes were 
significantly higher expressed in bone. “Bone marrow vs. bone” analysis of 
expression showed that 38 genes were significantly higher and five genes were 
less expressed in bone marrow compared to bone subclones. Comparing “Lung 
vs. bone marrow” metastases, 23 genes were recognised to be higher expressed 
in lung.  
Possible organ-specific patterns for the different metastases could be filtered out 
of the three comparisons. This was achieved by looking at the differentially 
expressed gene profiles in more detail and comparing them against each other 
(see Table 4.5). 
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Table 4.5: Genes differentially expressed in more than one comparison. Values are 
fold-change values. Bm, bone marrow. Genes in bold were especially notable. 
Gene Description Lung 
vs. bone 
Lung 
vs. bm 
Bm vs. 
bone 
Specific 
for 
AK1 adenylate kinase 1 -2.029  -2.923 bone 
C9ORF16 chr 9 open reading frame 16 -2.486  -3.318 bone 
CAMK2N1 calcium/calmodulin-dependent 
protein kinase II inhibitor 1 
-2.377  -2.990 bone 
CLPTM1 cleft lip and palate associated 
transmembrane protein 1 
-2.026  -3.450 bone 
CXCL10 chemokine (C-X-C motif) ligand 
10 
-5.101  -4.558 bone
FBXW2 F-box and WD repeat domain 
containing 2 
-2.727  -3.302 bone
FCF1 FCF1 small subunit (SSU) 
processome component homolog 
-2.323  -3.791 bone
GAMT guanidinoacetate 
N-methyltransferase 
-2.268  -2.337 bone
GAS1 growth arrest-specific 1 -2.690  -3.143 bone
GDF10 growth differentiation factor 10 -3.028  -3.929 bone
HERC6 hect domain and RLD 6 -2.638 -2.050  lung 
IFI44 interferon-induced protein 44 -4.726  -2.855 bone
IFI44L interferon-induced protein 44-like -7.259  -4.433 bone
IFI6 interferon, alpha-inducible protein 
6 
-3.175  -3.726 bone
KRT8 keratin 8 -2.113  -2.979 bone
MDFI MyoD family inhibitor -2.176  -2.846 bone 
MMP1 Matrix metallopeptidase 1 5.321 -2.999 15.955  
MRPL2 mitochondrial ribosomal protein 
L2 
-2.271  -3.014 bone 
OASL 2'-5'-oligoadenylate synthetase-
like 
-2.801 -2.138  lung 
PDGFC platelet derived growth factor C -3.283  -3.508 bone
PRCC papillary renal cell carcinoma -2.630  -2.986 bone
PTP4A1 protein tyrosine phosphatase type 
IVA, member 1 
-2.946  -3.137 bone
RAB4A member RAS oncogene family 5.103  4.933 bone
RAD23B RAD23 homolog B  -2.817  -3.752 bone
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Table 4.6 continued. 
Gene Description Lung 
vs. bone 
Lung 
vs. bm 
Bm vs. 
bone 
Specific 
for 
RPL23 ribosomal protein L23 -2.975  -3.459 bone
RPS11 ribosomal protein S11 4.987  7.652 bone
RSAD2 radical S-adenosyl methionine 
domain containing 2 
-2.177 -2.554  lung 
SLC16A3 solute carrier family 16, member 3  -2.338  -3.424 bone
SPAG16 sperm associated antigen 16 -3.335  -3.455 bone
UBE2M ubiquitin-conjugating enzyme 
E2M 
-2.452  -3.142 bone
ZYX Zyxin -2.888  -3.138 bone 
 
 
The list shows 27 genes that might be specific for bone. Of these, 25 are less 
expressed in bone than in lung and bone marrow while two are higher expressed 
in bone than in the other metastases. Three genes were significantly up-regulated 
in lung metastases compared to bone and bone marrow metastases. 
Several genes were especially noticeable due to their fold changes in the different 
comparisons of gene expressions. The genes CXCL10 (chemokine (C-X-C 
motif) ligand 10), GDF10 (growth differentiation factor 10), IFI44 (interferon-
induced protein 44) and IFI44L (interferon-induced protein 44-like) were down-
regulated in metastases isolated from the bone while the genes RAB4A (member 
RAS oncogene family) and PRS11 (ribosomal protein S11) were exclusively up-
regulated in metastases taken from the bone. 
The genes HERC6 (hect domain and RLD 6) and RSAD2 (radical S-adenosyl 
methionine domain containing 2) were up-regulated in lung metastases in 
comparison to bone and bone marrow metastases.  
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MMP1 (matrix metallopeptidase 1) showed very high expression values in 
especially bone-derived subclones and also lung metastases in comparison to 
bone marrow metastases.  
 
 
4.4.3.2 Analysis of comparisons between VH-64 and the derived subclones 
As described before, GeneSpring-derived comparative gene expression lists were 
analysed using IPA. A core analysis with default settings was performed for each 
comparison (for subclones included into the different comparisons see Table 
4.6). The aim of these comparisons was to identify a sub-set of genes, which may 
be responsible for imprinting through the in vivo microenvironment.  
 
 
Table 4.7: Comparisons of gene expression between the parental cell line VH-64 and 
deriving subclones. Microarrays from VH-64 were performed in biological replicates. 
Name of created comparison Parental line Subclones 
VH-64 vs. lung metastases VH-64 (2x) L004, L006, L062, Lr034, 
Lr043, Lr051, Lr052, 
Lr054 
 
VH-64 vs. bone metastases VH-64 (2x) K004, K006, Kr054 
 
VH-64 vs. bone marrow metastases VH-64 (2x) KM006, KM062, KMr043, 
KMr052, Kr054 
 
 
In more detail, the numbers of up- and down-regulated genes listed for these 
comparisons varied. In the comparison of “VH-64 vs. lung metastases” the 
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expression of 523 genes was significantly up-regulated (> 2-fold) in lung 
metastases and for three genes was down-regulated. The comparison of “VH-64 
vs. bone metastases” revealed up-regulation of the expression of 40 genes and 
down-regulation for six genes. Comparing “VH-64 vs. bone marrow metastases” 
87 genes were discovered to be up-regulated, while three genes were down 
regulated.  
The three comparisons showed 15 genes in common that were up-regulated and 
two genes that were down-regulated (see Table 4.7). When comparing the fold 
change of expression most genes showed values in the same range. Four genes 
have to be mentioned because their values were noticeable. CTCFL 
(CCCTC-binding factor (zinc finger protein)-like) showed an 6.9-fold up-
regulation in bone marrow metastases, while it’s up-regulation in metastases 
taken from the bone was nearly three times higher with a change of 18.7-fold and 
higher for lung metastases with a change of 10.3-fold.  
A very high difference in fold changes for the different organ-specific subclones 
was also observable for RSAD2 (radical S-adenosyl methionine domain 
containing 2). While the fold change of bone and bone marrow metastases 
compared to the parental cell line was 6.0 and 5.1, respectively, it was 13.0 when 
comparing lung metastases against VH-64.  
Furthermore, the genes RNF128 (ring finger protein 128) and TEX19 (testis 
expressed 19) were striking with extreme fold-changes in down-regulation 
compared to the parental cell line.  
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Table 4.8: Fold changes of genes differentially expressed in the organ-specific subclones in 
comparison to the parental cell line VH-64. Positive values indicate up-regulation, negative 
values indicate down-regulation in the subclones. Bm, bone marrow. Genes marked with ‘D’ 
were represented in duplicate. Genes in bold were especially noticeable. 
Gene Description Mean fold change 
VH-64 vs. lung 
metastases 
VH-64 vs. bone 
metastases 
VH-64 vs. bm 
metastases 
AHNAK AHNAK nucleoprotein 2.843 2.716 2.384 
CTCFL CCCTC-binding factor 
(zinc finger protein)-like 
10.296 18.692 6.938 
CTSK cathepsin K 3.060 2.791 3.657 
DLX1 distal-less homeobox 1 3.744 5.284 3.939 
DLX2 distal-less homeobox 2 5.139 6.099 4.498 
FAM26F family with sequence 
similarity 26, member F 
7.425 7.779 6.126 
KCTD12 potassium channel 
tetramerisation domain 
containing 12 
4.593 5.027 3.649 
PPP1R9A protein phosphatase 1, 
regulatory (inhibitor) 
subunit 9A 
5.635 5.262 5.214 
RNF128 ring finger protein 128 -10.207 -11.701 -14.697 
RSAD2 radical S-adenosyl 
methionine domain 
containing 2 
13.027 5.985 5.100 
SOX11 SRY (sex determining 
region Y)-box 11 
3.970 4.589 3.543 
SPHK1 sphingosine kinase 1 3.216 2.269 3.226 
TANC2 tetratricopeptide repeat, 
ankyrin repeat and 
coiled-coil containing 2 
4.846 3.460 4.040 
TBXA2R thromboxane A2 receptor 3.331 4.393 2.760 
TEX19 testis expressed 19 -17.495 -18.247 -17.159 
TP53I3 tumor protein p53 
inducible protein 3 
3.375 3.240 3.492 
ZNF618 zinc finger protein 618 4.734 2.969 4.531 
 
 
 
Chapter 4 – Metastasis model for Ewing’s sarcoma in NOD/Scid mice 
137 
Furthermore, some genes were regarded as interesting due to their functions and 
due in some cases to very high fold-changes in expression. In detail, these were 
ALDH1A1 (Aldehyde dehydrogenase 1 family, member A1) with a fold-change 
of -7.1 and IL-8 (Interleukin-8) with a fold-change -15.2 in the comparison of 
“VH-64 vs. bone metastases”. Furthermore, in the comparisons of cell line 
against bone and lung NRG1 (Neuregulin 1) was differentially expressed with 
fold-change values of –8.6 and -7.5, respectively. VCAN (Versican) was up-
regulated in lung and bone marrow metastases with fold changes of 6.5 and 5.8, 
respectively. 
 
For the comparison of “VH-64 vs. lung metastases” the IPA core analysis 
revealed 143 canonical pathways that were most relevant based on the listed 
genes. For “VH-64 vs. bone metastases” IPA discovered 56 relevant canonical 
pathways and for the comparison of “VH-64 vs. bone marrow metastases” 161 
canonical pathways were displayed as relevant.  
The top canonical pathways for the comparisons of the parental cell line to the 
organ-specific metastases are listed in Table 4.9. 
 
 
 
 
 
 
 
Chapter 4 – Metastasis model for Ewing’s sarcoma in NOD/Scid mice 
138 
Table 4.9: Top Canonical pathways associated with the comparisons between VH-64 and 
the different organ-specific subclones. 
Canonical Pathways p-value Ratio 
VH-64 vs. lung metastases   
   Hypoxia Signalling in the Cardiovascular System 0.0002 11.8% 
   Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses 0.0077 8.1% 
   Granzyme A Signalling 0.0079 17.6% 
   Cardiomyocyte Differentiation via BMP Receptors 0.0093 15.8% 
   Activation of IRF by Cytosolic Pattern Recognition Receptors 0.0163 7.8% 
VH-64 vs. bone metastases   
   Neuregulin Signalling 0.0123 2.1% 
   Glycerolipid Metabolism 0.0140 2.1% 
   Airway Pathology in Chronic Obstructive Pulmonary Disease 0.0157 12.5% 
   Hepatic Cholestasis 0.0253 1.5% 
   Aryl Hydrocarbon Receptor Signalling 0.0261 1.4% 
VH-64 vs. bone marrow metastases   
   p53 Signalling 0.0087 3.3% 
   T Cell Receptor Signalling 0.0095 3.0% 
   Sphingosin-1-phosphate Signalling 0.0119 2,7% 
   Glioma Invasiveness Signalling 0.0266 3.6% 
   Estrogen-Dependent Breast Cancer Signalling 0.0313 3.1% 
 
 
Table 4.10 lists the biological and disease processes, which IPA discovered as 
most relevant to the gene lists of the comparisons.  
The most relevant molecular and cellular process listed for all three comparisons 
is “Cellular Development”. For the comparisons of lung and bone marrow 
metastases to the parental cell line the processes of “Cellular Growth and 
Proliferation” as well as “Cellular Movement” play a dominate role.  
“Cancer” as a disease process is listed with very low p-values for all three organ-
specific comparisons.  
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Table 4.10: Top biological functions of genes listed in the comparisons between VH-64 and 
the different organ-specific subclones. 
Biological and disease processes # molecules p-value 
VH-64 vs. lung metastases   
Diseases and Disorders   
   Developmental Disorder 25 0.0000-0.0490 
   Cancer 104 0.0007-0.0490 
   Reproductive System Disease 17 0.0022-0.0248 
   Infectious Disease 9 0.0025-0.0025 
   Respiratory Disease 9 0.0025-0.0025 
Molecular and Cellular Functions   
   Cellular Development 65 0.0000-0.0497 
   Cellular Growth and Proliferation 74 0.0000-0.0490 
   Cellular Movement 42 0.0000-0.0490 
   Cell Morphology 25 0.0003-0.0490 
   Cellular Assembly and Organisation 25 0.0003-0.0490 
VH-64 vs. bone metastases   
Diseases and Disorders   
   Cancer 5 0.0013-0.0098 
   Neurological Disease 4 0.0015-0.0292 
   Dermatological Diseases and Conditions 2 0.0020-0.0121 
   Developmental Disorder 1 0.0020-0.0020 
   Genetic Disorders 5 0.0020-0.0425 
Molecular and Cellular Functions   
   Cellular Development 9 0.0001-0.0482 
   Cell Cycle 3 0.0001-0.0463 
   Cell Morphology  5 0.0001-0.0482 
   Cellular Movement 6 0.0002-0.0482 
   Cellular Assembly and Organisation 4 0.0002-0.0311 
VH-64 vs. bone marrow metastases   
Diseases and Disorders   
   Cancer 23 0.0047-0.0415 
   Connective Tissue Disorders 1 0.0047-0.0047 
   Developmental Disorder 4 0.0047-0.0233 
   Genetic Disorders 10 0.0047-0.0415 
   Hematological Diseases 4 0.0047-0.0130 
Molecular and Cellular Functions   
   Cellular Development 12 0.0006-0.0450 
   Cellular Growth and Proliferation 5 0.0016-0.0233 
   Cellular Movement 8 0.0026-0.0415 
   Amino Acid Metabolism 1 0.0047-0.0047 
   Cell-To-Cell-Signalling and Interaction 5 0.0047-0.0187 
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4.4.3.3 Validation of microarray results with qRT-PCR 
Selected genes were used to validate the microarray results. ALDH1A1 as well 
as MEG3 showed differential expression when bone-derived subclones were 
compared with the parental cell line VH-64. Microarray results suggested up-
regulation of ALDH1A1 and down-regulation of MEG3. NRG1 was chosen due 
to a suggested down-regulation in bone- and lung-derived subclones. Due to 
microarray results APOC1 was down-regulated in bone marrow metastases. All 
genes were selected because a literature research revealed research results for 
their function in proliferation, growth and other supportive functions and 
appearance in other types of cancer. Results of the performed qRT-PCRs are 
displayed in Figure 4.10.  
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Figure 4.10: qRT-PCRs performed for the validation of the microarray experiment. Cell 
lines VH-64 and TC-71 as well as primary organ-specific subclones were tested for the 
expression of ALDH1A1, MEG3, NRG1 and APOC1. Values are displayed as fold changes 
relative to the according parental cell line. K004, K006 are bone-derived subclones; L004, L006, 
L062, L132, L131, L130 are lung-derived subclones; KM006, KM062, KM132 are bone marrow-
derived subclones.  
 
 
Although the same RNA samples were used for both experiments, fold-change 
values from qRT-PCR and microarrays cannot be directly compared as the 
methods are quite different and samples were handled in a different way.  
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For NRG1 and APOC1 TC-71 and -derived subclones from lung respectively 
bone marrow were tested additionally to VH-64 and derived subclones and 
showed the same trend as VH-64-derived subclones.  
All verified genes showed the same trend previously suggested by microarray 
results. For ALDH1A1 fold-changes derived from the qRT-PCR data suggest a 
knock-down in subclones compared to the parental cell line (K004, 0.19; K006, 
0.44). The qRT-PCR derived fold-changes for NRG1 in the VH-64-derived 
subclones varried with little variation from 0.28-fold to 0.5-fold (K004, 0.44; 
K006, 0.28; L004, 0.36; L006, 0.5; L062, 0.49). Down-regulation in the TC-71-
derived subclones is less obvious with values of 0.73-fold to 0.86-fold (L132, 
0.76; L131, 0.73; L130, 0.86).  
For MEG3 the two tested bone-derived subclones showed up-regulation (K004, 
50.6; K006, 3.63) compared to VH-64 but the values showed high variability. 
For APOC1 a suggested up-regulation in bone marrow could not be entirely 
verified as one of the VH-64-derived subclones showed a slight down-regulation 
in comparison to the parental cell line (KM006, 0.90; KM062, 2.13). For the 
only TC-71-derived bone marrow subclones the values was 1.06-fold.    
However, due to the preliminary character of the data derived from qRT-PCR, it 
is not possible to make a reliable statement about significance and variability of 
values. The qRT-PCR experiments would have to be repeated with more 
subclones derived from the different tissues investigated (lung, bone and bone 
marrow). 
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4.5 Discussion 
Using a previously established mouse model of ES/PNET metastasis it was 
possible to isolate organ-specific metastases (Vormoor et al., 2001). The initial 
hypothesis that subclones would develop a preferential tendency to metastasise to 
specific organs was not proven. It can only be assumed that after re-
transplantation of subclones cells derived from lung metastases were able to 
establish in lung and bone marrow as the re-transplanted bone marrow-derived 
subclone was as well. However, it was not possible to analyse these results 
statistically due to small experimental numbers (see Table 4.3).  
Analysis of the time to metastasis after re-transplantation of the lung-derived 
subclone showed that these cells were able to establish metastases in a 
significantly shorter period of time compared to the parental cell line and the 
bone-derived subclone. There was no difference between the cell lines VH-64 
and TC-71. These data suggest that subclones were selected in vivo for their 
aggressiveness and proliferation rates. However, in vitro analysis of subclones 
showed that there was no difference in growth behaviour, cell cycle or 
clonogenicity. Morphologically subclones of VH-64 and TC-71 appeared to 
contain slightly more vacuoles and therefore might have a slightly higher 
metabolic rate compared to the parental cell lines which might indicate a higher 
activity (see Figure 4.8).  
 
Expression profiling of cell lines and organ-specific subclones revealed a subset 
differentially expressed in all subclones compared to the parental cell line 
VH-64. This subset might be composed of genes that play a general role in 
metastasis of ES/PNET and that advance aggressiveness and proliferation of 
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cells. However, it remains possible that this subset might be influenced by the 
fact that metastases were taken back into culture after isolation from the mouse. 
Interesting candidate genes will have to be further analysed to clarify their role in 
metastasis of ES/PNET. Amongst these genes might be the two genes CTCFL 
and RSAD2 which were extremely up-regulated in all subclones compared to the 
cell line. Furthermore, RNF128 and TEX19 were down-regulated to a great 
extend in comparison with the cell line VH-64. 
CTCFL, also known as BORIS, is an 11-zinc-finger factor involved in gene 
regulation. It utilizes different zinc fingers to bind varying DNA target sites thus 
activating transcription and is also able to influence histone methylation. CTCFL 
also positively influences hTERT (human telomerase reverse transcriptase) 
transcription, conferring cells with the ability to divide indefinitely (Nguyen et 
al., 2008; Renaud et al., 2010).  
RSAD2 is best known for its vital role in the anti-viral response after infection 
with different types of viruses (Jiang et al., 2008), where it inhibits steps in viral 
proteins and/or RNA biosynthesis (Jiang et al., 2010).  
RNF128, also known as GRAIL, is an E3 ubiquitin ligase associated with T cell 
tolerance. Until now not much is known about RNF128 in other contexts, 
however, GRAIL-deficient naive T cells, after activation, exhibited increased 
proliferation and cytokine expression (Nurieva et al., 2010). Thus, down-
regulation of RNF128 in ES/PNET cells might influence proliferation positively. 
The function and role of TEX19 remains to be fully elucidated. It is mainly 
expressed in adult testis and in undifferentiated embryonic stem cells (Kuntz et 
al., 2008).  
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The analysis of gene expression of organ-specific subclones directly against each 
other revealed subsets of genes that might harbour candidate genes that mirror 
the specific influence of the microenvironment in the organs from which the 
metastases were isolated. For bone down-regulation of CXCL10, GDF10, IFI44 
and IFI44L as well as up-regulation of RAB4A and RPS11 seemed to be 
specific.  
CXCL10 is secreted by several cell types in response to IFN-γ and binds to 
CXCR3. Expression of this chemokine leads to pleiotropic effects. These include 
stimulation of monocytes, migration of natural killer and T cells, as well as 
modulation of adhesion molecule expression. However, overexpression of 
CXCL10 is unfavourable for the survival and proliferation of cancer cells 
(Nagpal et al., 2006). Down-regulation of CXCL10 by bone-derived subclones 
might indicate that cells are trying to prevent a host immune response. This has 
been shown to play a role in tumour progression of ES/PNET (Zhang et al., 
2003; Berghuis et al., 2011).  
GDF10 is also known as BMP3B (bone morphogenetic protein 3B). BMPs are 
multifunctional cytokines involved in skeletal development and bone formation. 
In the exquisite interplay of BMPs, GDF10 is an antagonist of BMP2, which is 
usually expressed by osteoblasts and potently induces osteoblast differentiation 
in a variety of cell types (Marie et al., 2002). Thus it might be reasoned that 
down-regulation of GDF10 leads to increased osteoblast formation. 
The function of IFI44 is not entirely understood. However, there is indication, 
that overexpression of IFI44 cDNA impairs proliferation in vitro through 
IFN-alpha activation, even in cells that are not responsive to IFN-alpha. A model 
was proposed suggesting that IFI44 binds intracellular GTP, thus abolishing 
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extracellular signal-regulated kinase (ERK) signalling and resulting in cell cycle 
arrest (Hallen et al., 2007).  
Relatively little is known about RAB4A. It is, however, known that it plays a 
role in receptor recycling. Some receptors such as PDGF (platelet derived growth 
factor)-beta receptor recycle back to the membranes through vesicular transport 
dependent on the small GTPase Rab4a (Hellberg et al., 2009). Thus, up-
regulation of RAB4A might be supportive for cell proliferation and migration 
through recycling of PDGF-beta receptor back to the cell surface. 
RPS11 encodes a ribosomal protein that is a component of the 40S subunit of the 
ribosome. Up-regulation of RPS11 might indicate an increased protein synthesis 
and thus higher metabolic activity of the bone-derived subclones. 
Furthermore, HERC6 and RSAD2 might be specific markers for lung metastases 
as they were significantly up-regulated in lung subclones compared to the 
parental cell line. 
Comparing the three subclone-types it was also obvious that MMP1 is 
up-regulated especially in bone but also in lung metastases while it is not 
expressed to a greater extend in bone marrow metastases. MMP1 encodes for a 
secreted enzyme which breaks down the interstitial collagens, types I, II, and III. 
This is why it would have been expected to be up-regulated in metastases from 
the bone especially to support growth within the bone microenvironment, which 
contains collagen I to a great extent.  
Interesting genes and their functions are finally summed up again in Table 4.10. 
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Table 4.11: Notable genes flagging up in the different comparisons and their most striking 
functions known so far. 
Gene Regulation Functions and processes 
VH-64 vs. Metastases 
CTCFL ↑ in metastases DNA-binding, promoter binding, transcription activator 
activity 
RSAD2 ↑ in metastases Relatively unknown, catalytic activity 
RNF128 ↓ in metastases Ligase activity, ubiquination of transmembrane proteins 
TEX19 ↓ in metastases unknown 
Metastases amongst each other 
CXCL10 ↓ in bone metastases Chemokine-activity, receptor-binding, cell-cell-signalling 
GDF10 ↓ in bone metastases Cytokine activity, growth factor activity 
IFI44 ↓ in bone metastases Relatively unknown, response to virus 
IFL44L ↓ in bone metastases Relatively unknown, immune response 
RAB4A ↑ in bone metastases ATP-, GTP- and GDP-binding, signal mediation 
RPS11 ↑ in bone metastases Gene expression, translation 
HERC6 ↑ in lung metastases Ligase activity, protein-modification  
RSAD2 ↑ in lung metastases See above 
MMP1 ↑ in bone and lung metastases metalloendopeptidase activity, collagen catabolic process 
 
 
A further point one has to bear in mind is that there is a clonal variation 
influencing the comparisons and the resulting gene lists. As each metastasis 
derives from one cell/clone the grouping of the organ-specific metastases has to 
be seen critical.  
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4.6 Conclusions 
The described experiment indicates that there is no preference of cells derived 
from organ-specific metastases to re-metastasis to their organ of origin. This is 
why subsequent experiments will have to focus on specific genes, which were 
identified in the mentioned comparisons. Gain-of-function or loss-of–function 
experiments with certain genes of interest might clarify whether there is a 
mechanism regulating the organ-specific metastasis in ES/PNET and whether the 
specified genes have a potential to serve as markers or even therapeutic targets. 
However, to be able to give a final answer to the hypothesis this experiment will 
have to be repeated with primary material for transplantations. It is very likely 
that the fact of pre-selection for high proliferation rates and aggressiveness of 
cells in cell culture and the fact that cell lines lack a certain variety of cells 
influence this experimental setting negatively.  
Furthermore, it can be concluded that the identified genes in the comparison of 
the parental cell line against the organ-specific metastases stand for an increased 
aggressiveness and proliferation potential. However, further experiments will 
have to follow as functions and role of most of the interesting genes is still not 
entirely clear. These experiments could involve knockdown experiments and 
subsequent in vivo examination as well as in vitro experiments on functions.  
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5. Chapter – The role of CXCL12 in metastasis of Ewing’s 
sarcoma 
5.1 Introduction 
CXCR4 is overexpressed in a variety of different cancer types and cancer cell 
lines. The role of the CXCL12/CXCR4-axis in breast cancer, prostate cancer and 
melanoma has been well established (see chapter 1.3.2) and its potential role in 
ES/PNET is discussed in chapter 1.3.3.  
RNA interference (RNAi) was used to knockdown CXCR4 in ES/PNET cell 
lines to be able to investigate features of the role of this cytokine/receptor-
couple.  
 
 
5.1.2 RNA interference 
In 2006, Craig Mello and Andrew Fire were honoured with the Nobel Prize in 
Physiology or Medicine for their work on RNAi (Zamore, 2006). They and their 
co-workers were the first to demonstrate that double-stranded RNA (dsRNA) 
triggers gene-silencing in Caenorhabditis elegans (Fire et al., 1998). Shortly 
after the discovery, it became clear that mammalian cells operate with the same 
RNAi mechanism and that this could potentially be used for therapeutic 
approaches (Elbashir et al., 2001).  
Subsequently, this landmark discovery developed into a technique that is now 
widely used to target genes directly by silencing through RNAi, enabling 
researchers to investigate the role of genes in a very elegant and isogenic way.  
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5.1.2.1 Gene expression control in eukaryotic cells 
There are many mechanisms controlling the expression of genes. Pre-
transcriptional control is achieved through epigenetic modifications of the DNA. 
Post-transcriptionally RNAi offers a natural possibility of gene expression 
control. This mechanism is believed to regulate vertebral differentiation and 
development. Due to the complexity of the RNAi processes and further features 
of gene expression control, the topic will not be described in all details (see 
review Carthew and Sontheimer, 2009). 
After its discovery and alongside its investigation, the mechanism of RNAi has 
been used to develop techniques which are able to specifically knockdown and 
investigate genes of interest (see Figure 5.1).  
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Figure 5.1: The RNAi pathway in vertebrate cells. The left side of the picture presents 
possibilities of interference into the natural process of RNAi by introducing siRNAs (small 
interfering), shRNAs (small hairpin RNAs) transcribed by RNA Pol III or artificial pri-miRNAs 
(primary micro RNA) into the cells. Not all factors involved in the process are shown. Ago2, 
Argonaute-2; Dicer, Helicase; Drosha, RNAse III; Exp5, Exportin-5; Pol II and Pol III, 
polymerases II and III; RISC, RNA-induced silencing complex (Cullen, 2005). 
 
 
The natural process of RNAi in vertebrates is driven by endogenously encoded 
micro RNAs (miRNAs). These are single-stranded and composed of 
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~22 nucleotides (nt) which match part of the sequence of a specific mRNA. In 
the human organism the number is currently estimated to up to 1000 miRNAs 
which control the expression and activity of approximately 30% of the human 
genes (Kurreck, 2009). This gives RNAi an impact that is as important as the 
impact of transcription factors in gene regulation.  
Polymerase II transcribes a ~85nt long primary miRNA (pri-miRNA). The 
miRNA is part of a hairpin loop as secondary structure. Subsequent to 
transcription, the pri-miRNA is processed by the RNAse III Drosha into a pre-
miRNA by cleaving the hairpin ~22nt away from the loop structure leaving a 
characteristic 2nt 3’-overhang (Lee et al., 2002, 2003). Transported to the 
cytoplasm by Exportin-5, the pre-miRNA is bound by the helicase Dicer. It 
recognises the characteristic overhang and cleaves ~22nt away from the end so 
that the loop is removed and a second 2nt 3’-overhang is produced (Bernstein et 
al., 2001; Elbashir et al., 2001; Zhang et al., 2004).  
The resulting duplex is bound by one of the four members of the Argonaute 
subfamily of proteins (Ago proteins) and becomes part of the forming RISC 
(RNA-induced silencing complex). This programming of RISC allows the 
specific down-regulation of homologous mRNA (Cullen, 2004).  
Two steps are necessary to complete RISC assembly: loading and unwinding of 
the miRNA. Similar aspects apply to small interfering RNA (siRNA) duplexes 
that can be introduced artificially. It is not yet completely known how RISC is 
loaded in mammals. However, there seem to be two possible pathways – a Dicer-
dependent one and a Dicer-independent one.  
Once the duplex is loaded onto the RISC, one of the two strands has to be 
discarded in order to make a single strand able to bind to homologous mRNA. 
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The determination of the strand to be cleaved is not random but follows 
thermodynamic rules: The thermodynamic stability of the bases 1-4 at each end 
is determining and the strand with a less stable 5’-end serves as the guide strand 
and remains bound to RISC (Khvorova et al., 2003; Schwarz et al., 2003).  
All four Ago proteins can repress translation of gene transcripts, but only one of 
them, AGO2, has a cleavage (slicer) activity (Liu et al., 2004). This leads to the 
passenger strand of the siRNA duplex being degraded as well as the bound 
mRNA that is supposed to be destroyed. As target cleavage requires extensive 
base pairing; only high complementary siRNA duplexes are processed by AGO2. 
Most endogenous duplexes, however, harbour some mismatches. 
The Slicer-independent version of the unwinding process of small RNA duplexes 
is still not understood entirely. Recent findings suggest, that mismatches in 
specific regions of the small RNA duplexes guide the process of slicer-
independent unwinding (Kawamata et al., 2009; Yoda et al., 2010). There is 
strong evidence for the assembly of many different factors involved in the decay 
of RNA, such as decapping proteins, nucleases and others in a complex called p-
body (Franks and Lykke-Andersen, 2008). Further investigations, however, are 
required to fully understand this mechanism. 
Both, slicer-dependent and –independent processes lead to elimination of 
passenger strand debris or the whole passenger strand from the RISC. Debris and 
whole strands are immediately degraded by nucleases so that the process is 
essentially irreversible (Kawamata and Tomari, 2010).  
Furthermore, the Ago proteins can also be loaded with single-stranded siRNA 
via a so called “bypass loading”. This fact can be used to specifically knockdown 
genes with exogenous siRNAs that are transferred into cells (Kurreck, 2009).  
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5.1.2.2 Using shRNA for silencing of genes 
SiRNAs form a class of double-stranded RNAs which play a decisive role in 
biology. Amongst others, the most notable role is the involvement of siRNA in 
RNAi, where it interferes with the transcrips of specific genes and thus their 
expression. 
Quickly, siRNA had been proven to offer a possibility of gene silencing in vitro 
and in vivo (de Fougerolles et al., 2007) although there are certain disadvantages 
of naked as well as of lipid-complexed siRNA. One of these is the delivered 
siRNA has a short half-life. The intracellular expression of siRNA for a sustained 
silencing of genes was achieved through especially constructed DNA vectors 
which were transferred into cells. In general, the so called short hairpin RNA 
(shRNA) is expressed through polymerase III (Pol III) promoters and the RNAi 
machinery can be employed for the purpose of post-translational gene control 
(Brummelkamp et al., 2002; Paddison et al., 2002). 
The usage of viral approaches for transfection of plasmid-encoded shRNA leads 
to a stable expression of shRNA and subsequently knockdown of targeted 
mRNA following integration of the viral vector into the host genome. However, 
there are also certain disadvantages to viral systems such as antiviral responses 
being triggered through the presence of viral dsRNA resulting in expression of 
factors that lead to an inhibition of the complete translation and subsequently 
may lead to apoptosis of cells (Williams, 1997). Furthermore, the use of viral 
vectors that cause insertion of DNA might result in destruction or alteration of 
genes or their expression. 
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5.1.3 The vector pEPI-1 and the promoter H1 
In this project, a shRNA approach was used to attempt knockdown of CXCR4 in 
ES/PNET cell lines using the vector pEPI-1 (see chapter 4.1.4) and the pol III 
promoter H1.  
The pEPI-1 vector is a non-viral and episomal vector that does not integrate into 
the host’s genome. Therefore, it is less likely to interfere with any existing 
genetic functions and furthermore does not rely on any position-depending 
expression and thus has predictable characteristics. 
The central element of this vector is the scaffold/matrix attachment element 
(S/MAR) derived from the 5’-region of the human gene interferon β which 
allows the attachment of certain chromatin domains to the protein skeleton of the 
nucleus which makes vectors using this element very likely to be stabely 
expressed and to be passed on during division of cells (Bode et al., 1992). 
However, S/MARs have further advantages such as promotion of transcription 
and replication of the vector using the cells machinery as well as protection of 
the alien genetic material.  
Furthermore, pEPI-1 harbours a Kanamycin/Neomycin-resistance gene allowing 
for selection of positive clones during the cloning process as well as for the 
resulting cell line. 
This vector is stable within cells for several hundred generations without any 
necessity of selective pressure (Piechaczek et al., 1999).  
The described vector was used as a basis construct. It was necessary to insert a 
pol III promoter for the expression of shRNA. In this case, the H1-RNA gene 
promoter was chosen as pol III promoter because it creates a small RNA 
transcript lacking a polyadenosine tail. Furthermore, it has a precise start of 
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transcription and a termination signal involving five thymidine bases in a row 
(T5). The most significant advantage is the fact that the transcribed shRNA is 
cleaved after the second uridine (U) of the termination site. This produces a 
transcript with ends resembling the ones of synthetic siRNAs as it also contains 
two 3’ overhanging T or U nucleotides (Baer et al., 1990; Brummelkamp et al., 
2002).  
 
 
5.2 Aims 
CXCR4 plays a role in different cancer types such as breast cancer and prostate 
carcinoma, and there is evidence that the CXCR4/CXCL12-axis might play a 
role in the metastasis of ES/PNET, including consistent high expression in nearly 
all ES/PNET cell lines and many primary tumours. Nevertheless, there is still a 
need for a direct proof of this assumption. Given this, a knockdown system for 
CXCR4 would allow researchers to investigate the importance and role of 
CXCR4 in ES/PNET and the consequences of a CXCR4-knockdown in 
ES/PNET cell lines. 
 
The specific aims of this chapter were as follows: 
 
 to create a knockdown vector against the cytokine receptor CXCR4 
 to investigate functionality and influence of the knockdown vector 
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5.3 Methods and Materials 
 
5.3.1 Cloning strategy for the knockdown construct 
The extra-chromosomal vector pEPI-EGFP (Figure 5.2) is a derivate of pEPI-1 
containing an additional sequence for the eGFP gene and was kindly provided by 
Prof. Dr. Lipps (University Witten-Herdecke, Witten, Germany). The aim of the 
cloning strategy was to insert a pol III promoter as well as a sequence coding for 
a shRNA directed against CXCR4 into pEPI-EGFP to create a knockdown 
plasmid.  
The pSUPER (Oligoengine, Seattle, USA; Figure 4.2) vector system was used to 
create a cassette containing the H1-RNA pol III promoter and a custom DNA 
sequence encoding for a shRNA against CXCR4.  
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Figure 5.2: Map of the pSUPER vector. Important sites are H1 pol III promoter: 708-934; pUC 
origin: 1373-2040; PstI: 705; BglII: 928; HindIII: 934; KpnI 974. Restriction sites used for 
insertion of oligonucleotide for shRNA marked with red arrow, restriction sites used for excision 
of cassette containing H1 pol III promoter and oligonucleotide marked with blue arrow.  
 
 
A pair of custom oligonucleotides was purchased (Purimex, Grebenstein, 
Germany) that contained amongst other features unique sequences in sense and 
antisense orientations (capital letters) derived from the mRNA transcript of 
CXCR4, separated by a spacer (Wang et al., 2005). The antisense strand of the 
resulting shRNA duplex hybridises to the target region of the CXCR4-mRNA 
(yellow).  
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5’  gatccccCACCCTGTTTCCGTGAAGAAttcaagagaTTCTTCACGGAAACAGGGtttt 
3’      gggGTGGGACAAAGGCACTTCTTaagttctctAAGAAGTGCCTTTGTCCCaaaa 
 
 
tctaga aag      3’ 
agatct ttcagct  5’ 
 
 
The 5’-end of the forward oligonucleotide formed an altered BglII restriction site 
(in red, alteration in blue), that is able to bind to a BglII overhang in the restricted 
vector but can afterwards not be used as a BglII restriction site again and a SalI 
restriction site (in green). Furthermore, an XbaI restriction site (in purple) was 
inserted after the T5 sequence.  
The whole cassette containing the H1 pol III promoter, the sequence coding for 
the shRNA directed against CXCR4 and the additional XbaI restriction site was 
restricted using this XbaI restriction site and the PstI restriction site up-stream of 
the H1 pol III promoter. To avoid methylation of especially the XbaI restriction 
site a dam- E. coli strand was used (see chapter 2.1.1) which is impaired in its 
ability to methylate DNA. 
 
Both restriction sites, XbaI and PstI are located within the MCS (multiple 
cloning site) of pEPI (see Figure 4.3) so that the cassette could be ligated into 
pEPI. Hereafter, the resulting vector is called pEPI-EGFP-shCXCR4. 
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Figure 5.3: Map of the pEPI-EGFP vector. Important sites are S/MAR: 1-1983; 
Neomycin/Kanamycin resistance: 3251-4046; PstI: 1994; KpnI: 2006; XbaI: 2028. Restriction 
sites are located within the MCS (provided by Prof. Dr. Lipps). 
 
 
All restrictions were verified by PCR, all ligations were tested with test 
restrictions and finally plasmids were sequenced (primers see chapter 3.3.15). 
As a control construct the cassette containing H1 pol III promoter and a sequence 
coding for a shRNA directed against the fusion transcript MLL-AF4 was cloned 
into pEPI-EGFP which should not affect ES/PNET cells because this fusion does 
not occur in ES/PNET. The pSUPER containing the custom DNA construct 
coding for the shRNA was kindly provided by Dr. Frida Ponthan. The cassette 
was linearised using the restriction enzymes PstI upstream of the H1 promoter 
and KpnI downstream of the custom DNA sequence. KpnI is also contained in 
the MCS of pEPI-EGFP so that the cassette could be ligated into the 
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appropriately digested vector and be subsequently used as a control. Following, 
the resulting vector is called pEPI-EGFP-shMA6-Mut1. 
 
 
5.3.2 Fluorescence activated cell sorting 
TC-71 and VH-64 cell lines were transfected using LipofectaminTM according to 
chapter 3.5.6. Cells were cultured until approximately 5 x 106 cells could be 
harvested from a T25 culture flask (90% confluence).  
The protocol from chapter 3.5.8 was used to sort cells. When enough cells could 
be collected, 300-500 sorted cells were re-acquired to assess purity of the desired 
population. 
 
 
5.3.3. G418 selection of clones 
Enriched clones derived from fluorescence activated cell sorting were further 
treated with G418 (aminoglycoside antibiotic similar in structure to gentamicin 
B1; GIBCO). This blocks the polypeptide synthesis by inhibiting the elongation 
step in both prokaryotic and eukaryotic cells. Resistance to this antibiotic is 
delivered by the Neo/Kan gene from Tn5, which codes for an aminoglycoside 
3‘-phosphotransferase and is contained in the sequence of pEPI-EGFP. 
Transfected and then FACS-sorted cultures were treated with different end 
concentrations of G418 ranging from 100 to 500μg/ml. The determined 
concentrations for selection of the different pEPI-EGFP clones were 200μg/ml 
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for transfected VH-64 cells and 300μg/ml for transfected TC-71 cells. Treatment 
was administered for a minimum of 14 days.  
 
 
5.4 Results 
 
5.4.1 Examination of stability of pEPI-EGFP in Ewing’s sarcoma cell lines 
To investigate the possibility of transfection and the stability of pEPI-EGFP in 
ES/PNET cell lines, TC-71 and VH-64 were transfected with the plasmid using 
LipofectaminTM. Subsequently, cells were tested for the production of eGFP 
using a flow-cytometer. Furthermore, the transfected cells were sequentially 
sorted using FACS and the cell lines resulting from the different and sequential 
sorts were examined for their fluorescence over a longer period of time. Data are 
shown for TC-71 and pEPI-EGFP-transfected TC-71 (Figure 5.4). 
Transfection resulted in very low numbers of cells being positive for the plasmid 
and thus fluorescent. With sequential sorting using FACS fluorescence-positive 
cells could be enriched. Therefore, transfected cells were sorted, the selected 
cells were cultivated until enough cells for a second sort could be harvested. The 
resulting three different cultures were followed up with flow cytometry 
demonstrating that the cells of the second sort were still positive two month post-
transfection (Figure 5.4B).  
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Figure 5.4: Flow-cytometric verification of e-GFP positivity of pEPI-EGFP-transfected 
TC-71 cells. A, negative control TC-71; B, pEPI-EGFP-transfected TC-71 cells, first sort, second 
sort and second sort after 72 days (cells in Q4 were judged as eGFP-positive in FITC-A channel). 
 
 
The percentages of positive cells resulting from the flow-cytometric tests of 
TC-71, TC-71 pEPI-EGFP, TC-71pEPI-EGFP 1.sort and 
TC-71pEPI-EGFP 2.sort are visualised in Figure 5.5. All cultures were tested 
over time with the first sort performed between day 0 and day 24 and the second 
sort performed out of the cultured cells of the first sort between day 24 and day 
35. At all times the very low positivity of the unsorted TC-71pEPI-EGFP culture 
remained visible. However, the variability of eGFP-positivity on days 24, 35, 72 
and 93 can be assumed as a variation of handling and individual measurement. 
Follow-up measurements of eGFP-positivity on days 115 and 128 showed lower 
persentages. With a positivity of over 60% after 128 days the second sort of 
TC-71pEPI-EGFP suggests the applicability of pEPI-EGFP as a stably 
transfectable plasmid for knockdown experiments. 
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Figure 5.5: Examination of stability of pEPI-EGFP expression in TC-71 over time. Graph 
shows percentage of eGFP-positive and thus pEPI-EGFP positive cells from flow-cytometric 
analysis of the different sorts over the period of 128 days. 
 
 
Taking all results into account it can be assumed that it is possible to transfect 
ES/PNET cell lines with the plasmid pEPI-EGFP, that the plasmid is expressed 
in the cells and stable over a long period of time. This suggests that it could 
allow for a stable knockdown of CXCR4 using a designed knockdown plasmid 
based on pEPI-EGFP without any long-term selection pressure on the positive 
cells. Thus, knockdown cells could be used for in vivo experiments without any 
additional treatment of mice necessary. This is why in this project pEPI-EGFP 
was used for further cloning of a knockdown plasmid against CXCR4 (strategy 
see chapter 5.3.1). 
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5.4.2 Verification of CXCR4-positivity of Ewing’s sarcoma cell lines 
Preliminary experiments on CXCR4 expression in ES cell lines were performed 
in Münster to be able to phrase a hypothesis for a knockdown project on CXCR4. 
To verify these results, preparing flow cytometry experiments were performed to 
investigate the expression of CXCR4 in ES cell lines. These showed that cell line 
VH-64 is positive for CXCR4, while cell line TC-71 showed a weaker positivity.  
 
 
 
Figure 5.6: Examination of CXCR4 (CD184)-positivity of the ES cell lines VH-64 and 
TC-71. Cells were CD184 stained and flow-cytometrically examined with unstained cells as a 
control.  
 
 
Flow-cytrometic examination of the CXCR4-positivity of the cell lines VH-64 
and TC-71 showed, that expression and the resulting presentation of CXCR4 on 
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the cell surface of VH-64 cells was slightly higher than in TC-71 cells (see 
Figure 5.6).  
Both cell lines were chosen for the following knockdown experiments using 
constructed vectors containing a DNA-sequence, which is able to form a shRNA 
for CXCR4-knockdown. This decision was made due to the fact that the majority 
of experiments in the differents project parts were performed on those two cell 
lines.  
 
 
5.4.3 Verification of knockdown plasmid-positive Ewing’s sarcoma cell lines 
Before transfection of cells plasmids were sequenced using the service of 
Eurofins MWG Operon (compare chapter 3.2.15) to verify that pol III H1 
promoter and the DNA-sequences coding for the shRNAs coding for mRNAs of 
CXCR4 (shCXCR4) and the fusion MLL-AF4 (shMA6-Mut1) were cloned into 
pEPI-EGFP resulting in the knockdown plasmid pEPI-EGFP-shCXCR4 and 
negative control plasmid pEPI-EGFP-shMA6-Mut1. 
After transfection of ES/PNET cell lines TC-71 and VH-64 a first verification of 
plasmid uptake and eGFP production was performed. Therefore, pictures were 
taken of the resulting transfected cell lines using a fluorescence microscope 
(Figure 5.7). 
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Figure 5.7: First examination of transfected cells using a fluorescence microscope. All 
transfected cells showed fluorescence. A, TC-71pEPI-EGFP; B, TC-71pEPI-EGFP-shCXCR4; 
C, TC-71pEPI-EGFP-shMA6-Mut1; D, VH-64pEPI-EGFP; E, VH-64pEPI-EGFP-shCXCR4; 
F, VH-64pEPI-EGFP -shMA6-Mut1.  
 
 
All produced cell lines showed plasmid-uptake resulting in eGFP expression and 
thus green fluorescence of cells that could be visualised in the fluorescence 
microscope. This led to the assumption that cells could be analysed flow-
cytometrically for plasmid expression as well as be sorted using FACS. 
 
 
5.4.4 Selection of plasmid-positive cells 
Subsequent to the first verification, transfected cells were sorted for eGFP-
positivity using FACS and subsequently, enriched cell lines were further selected 
using G418. 
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As previously shown for the preliminary experiment in which cells were 
transfected with pEPI-EGFP, it was possible to serially FACS-sort for the 
positivity of the knockdown plasmid and the control plasmid as well.  
 
 
5.5 Discussion 
The plasmid pEPI-EGFP proved to offer a good opportunity for stable 
transfection of ES/PNET cell lines as transfected cells showed expression of 
eGFP encoded by the plasmid over a long period of time. After more than four 
months both transfected cell lines were still positive for the expression of eGFP 
through pEPI-EGFP. 
Following these results, a knockdown-plasmid containing DNA coding for a 
shRNA against CXCR4 was constructed. Therefore, a cassette containing the 
promoter H1 and the DNA encoding the shRNA was cloned into pEPI-EGFP. 
All constructed plasmids were verified through sequencing. 
First and very preliminary qRT-PCR experiments after transfection and selection 
of cells from the two cell lines TC-71 and VH-64 were performed. A slight 
knockdown of CXCR4 could be seen in TC-71pEPI-EGFP-hCXCR4. No 
knockdown, however, was detected in VH-64pEPI-EGFP-shRNA (data not 
shown due to missing repetitions and thus questionable significance). Due to 
restriction of time no further experiments were performed and it was not possible 
to fully examine the effect of CXCR4 knockdown on the cell phenotype. In the 
future, verification of expression knockdown using qRT-PCR will have to be 
performed. Furthermore, it will be necessary to perform functional experiments 
after knockdown has been confirmed in the transfected cell lines. As previous 
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work in CaP and breast cancer research has investigated the involvement of 
CXCR4 in the metastasis of cells of these types of cancer it would be of interest 
to investigate whether the knockdown of CXCR4 in ES/PNET cell lines 
influences migration, adhesion and proliferation of cells. Subsequently, it would 
be interesting to investigate the effect of a CXCR4-knockdown in the previously 
established preclinical i. v. model which reflects the metastasis of ES/PNET as 
seen in patients. Especially metastasis via the blood stream to bones in certain 
types of cancer positive for CXCR4 has been shown to take place in a 
CXCL12-dependent way (compare chapter 1.3.2).  
There is evidence suggesting a role of the CXCL12/CXCR4 axis in ES/PNET as 
well. High expression of CXCR4 was discovered to be correlated with a 
metastatic behaviour and worse survival rates in ES/PNET patients. Moreover, 
knockdown experiments targeting the fusion transcript EWS/FLI1 discovered 
that CXCR4 expression seems to be up-regulated directly or indirectly through 
this aberrant transcription factor. This supports a role of CXCR4 in the biology 
of ES/PNET cells. 
Subsequent to research performed in ES/PNET cell lines it should also be 
considered to investigate the role of CXCR4 on primary material if possible. As 
CXCR4 is currently considered to be a stem cell like marker, cultivation of cell 
lines for a long time might have selected cells for their in vitro growth and as a 
result of this might have left cells altered in their expression of several surface 
markers. Furthermore, it might be interesting to consider a closer look especially 
on the group of patients showing metastatic disease as the relation of metastatic 
behaviour of ES/PNET to the expression of CXCR4 has been suggested 
previously. 
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5.6 Conclusion 
To date, there is still a need for a direct proof of the responsibility and role of the 
CXCL12/CXCR4-axis in the metastasis of ES/PNET. But taking the expression 
levels of CXCR4 in nearly all ES/PNET cell lines and many primary tumours as 
well as the role of this axis in other cancers into account there is strong indication 
for an involvement of CXCR4 in the metastasis or even the organ-specific 
metastasis of ES/PNET. 
First results indicated that the constructed knockdown plasmid could be of value 
as a system to stably repress expression of CXCR4. This is why further 
investigations on the knockdown capacity of the constructed plasmid should be 
carried out to be able to subsequently investigate on the effect of CXCR4 
knockdown. 
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6. Chapter – Development, establishment and validation of 
preclinical orthotopic mouse models for bone malignancies 
6.1 Introduction 
Many varying models for investigations of the different aspects of ES/PNET 
have been developed and used in studies (for a short overview see 6.1.2.2). 
However, only orthotopic models can reflect and discover the interactions of 
tumour cells in their “natural” microenvironment. Thus, i. f. transplantation into 
the bone marrow cavity of immunodeficient mice might offer a more relevant 
preclinical model for OS, ES/PNET and cancers that are known to metatstasise to 
the bone marrow. 
 
 
6.1.1 Further malignancies of the bone 
The continuity of bone tissue relies on the balance between osteoblasts and 
osteoclasts forming and resorbing new bone tissue, respectively. The presence of 
cancer cells in this tissue and their interaction with the normal cells disturbs this 
fragile equilibrium and can lead to aberrant new bone formation or destruction. 
Although typically both processes may be observed in bone cancers such as 
ES/PNET or OS, one is usually more prominent in each particular case 
(Coleman, 2001). Factors released from the bone through bone remodelling are 
believed to stimulate tumour growth and tumour cells are in turn able to produce 
factors that stimulate osteoclast differentiation and activity. This results in the 
establishment of a host-tumour relationship, often believed to be a “vicious 
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cycle” due to its progressively destructive nature (Chirgwin and Guise, 2000). 
The mechanisms of stimulation of osteogenesis through tumour cells associated 
with osteoblastic lesions are still not well understood (Goltzman et al., 2000). 
In childhood and adolescents, OS is the most frequent primary malignancy of the 
bones and can originate in any bone, but is most commonly detected in the 
metaphyses of long bones. Most common sites are the proximal humerus, the 
distal femur or the proximal tibia with approximately 50% of cases occurring 
around the knee area (Dahlin and Coventry, 1967; Weinfeld and Dudley, 1962; 
Estrada-Aguilar et al., 1992). It develops mainly before the age of 30 years 
(Pringle, 1999) with a metastatic spread mainly to the lungs, as seen in 20% of 
presenting patients, which correlates with poor prognosis (Link et al., 1991; 
Saeter et al., 1997). Based on the radiologic appearance bone lesions caused by 
OS are characterized either as osteolytic, osteoblastic, or as mixed lesions 
(Mundy, 2002). However, osteolysis is a common feature associated with OS, as 
even predominantly osteoblastic lesions show osteolysis and this is mainly 
caused by activation of osteoclasts and their bone-resorbing activity (Goltzman, 
2001).  
Furthermore, bone tissue is one of the most common sites for a metastatic course 
of disease in many cancers including prostate carcinoma (CaP), breast and lung 
cancer (see also chapter 1). This destruction of bone causes severe symptoms in 
both bone sarcoma patients as well as cancer patients with metastatic disease of 
the bone. 
As a prominent example for a cancer type metastasising to the bone, more than 
two thirds of advanced CaP cases develop bone metastases, with the axial 
skeleton being most frequently affected (Reid and Hamdy, 2007). Furthermore, 
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metastasis to weight-bearing bones can lead to pathological fractures and is 
indicative of a worse prognosis (Oefelein et al., 2002).  
To be able to grow both, cells of primary tumours as well as cells of metastatic 
lesions need to interact with the matrix of the bone microenvironment so that the 
restricting nature of the mineralized bone tissue can be overcome. This is 
promoted by the mixed osteoblastic and osteolytic nature of bone tumours and 
secondary lesions (Roodman, 2004). While the basic mechanisms of metastasis 
of CaP to the metastatic niches have been explored (Lokeshwar et al., 1993; 
Birchmeier and Behrens, 1994; Nagle et al., 1994), details of the mechanisms 
still remain unknown. Furthermore, the process of bone remodelling in primary 
bone tumours is still unclear and requires further investigation.  
This lack of understanding of the biology of the underlying mechanisms of bone 
remodelling has so far prevented the development of effective treatments for 
osseous disease. The validation of a clinically relevant preclinical model should 
provide a tool for both studying the mechanisms involved in disease progression, 
and to examine novel treatments targeting the interaction of tumour cells with the 
bone microenvironment.  
 
 
6.1.2 Preclinical models for bone malignancies 
Currently, many preclinical models of bone cancer still use s. c. xenografts, 
which clearly do not mirror well the site of disease in patients. If the 
effectiveness of a drug has been proven in vitro, it’s tolerance in vivo can easily 
be tested in a simple mouse system. However, the more interesting and important 
question is, whether the distribution of the drug and it’s interaction with the 
Chapter 6 – Development, establishment and validation of preclinical orthotopic mouse models 
for bone malignancies 
174 
designated target is given and comparable to the situation in patients. One of the 
experimental ways to address this problem is to employ an orthotopic model for 
the research of new drugs and their effectiveness (Bibby, 2004).  
 
 
6.1.2.1 Preclinical models of primary bone malignancies 
A lot of preclinical models were developed using s. c. or i. v. techniques for 
transplantation of xenografts. These techniques have their very own application 
areas. 
Subcutaneously transplanted ES/PNET cell lines (such as TC-71 and VH-64 in 
own experiments) will form a solid tumour without difficulty so that this 
technique is the most common one for investigations on different aspects of 
tumour development and also used for pharmaceutical studies. There are, for 
example, several research projects employing s. c. models to test the efficiency 
of drugs against ES/PNET cells in vivo (Jia et al., 2006; Dalal and Burchill, 
2009). 
Injected into the flanks of athymic nude mice, development of tumours can be 
supervised by eye and tumour volumes can easily be assessed with a calliper. 
The measured length and width of the tumours are used to calculate the volume 
applying specific formulas (Scotlandi et al., 2002; Sancéau et al., 2002). This 
technique is applied vastly for the analysis of pharmacological aspects as it is a 
simple readout-system. However, no interaction of tumour cells with the suitable 
microenvironment of organs is given and thus tumours do not reflect the 
situation in patients very well. 
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As already mentioned before, i. v. transplantation of xenograft cells offers the 
possibility to analyse the haematogenous metastatic behaviour of ES/PNET and 
allows the interaction of these cells with the local microenvironment of tissues 
and organs (see chapter 3.1.2.3). Transplantation of ES/PNET cells into 
NOD/Scid mice leads to a pattern of metastasis similar to that seen clinically, 
providing research with a suitable and reliable system for studying metastasis of 
this disease. However, only relatively small numbers of the experimental mice in 
these studies developed assessable bone metastases (Scotlandi et al., 2000; 
Vormoor et al., 2001). This is why, it requires more effort to localise bone 
metastases within this i. v. model and ideally involves the possibility to use non-
invasive imaging equipment. 
OS can be induced in experimental animals through radiation. These tumours, 
however, usually grow at a very low rate and are no xenographs and thus not of 
human origin. This can hold problems for research (Witzel et al., 1992; Tinkey et 
al., 1998). The development of xenograft models has been challenging, because 
not all OS cell lines were able to manifest disease in vivo in 
immunocompromised mice. However, several s. c and i. v. models using the cell 
lines U2OS and SaOS-2 and derivates of those could be established (Zhou et al., 
1996; Jia et al., 1999; Manara et al., 2000).  
 
 
6.1.2.2 Orthotopic preclinical models for primary bone malignancies 
On-going from these established types of preclinical models it was necessary to 
be able to model the primary tumour in its “natural” environment and tissue of 
origin. Placing the transplant in the normal physiological location, such models 
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would be more likely to mirror the human disease state. Therefore, more refined 
techniques were developed referred to as orthotopic models.  
In small experimental animals such as mice, ideal locations for orthotopic 
transplantations would be the long bones of the leg: tibiae and femurs. An 
orthotopic approach is usually technically more difficult than i. v. 
transplantation, as animals have to be anaesthetised rather than simply restrained 
for the procedure. However, demonstrably better results in these models justify 
the additional effort and stress for the animals. 
One of the methods uses transplantation of the xenograft directly into the tibia of 
the mice. Zhou et al. established an orthotopic bone tumour model by 
transplanting ES/PNET cells into the tibia of athymic nude mice. In this study 
transplanted mice where treated with zoledronic acid or paclitaxel to investigate 
the effect of these drugs on the developing tumours (Zhou et al., 2005). This i. t. 
model was also employed for the analysis of the effects after knockdown of 
VEGF (vascular endothelial growth factor) through siRNA (Guan et al., 2005).  
There are more i. t. models for ES/PNET suggesting minimal-invasive 
transplantation of tumour cells into the tibia of mice being a good opportunity to 
investigate tumour-microenvironment interaction (Odri et al., 2010). 
However, i. t. transplantation occasionally can imply an operation of the mouse 
tibia due to difficulties of achieving injection through a punctual percutaneous 
intraosseous intervention. This means a rather stressful procedure for the 
experimental animals as well as a risk of infection. 
This is why we suggest the method of i. f. injection for induction of orthotopic 
tumours. As the state of research suggests a MSC to most likely be the cell of 
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origin for ES/PNET (see chapter 1.1.7), placement of tumour cells within the 
bone marrow cavity would be appropriate.  
The method of i. f. transplantation provides a technically feasible and 
reproducible system for cancer types associated with the bone or bone marrow 
(Mazurier et al., 2003) and gives rise to tumours that are detectable by in vivo 
imaging or with a certain size by palpation of the animals. One of the advantages 
of an i. f. model is the relative good accessibility of the distal end of the femur 
which has a larger diameter than the tibia. Therefore, this preclinical model 
suggests being a good alternative orthotopic transplantation technique to the 
technique of i. t. transplantation. 
Recently, several orthotopic models for OS mainly using i. t. transplantation 
have been established (Cao et al., 2005; Dass et al., 2005; Yuan et al., 2007). 
However, as it still remains problematic to establish tumour formation in mice 
after orthotopic transplantation some of these models employ genetically 
modified cell lines. Therefore, they cannot be a true representation of the human 
condition which has to be taken into account when using an orthotopic model.  
 
 
6.1.2.3 Preclinical models for CaP metastases of the bone 
In this project CaP was used as an exemplary type of cancer metastasising to the 
bone. The metastasis of CaP to the bone has been studied extensively. Metastatic 
behaviour of cell lines could be achieved through intracardiac as well as i. v. 
transplantation and bone metastases could be observed (Glinskii et al., 2005; 
Schneider et al., 2005). To be able to induce bone metastases directly, i. t. 
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injections were performed resulting in tumours located within the bone (Corey et 
al., 2002). 
 
 
6.1.2.4 Development of the intrafemoral transplantation method 
Orthotopic intraosseous transplantation could also be achieved through the 
development of an i. f. model. Originally, this model was developed for the 
transplantation of haematopoietic stem cells directly into the bone marrow cavity 
(Mazurier et al., 2003).  
Mazurier et al. showed that a class of cells with repopulating capability usually 
found in the CD34+CD38lowCD36- compartment of human bone marrow was 
detectable when human xenografts were injected directly into the murine femur. 
As the majority of normal and malignant haematopoietic cells are located within 
the bone marrow the process of homing through the circulatory system after i. v. 
injection could be avoided through employment of the direct transplantation of 
cells into the bone marrow cavity. This is especially important for cells which 
lack the ability to migrate as they will not survive and establish in the bone 
marrow. Thus, false negative results would be created. Indeed, previous research 
suggested that the lack of this ability to migrate and home to the bone marrow 
might be the cause for reported low seeding efficiency of no more than 10% of 
human repopulating cells in mice (van Hennik et al., 1999). 
This indicates that orthotopic injection of human xenografts is able to better 
reflect the patient’s primary tumour as opposed to tumours derived through other 
injection methods. The cell of origin for ES/PNET is still unknown but might 
most possibly be a primitive pluripotential cell that exists in the bone marrow 
Chapter 6 – Development, establishment and validation of preclinical orthotopic mouse models 
for bone malignancies 
179 
(Lin et al., 2011). This is why an orthotopic technique of transplantation is 
thought to be suitable for transplantation of human ES/PNET cells directly into 
their physiological appropriate microenvironment. 
 
 
6.1.2.5 NSG mice 
As described previously (chapter 3), immunocompromised mouse strains became 
more and more important for preclinical studies. One of the more recently 
developed mouse strains, offering an even higher grade of immunodeficiency 
than NOD/Scid mice is the mouse strain NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG, 
The Jackson Laboratory) developed by Shultz et al. (Shultz et al., 2005). The 
motivation for the development of this mouse strain resulted from the 
observation that NOD/Scid and other mouse strains with NOD background were 
less able to reject implanted xenografts when the NK cell activity was further 
depleted, e.g. through ionising radiation or anti-CD122 treatment (Hudson et al., 
1998; Shultz et al., 2003). However, irradiation of mice bares the disadvantage 
that a strict and meticulous animal support is required and that significant 
mortality rates can be observed (Hayakawa et al., 2009). 
To obtain a mouse strain with a complete lack of NK cell activity, NOD-scid 
females were crossed with B6.129S4-IL2Rγtm1Wjl/J males (IL2Rγ mutation is 
X-chromosome-linked). The resulting (NOD x B6) F1 +/scid IL2Rγnull 
hemizygous male offspring was backcrossed with NOD/Scid females for two 
generations. Subsequently, females homozygous for scid and heterozygous for 
the disrupted IL2Rγ gene were identified and the IL2Rγnull allele was backcrossed 
for 8 generations onto the NOD-scid background. Resulting 
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NOD.Cg-Prkdcscid IL2RγTm1Wjl/Sz (hereafter named NOD-scid IL2Rγ+/null) females 
were crossed with NOD-scid IL2Rγnull/Y males. The NOD-scid IL2Rγnull female 
and NOD-scid IL2Rγnull/Y male offspring was identified and intercrossed to 
obtain the desired new mouse strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Shultz et 
al., 2005). These mice have a high level of immunodeficiency as they lack 
mature T and B cells, functional NK cells and are depleted in cytokine signalling. 
Additionally, the latter leads to these mice lacking the predisposition to thymic 
lymphoma which is prevalent in the parental NOD/Scid strain. To avoid 
confusion with other strains that have a NOD/scid background, The Jackson 
Laboratories decided to give the strain the now common abbreviation of NSG 
(NOD scid gamma). 
Recently, several publications described that this mouse strain allows better 
engraftment of human haematopoietic stem cells and cancer stem cells with 
almost no rejection of xenotransplants due to the almost total absence of a 
functional immune system. This makes this mouse strain a preferred tool for 
research using preclinical models of diseases in this field (Agliano et al., 2008; 
Goldstein et al., 2010). Based on these reports, the decision was made to use 
NSG mice for the development of a novel preclinical and orthotopic model for 
bone malignancies. Classically, NOD/Scid mice had been used for an i. v. model 
of ES/PNET. These mice had to be irradiated before transplantation to deplete 
the residual NK cell activity eventually causing rejection of xenografts. 
However, irradiation led to a high burden of stress for experimental mice and 
treatment-related deaths. Thus, the decision was made for NSG mice. 
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6.1.3 Imaging techniques 
A major difficulty in using orthotopic models of any cancer preclinically has 
until now been the measurement of disease burden in a non-accessible site.  
X-ray imaging was without a doubt a revolutionary innovation for medicine and 
improved diagnosis to a great extent. However, more distinct and elegant 
methods for imaging have been developed that allow to image and investigate 
more features of the body and its diseases.  
The current way of diagnosing ES/PNET is to scan the patient by X-ray in two 
planes and take a biopsy of the possible tumour mass. MRI is used to examine 
the patient’s stage of disease (Bernstein et al., 2006; Schmidt et al., 2007). 
Ideally, all bones making up involved joints are imaged to be able to identify 
possible skip lesions. CT is performed to be able to diagnose possible lung 
metastases. PET is usually not used as a primary imaging modality for ES/PNET 
and OS but may play a role in assessing treatment response. The variety of these 
methods can nowadays also be applied for small animals using NanoCT- (in the 
following referred to as CT), PET- or high-resolution MRI-machines.  
The use of these newer in vivo imaging techniques offers the opportunity to 
detect and monitor development and progression of the disease in clinically 
relevant sites in transplanted mice and with the development of small animal 
imaging technologies it is possible to develop and monitor orthotopic models of 
disease investigating new drugs and cutting down animal numbers. 
This chapter will not explain the techniques in detail but comment on advantages 
and disadvantages of the different imaging opportunities (for details refer to 
chapters 3.6.6, 3.6.7, and 3.6.8). 
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6.1.3.1 Computed tomography 
CT uses the technique of X-ray imaging. While X-ray images show one defined 
plane and direction, a series of thousands of two-dimensional X-ray images taken 
from changing perspectives can be calculated into a three-dimensional image. 
Therefore, the exact absorption of radiation at a given location is recorded and 
the obtained data can be reconstructed by a computer.  
On the one hand, a disadvantage of the CT is the high dose of radiation patients 
are exposed to. One abdominal CT is equivalent in radiation dose to 500 chest 
X-rays (Rajarubendra and Lawrentschuk, 2010). This is why the diagnostic 
benefit of a CT always has to be compared against the radiation exposure of the 
patient.  
On the other hand, the technique of CT images is able to show bony metastases 
in detail. Bone structure, osteolytic as well as osteoblastic lesions, soft tissue 
involvement and bone marrow metastases can be judged at early stages. Thus, 
sensitivity of CT was reported to range from 71 to 100% (Gainford et al., 2005). 
CT offers a good opportunity for preclinical research as images can be acquired 
relatively fast and, therefore, many animals can be scanned in a row with short 
anaesthesia times. Furthermore, newer small animal CT scanners offer high 
resolution images that allow judging on processes taking place in the skeleton of 
small experimental animals such as mice. 
 
 
6.1.3.2 Positron emission tomography 
FDG-PET imaging uses the fact that most malignant tumour cells exhibit 
increased glucolysis (Smith, 1998). Most commonly, FDG is used as it behaves 
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as a glucose analogue being accumulated by metabolically active cells. Thus, it is 
able to provide qualitative and quantitative metabolic information leading to an 
evaluation of a lesion.  
The whole body can be scanned so that this technique also detects disease and 
metastases in regions not routinely included in other imaging studies 
(Rajarubendra and Lawrentschuk, 2010). Sensitivity of PET to detect metastases 
has been estimated to 62 to 100% (Gainford et al., 2005).  
To follow the progress of metastasis of ES/PNET non-invasively in the living 
animal, high-resolution PET seems to constitute a useful tool and has been used 
in several studies (Franzius et al., 2006).  
 
 
6.1.3.3 Magnetic resonance imaging 
One of the biggest advances of MRI is the fact that no ionizing radiation has to 
be used to produce images. In the presence of a magnetic field the magnetic 
moments of some of the protons of H2O change and align with the direction of 
the field. Applied radiofrequency radiation is used to produce an electromagnetic 
field which flips the spin of the aligned protons in the body. When the field is 
turned off, the protons decay to the original spin-down state. The difference in 
energy between the two states is released as a photon, which produces the 
electromagnetic signal that the scanner detects and which is used to calculate 
cross-sectional images of the body in any chosen plane (Rajarubendra and 
Lawrentschuk, 2010).  
Differences in intensity between the scanned tissues e.g. between tumour tissue 
and bone or bone marrow make a detection and dimensioning of metastases 
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possible. Furthermore, MRI is the only imaging modality that directly visualises 
bone marrow and thus lesions can be found before destruction of the bone cortex 
and before any osteoblastic or osteolytic changes occur (Vanel et al., 1998).  
However, a disadvantage is the inability of MRI to depict destruction of the bone 
structure as cortical bone does not give any signal. This is why, the current use of 
imaging for diagnosis and staging of bone malignancies can only be a 
combination of the three imaging techniques and CT and PET are often used in 
combination as PET/CT with the images taken being overlaid. 
 
 
6.2 Aims 
The interaction between cells from certain types of cancer and the local 
microenvironment of the bone remain undefined. There is a vast field of 
preclinical research employing s. c. or i. v. models, but less work on orthotopic 
models of bone cancer. As such, the aims of this chapter were as follows:  
 
 to develop an orthotopic in vivo model for malignant bone disease 
(primary and metastatic) for preclinical drug testing. 
 to develop a model for studying the interaction between tumour cells and 
bone (remodelling of the tumour microenvironment). 
 to investigate the opportunities for small animal in vivo bio-imaging to 
monitor local disease progression. 
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6.3 Results 
 
6.3.1 Preliminary experiments  
Preliminary experiments were performed to investigate whether the development 
and establishment of an orthotopic model for primary bone sarcomas was 
achievable through i. f. transplantation. Therefore, first i. f. transplantations in 
small numbers were performed to investigate whether chosen cell lines TC-71 
and VH-64 (ES/PNET), SaOS-2 (OS) and PC3M (CaP) were able to form 
tumours in the desired orthotopic site. Furthermore, this preliminary experiment 
was used to establish the imaging techniques and histology. These data are 
included in the study and are presented together with the following results. 
Additionally, mice that did not receive any treatment were used as controls in the 
preliminary experiments (see Figure 6.1). 
 
 
 
 
 
 
 
Chapter 6 – Development, establishment and validation of preclinical orthotopic mouse models 
for bone malignancies 
186 
 
 
Figure 6.1: Normal structure of a murine femur. A, Femur shaft with bone marrow cavity in 
the centre (H&E staining, original magnification x10); B, detailed image of the cortex of a femur 
with osteocytes within the bone tissue and periosteum lining the cortex at the outer border (H&E 
staining, original magnification x40); C, distal end of the femur with growth plate and trabecular 
bone structures (H&E staining, original magnification x4). 
 
 
Images taken of histological H&E-stained sections showed intact bone marrow 
(Figure 6.1 A), osteocytes within the cortical bone (Figure 6.1 B) and trabecular 
bone as well as the growth plate within the distal end of the murine femur 
(Figure 6.1C). 
CT and PET images of transplanted mice were acquired as full-body images and 
generally were overlaid in the first set of experiments (as described in 3.6.6 and 
3.6.7, see Figure 6.2 to 6.4).  
Generally, eyes, heart, intestines and in some animals the brain showed FDG 
accumulation. Furthermore, the bladder and in some cases the kidneys as well 
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showed FDG signal due to the FDG excretion. Muscles showed background 
signal to a small extend in some cases. 
 
 
 
Figure 6.2: PET/CT image of a VH-64 i. f. transplanted mouse. A, Image taken after 21 days; 
B, Image taken after 42 days with the tumour marked with a white arrow (Maximum Intensity 
Projection (MIP) CT image overlaid with FDG-PET image, dorsal view). 
 
 
The PET/CT image taken of the ES/PNET cell line VH-64 i. f. transplanted 
mouse did not show a tumour in the region of the right femur 21 days after 
transplantation. After 42 days the PET/CT image showed formation of a tumour 
surrounding the right femur. However, the contrast of the PET had to be very 
high to make the tumour visible. This led to a lot of background and a very bright 
heart signal making it impossible to judge whether there was pathologic 
involvement of the lung (Figure 6.2).  
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Figure 6.3: PET/CT image of a TC-71 i. f. transplanted mouse. A, Image taken after 22 days; 
B, Image taken after 42 days with the tumour marked with a white arrow (MIP-CT image 
overlaid with FDG-PET image, dorsal view). 
 
 
The same accounts for the PET/CT image taken of the ES/PNET cell line TC-71 
i. f. transplanted mouse. No tumour formation was visible in the region of the 
right femur 22 days after transplantation. Forty-two days after transplantation the 
PET/CT image showed a tumour surrounding the right femur. In this picture the 
contrast is not as high as in the image taken of the VH-64 transplanted mouse but 
there is still a lot of background and a very bright heart signal (Figure 6.3). 
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Figure 6.4: PET/CT image of a PC3M i.f. transplanted mouse. A, Image taken after 21 days; 
B, Image taken after 48 days with the tumour marked with a white arrow (MIP-CT image 
overlaid with FDG-PET image, dorsal view). 
 
 
The PET/CT image taken of the CaP cell line PC3M i. f. transplanted mouse did 
not show tumour formation 21 days after transplantation. After 48 days the 
PET/CT image showed tumour formation around the right femur. Again, the 
contrast of the PET had to be very high to make the tumour visible. In this case 
the kidneys gave a bright signal, which might be due to the excretion of the FDG 
(Figure 6.4). 
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6.3.2 Reduction of background signal in positron emission tomography 
To be able to image potential metastasis to the lung the bright heart signal had to 
be reduced. This is why, VH-64 and TC-71 cells were transplanted s. c to 
produce tumours that were easy to locate and monitor.  
Three mice each were anaesthetised with the inhalable anaesthetic Isoflorane and 
with the injectable combination of Ketamine/Medetomidine (as described in 
3.6.2). Thirty-three days after transplantation of VH-64 a palpable tumour had 
formed on the right flank of all six experimental animals. S. c. TC-71 tumours 
grew faster so that 5 out of 6 mice had to be culled before the planned FDG-PET 
procedure. However, one remaining mouse with an s. c. TC-71 tumour was 
imaged under Ketamine/Medetomidine anaesthesia and the tumour was visible 
comparable to the VH-64 tumour shown in Figure 6.5. 
As expected and seen before, the mice anaesthetised with Isoflorane showed a 
bright signal of the heart muscle. In contrast to this, mice injected with 
Ketamine/Medetomidine showed no signal of the heart muscle (see Figure 6.5). 
This is why it can be assumed that possible lung metastases could be identified 
easier when mice are anaesthetised with this injectable anaesthesia. 
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Figure 6.5: PET/CT images comparing inhalable and injectable anaesthesia. A, Exemplary 
mouse with s. c. VH-64 tumour anaesthetised with inhalable Isolflurane, picture showing 
accumulation of FDG within the tumour but as well in the heart and bladder; B, Exemplary 
mouse with s. c. VH-64 tumour anaesthetised with injectable Ketamin/Medetomidine. (each right 
picture, MIP-CT; each left picture, section through the sagittal plane in the heart region). 
 
 
However, due to a high noise to signal ratio of the PET images in the preliminary 
experiment this technique was not used in the further development of the 
orthotopic model for bone malignancies.  
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6.3.3 Development of an orthotopic model for bone malignancies 
Previous work has used i. v. transplantation to investigate the metastasis of 
ES/PNET cell lines in vivo or i.t transplantations to achieve tumours in the bone. 
To be able to study the direct interaction of different malignant cell types with 
bone we developed a preclinical orthotopic model by injecting cells of different 
tumour types directly into the femur of young NSG mice (see Table 6.1), a 
method that is easily to perform even on young and not full-grown mice. 
 
 
Table 6.1: Experimental mice for the development of an orthotopic model for bone 
malignancies. VH-64 and TC-71, ES/PNET cell lines; SaOS-2, OS cell line; PC3M, CaP cell 
line; Medium, mice were injected with medium alone.  
Transplant Identification  
of mice 
Age at transplantation 
(weeks, median, range) 
Time to reach protocol 
limits (d, median, range) 
Tumour 
formation 
VH-64 F1921LN, F1921BN, 
F4901RN, F4901BN, 
F4901NN, F4968LN, 
F4968N 
12 (11-12) 38 (29-42) 100% (7/7) 
TC-71 F1920RN, F4968BN, 
F4968NN, F4965LN, 
F4965RN, F4965BN 
12 (11-12) 31 (15-42) 83.3% (5/6) 
SaOS-2 F4967LN, F4967RN, 
F4905LN, F5187LN, 
F5187RN 
12 (10-12) 70 (70-83) 100% (5/5) 
PC3M F1927RN, F1927NN, 
F4902LN, F4902RN, 
F4902BN, F4902NN, 
F4901LN 
12 (12-13) 29 (29-31) 100% (7/7) 
Medium F4965NN, F4970LN, 
F4970RN, F4970BN, 
F4970NN 
11 (11-12) na 0% (0/5) 
 
 
Mice were transplanted with a median age of 11 to 12 weeks. Transplanted 
ES/PNET cell lines VH-64 and TC-71 developed tumours leading to euthanasia 
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after 38 and 31 days, respectively. PC3M-transplanted mice had to be euthanized 
after 29 days and SaOS-2-transplanted mice lived at mean 70 days. Except one 
TC-71 transplanted mouse all experimental animals developed tumours at the site 
of injection. 
 
 
6.3.3.1 Induction of pathological new bone formation 
CT images of the femurs injected with ES/PNET and OS cell lines showed 
remodelling of the murine bone with induction of pathological new bone 
formation. In all cases, the ES/PNET cell line VH-64 led to formation of 
calcified structures, which were clearly visible in CT. In most cases these new 
formations were manifested as sunray spicules, directly coming of the murine 
femur (see Figure 6.6 A).  
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Figure 6.6: Induction of new bone formation after VH-64 transplantation. A, Exemplary CT 
image 42 days after transplantation (cross section of a femur, white arrow indicates sunray 
spicules); B, Large periosteal reaction induced by the tumour and reactive bone (H&E staining, 
original magnification 2x, arrows indicate the periosteum); C, Formation of cartilage in fibrous 
bands (H&E staining, original magnification 10x); D, Spicules of new bone formation most 
probably coming off the murine femur (H&E staining, original magnification 40x).  
 
 
H&E stained histological sections of femurs injected with the ES/PNET cell line 
VH-64 confirmed findings of the CT scans. Structures identified as sunray 
spicules of immature bone arose directly from the murine femurs (Figure 6.6 A, 
B, D) and led to progressively destroyed cortical bone. Furthermore, tumours 
invaded the surrounding soft tissues. However, different from findings in patients 
transplanted ES/PNET cells in this model seemed to induce formation of 
cartilage as well. 
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The ES/PNET cell line TC-71 showed a mixed pattern with CT pictures giving 
evidence of both bone resorption as well as very weak induction of bone growth 
(see Figure 6.7). 
 
 
 
Figure 6.7: Lysis of bone and induction of new bone formation after TC-71 transplantation. 
A, Exemplary CT image 15 days after transplantation (cross section of a femur, white arrow 
indicates lysis of bone); B, Exemplary CT image 15 days after transplantation (longitudinal 
section of a femur, white arrow indicates lysis of bone); C, Large periosteal reaction induced by 
the tumour and reactive bone (H&E staining, original magnification 4x, arrows indicate the 
location of the periosteum); D, Spicules of immature bone formation most probably coming off 
the murine femur (H&E staining, original magnification 60x, arrows indicate flattened cells on 
the bone surface). 
 
 
Therein some areas of bone was resorbed and the cortical bone destroyed to a 
great extent as seen in histology, whilst in others new and immature bone 
Chapter 6 – Development, establishment and validation of preclinical orthotopic mouse models 
for bone malignancies 
196 
formation was induced with the periosteum lifted of the cortical bone like in VH-
64 transplanted mice (see Figure 6.7). 
The fact that newly induced bone was not explicitly visible in CT suggests the 
immaturity and thus poor calcification of bone. However, flattened cells were 
visible on the surface of the reactive bone, which most probably are osteoclasts 
induced through the presence of tumour cells (see Figure 6.7 D).  
 
Murine femurs injected with the OS cell line SaOS-2 showed induction of new 
bone formation in CT. In some cases lifting of the periosteum could be observed 
in histological slides that resulted in formation of sub-periosteal new bone that 
seemed to come of the murine cortical bone as it was the case in ES/PNET 
transplanted mice (see Figure 6.8). However, the induction of reactive bone was 
to a lesser extent than reactive bone formation as induced by VH-64 cells. 
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Figure 6.8: Lysis of bone and induction of new bone formation after SaOS-2 
transplantation. A, Exemplary CT image 77 days after transplantation (cross section of a femur, 
white arrow indicates lysis of bone); B, Large periosteal reaction induced by the tumour and 
reactive bone (H&E staining, original magnification 20x, arrows indicate the location of the 
periosteum); C, Massive induction of reactive bone coming of the murine cortical bone of the 
femur (H&E staining, original magnification 20x, arrow indicates reactive bone); D, Destruction 
of the cortical bone by tumour cells growing through the existing bone (H&E staining, original 
magnification 4x). 
 
 
6.3.3.2 Malignant new bone formation 
In addition to the induction of reactive bone, CT scans of femurs transplanted 
with the OS cell line SaOS-2 showed formation of calcified structures within the 
tumour mass itself. The destructive and permissive growth of the cells (see 
Figure 6.9) had led to big tumour masses outside the femoral shaft as well and 
the calcified structures within this tumour mass were not directly linked to the 
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cortical bone of the murine femurs but appeared to be arising from the tumour 
cells themselves.  
 
 
 
Figure 6.9: Malignant bone formation within the tumour mass after SaOS-2 
transplantation. A, Exemplary CT image 77 days after transplantation (cross section of a femur, 
white arrow indicates malignant bone formation); B, Exemplary CT image 15 days after 
transplantation (longitudinal section of a femur, white arrow indicates malignant bone 
formation); C, Immature malignant bone within tumour mass (H&E staining, original 
magnification 20x); D, Malignant bone within necrotic part of the tumour mass (H&E staining, 
original magnification 20x). 
 
 
These findings could be verified histologically. The malignant bone formed 
within the tumour mass was unstructured and less organised than the normal 
murine bone. Furthermore, the malignant bone seemed to arise from fibrous 
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structures within the tumour mass. In necrotic parts of the tumour malignant 
bone remained as pointy sclerotic structures. 
 
 
6.3.3.3 Induction of osteolytic lesions 
As a comparison to the primary bone tumour cell lines the CaP cell line PC3M 
was used to create a model for CaP in bone as its most common site of 
metastasis. On CT images injected femurs showed mainly heavy signs of 
resorption of bone leading to pathological fractures of the femur in two out of 
seven injected mice (see Figure 6.10).  
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Figure 6.10: Osteolytic lesion caused by injection of PC3M. A, Exemplary CT image 29 days 
after transplantation (cross section of a femur, white arrow indicates lysis of the femur); B, 
Exemplary CT image 29 days after transplantation (longitudinal section of a femur, white arrow 
indicates lysis of the femur); C, Tumour mass destroying and dislocating femoral bone (H&E 
staining, original magnification 10x, black arrow indicating gap in the cortex); D, lysis of the 
bone with resorption pits of osteoclasts (upper black arrow) and osteoblastic reaction (lower 
black arrow, H&E staining, original magnification 40x). 
 
 
In histological H&E stained slides PC3M injected femurs showed a vigorous 
resorption of bone material. The resorptive pits formed by active osteoclasts 
could be visualised in histological sections. The outer shape of the femurs did not 
appear as smooth as in controls but showed multiple sites of bone resorption (see 
Figures 6.10 C and D). Furthermore, on the opposite site of the cortical bone, 
osteoblastic formation of bone appeared as a compensational reaction. However, 
this bone appeared less organised and mature.  
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6.3.3.4 Documentation of soft tissue involvement using MRI  
Where possible, tumour mass was documented by MR imaging immediately 
before dissection. In all cases MRI was a useful technique to visualise and 
investigate the tumour mass growing at the site of previous injection. It was 
possible to calculate volumes of tumours by selecting the region of interest (ROI) 
in sections that showed tumour mass (see Figure 6.11). In all investigated cases 
(VH-64, PC3M and SaOS-2 transplanted mice) it was possible to measure the 
ROI with results showing that the tumour volume had a nearly Gaussian 
distribution.  
 
 
 
Figure 6.11: MR imaging of VH-64 Ewing sarcoma of the injected femur showing a larger 
extra-osseous tumour component. A, The region of interest (red circle) was measured in slices 
that showed tumour and from these the volume of the tumour was calculated. Thickness of slices 
was 2 mm; B, graphical distribution of region of interest volume showing a Gaussian distribution. 
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MRI was also able to pick up metastases that were located in the liver of TC-71 
and PC3M transplanted mice. Due to the small size of mice and the high 
frequency of their respiration resulting images were of poor quality with the 
given equipment. Thus, it was not possible to make reliable judgment about 
metastases in the lungs in the given circumstances. Furthermore, due to 
respiration abdominal metastases were also hard to judge. No metastases could 
be documented for i. f. transplanted VH-64 and SaOS-2 in MRI.  
Organs of representative mice of the experiment were analysed 
immunohistochemically. TC-71 and PC3M i. f. transplanted mice showed liver 
metastases and furthermore in a mouse transplanted with PC3M numerous very 
small lung metastases could be observed in immunohistology. Therefore, tissue 
slices were stained with huCD99 (staining process involved universal probe from 
Menapath Kit, HPR polymer, and VectaStain ABC as well as counterstaining 
with Harris’ hematoxylin; see 3.7.1) and examined microscopically. Cells of 
metastases with human origin stained positively and thus could be distinguished 
form the murine organ-tissue (Figure 6.12).  
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Figure 6.12: Metastases identified in histology. A, Liver metastasis after i. f. transplantation of 
ES cell line TC-71; B, Liver metastasis after i. f. transplantation of CaP cell line PC3M; C, Small 
lung metastases after i. f. transplantation of CaP cell line PC3M (T, tumour; L, liver tissue; Lu, 
lung tissue; all sections stained with huCD99). 
 
 
Occasionally, it was possible to image metastases by MRI. However, due to the 
distance between housing of the animals and the MRI facility it was not possible 
to image all mice as these mice had to be euthanized as soon as they showed 
signs of disease. Figure 6.13 displays an exemplary image of a metastasis 
occurring in the liver of a PC3M-transplanted mouse. 
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Figure 6.13: Series of three MRI images of the abdomen of a PC3M-transplanted mouse. 
The white arrows indicates  the tumour mass within the abdomen.  
 
 
6.4 Discussion 
The described findings show that all human cell lines tested were able to interact 
with the murine bone microenvironment and to induce development of tumours. 
While the ES cell lines induced reactive bone growth, the OS cell line was 
additionally able to form malignant bone within the tumour mass itself. These 
findings correlate to a great extent with the clinical situation of ES/PNET and OS 
patients.  
The CaP cell line PC3M formed tumours inducing lysis of the murine bone and 
in two cases even caused pathological fractures. This correlates with the clinical 
findings. However, most commonly osteoblastic lesions are observed in CaP 
patients with metastatic disease. Nevertheless, pathological fractures are 
frequently seen in CaP patients with osseous lesions as well (compare 
introduction chapter 6). Until today, there are only very few preclinical models 
that are able to mirror the osteoblastic features of bone metastases caused by 
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CaP. In the majority of models in which CaP cells are transplanted directly into 
the bone osteolysis is observed. 
Mice transplanted with the ES/PNET cell lines VH-64 and TC-71 had to be 
euthanized 38 and 31 days after transplantation, respectively. Mice transplanted 
with the prostate cancer cell line PC3M reached protocol limits after 29 days. 
However, the development of tumour sizes leading to euthanasia after SAOS-2 
transplantation took 70 days which is significantly longer than development of 
all other investigated tumour cell lines. 
For a long time there has been the need for the development of orthotopic models 
for bone malignancies. Currently, there are several orthotopic models available; 
however, one of the advantages of an i. f. model is the relative accessibility of the 
femur by simply bending the knee and accessing it through the distal end. 
Compared to other systems such as transplantation of tumour cells into the ribs, 
i. f. injection is a minimally invasive and a non-traumatic procedure, which 
provides us with a reliable preclinical orthotopic model for bone malignancies. In 
comparison to i. t. transplantation, transplantation into the bigger femur during 
i. f. transplantation offers an easier approach. As the state of research suggests a 
MSC to most likely be the cell of origin for ES/PNET (see chapter 1.1.7), it can 
be assumed that the placement of tumour cells within the bone marrow cavity 
would be appropriate and leave the ES/PNET cells in the orthotopic 
environment.  
New imaging techniques such as CT, PET and MRI can be of great help in 
following the progression of disease in a preclinical model. Furthermore, 
numbers of experimental animals can be cut down dramatically. In more detail, 
CT proved to be a reliable tool for the investigation of bone reactions to 
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transplanted cells while MRI was able to describe the soft tissue component of 
the developed tumours. FDG-PET was not the technique of choice for this 
project as the background signal was quite high so that the primary tumour was 
difficult to define on the images. Furthermore, there was a high signal of the 
heart muscle due to the routinely used Isoflorane. An experiment with s. c. 
tumours induced through ES/PNET cell transplantation showed that by using the 
injectable anaesthetics with Ketamine/Medetomidin avoids the strong 
background signal from the heart. Therefore, this type of anaesthesia might be 
the better choice for future PET studies. However, Ketamine/Medetomidin is not 
as well-tolerated as inhalable anaesthesia with Isoflorane is (personal 
experience).  
PET was used in i. v. experiments performed before although it was here shown 
not to be the technique of choice. This is due to the fact that the i. v. experiments 
were performed in Münster, where PET was the only modern imaging 
technology available at that time point. Even with input from clinically very 
experienced radiologists metastases on PET images could only be detected when 
analysing individual planes rather than looking at summation images. For the 
experiments of the i. f. model, which was developed and investigated in 
Newcastle, different PET equipment was used and thus results of PET imaging 
performed here demonstrated that FDG-PET is not a very sensitive technique to 
study local progression and systemic dissemination of ES/PNET in preclinical 
models. 
As by now, however, there are a lot of different radiolabelled compounds used as 
tracers for tumour cells, which allow to study basically any biochemical process 
of cellular function in vivo (Chatziioannou, 2002; Lewis et al., 2002). Thus, 
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employing this orthotopic model of bone malignancies it will be possible to 
investigate, if these components are more suitable for imaging of ES/PNET in 
vivo. Succesfully tested tracers can than be employed in clinics and patients will 
ultimately be able to benefit from this. 
There are more in vivo imaging opportunities such as fluorescence and 
bioluminescence imaging that can be used to visualise labelled cells in 
preclinical models. Bioluminescence can visualise cells that are for example 
transfected with plasmids encoding for appropriate genes such as luciferase. This 
leads to light emission without the need of excitation when luciferin is injected. 
This fact and the longer wavelength of the produced signal lead to better images 
than images produced using cells labelled with eGFP. Currently, our group is in 
the progress of developing preclinical models using bioluminescence to track 
human tumour cells in vivo in the mice. This will provide further experimental 
opportunities for this orthotopic model in the future. 
 
 
6.5 Conclusions 
The orthotopic model for bone malignancies offers a reliable and highly 
reproducible tool for research on primary malignancies of the bone such as 
ES/PNET and OS and other cancers that induce bone metastases. Further to the 
development using different cell lines it will be necessary and interesting to 
investigate the behaviour of primary material in this preclinical model.  
The described i. f. model is established within the Northern Institute for Cancer 
Research and will be used in further and on-going studies on pharmaceuticals for 
therapy of ES/PNET. Furthermore, it offers a great opportunity for studying the 
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interaction between tumour cells and their microenvironment in the bone and 
thus for dissecting the biology of ES/PNET, OS as well of bone metastases 
caused by other types of cancers. It will also give the possibility to further 
investigate the effects of CXCR4-knockdown on ES/PNET cell lines as well as 
the involvement of different genes and their products that were found to be 
differentially expressed in different organ-specific metastases.  
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7. Chapter – General Discussion and Conclusions 
The aim of this thesis has been to investigate different aspects of the mechanisms 
of organ-specific metastasis in ES/PNET and whether it would be possible to 
identify an organ-specific pattern of gene expression that would correlate with 
organ-specific metastasis. Furthermore, a knockdown system was designed to 
investigate the role of CXCR4 as a possible driver for metastasis in ES/PNET.  
Finally, to be able to focus on the interaction of ES/PNET cells with their 
orthotopic environment in the bm/bone, an i. f. mouse model was developed 
using in vivo imaging. 
 
 
7.1 General Discussion 
Although in the past decades great progress has been made in our understanding 
and the treatment of ES/PNET the knowledge of the basic mechanisms 
underlying metastasis and tumour progression is still limited. Furthermore, 
although treatment has changed immensely with the introduction of 
chemotherapy and patients have better outcomes than ever, differences between 
patients with localised and metastatic disease are still enormous. Patients with 
metastases to the bones still have a particularly poor and unsatisfying outcome.  
A first step to understanding the differences between patients with metastasis to 
different organs has been undertaken. It was possible to identify differentially 
expressed genes when comparing metastases from different organs in a 
preclinical model of ES/PNET metastasis.  
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The initial hypothesis of the presence of subclones within tumour cell lines with 
the ability of inducing organ-selective metastases could not be verified. After 
re-transplantation tumour cells recovered from lungs or bone/bone marrow were 
able to metastasise to other organs as well. However, (although no statistical 
analysis could be performed due to the small number of experimental mice) it 
appeared that re-transplanted clones derived from lungs of primary mice were 
able to form metastases in secondary mice after a shorter period of time.  
Furthermore, the results suggest that transplantation selected for an aggressive 
type of cells as these were able to establish in different organs again after re-
transplantation. The function of some of the genes that could be identified in all 
comparisons of gene expression lists of the parental cell line versus the different 
metastases fit this hypothesis and may be responsible for the more aggressive 
growth and increased proliferation in vivo. Future research will need to identify 
the key drivers of this aggressive phenotype, particularly as the functions of 
many of the genes on the list are unknown.  
Genes that were noticeable in comparisons of microarrays of clones derived from 
different organs directly against each other might mirror the influence of the 
specific microenvironments on the cells that settled in these.  
A further fact that has to be taken into account in this experiment is clonal 
variation as every metastasis originates from one single cell that homed, settled 
and subsequently developed a metastasis. This might also have influenced the set 
of genes that is regarded as specific for the organ-specific metastases grouped 
together and, therefore, the analysis needs to be extended to a higher number of 
clones. 
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Most importantly, cell lines may not reflect tumour cell heterogeneity in primary 
material. These cells have undergone selection in cell culture over a long period 
of time and are expected to be less microenvironment-dependent as compared 
with primary tumour cells. Thus, it would be of interest to underline and 
strengthen these results with transplantation of primary material. 
Attempts have been made to analyse specific gene patterns that would allow to 
predict the course of disease and outcomes (prognostic biomarkers). Ohali et al. 
suggest a gene pattern that might be able to give a classification of patients into 
high- and low-risk subgroups and they have the identified overexpressed genes 
from tumours with a poor prognosis that might be targets for the new cancer 
therapies (Ohali et al., 2004).  
Further work tried to describe molecular signatures that distinguish localised and 
metastatic disease (Schaefer et al., 2008) or to identify marker genes which 
reflect tumour resistance to chemotherapy using material from primary tumours 
and metastases (Scotlandi et al., 2009). 
However, to date there is a lack of research on the molecular programme that 
drives the metastatic phenotype in ES/PNET and results in the different outcome 
in patients with localised and metastatic disease.  
Any hypotheses derived from the described xenograft mouse model will need to 
be validated in primary patients. It would be especially interesting to analyse the 
differences in gene expression in cells of different metastases from patients 
directly. However, it is ethically difficult to obtain not only material from 
primary tumours but also material from metastases as most patients are children 
or adolescents and biopsing metastases would be purely for scientific reasons and 
of no benefit for the patient. Material from metastases might be available after 
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treatment, if metastases have to be removed. However, cells of this material have 
undergone at least chemotherapy and thus will have altered characteristics and 
biology. This is why, it will remain a challenge to investigate why outcomes for 
patients with pulmonary and bone metastases remains so poor. 
 
As mentioned before, some cancer types such as breast and prostate cancer as 
well as melanoma metastasise in a CXCL12/CXCR4-dependant manner. This 
involves metastasis via the blood stream and subsequent homing to CXCL12 rich 
tissues such as bone.  
In previous research high expression of CXCR4 was correlated with a metastatic 
behaviour and worse prognosis for ES/PNET patients, which might indicate a 
role of the CXCL12/CXCR4 axis in the biology of ES/PNET cells. Due to this 
evidence, investigations involving knockdown of this cytokine-receptor was 
undertaken.  
For the construction of a knockdown plasmid pEPI-EGFP was selected and 
proved to be stable in ES/PNET cell lines without the need of a constant 
selection pressure. It was possible to construct a knockdown plasmid against 
CXCR4. But due to lack of time, it was not possible to investigate the 
consequences of CXCR4 knockdown in this thesis. 
If knockdown of CXCR4 in ES/PNET cell lines leads to a phenotype it would be 
essential to validate these findings on primary material. Most ES/PNET cell lines 
only show a weak expression of CXCR4 while it has been shown that primary 
material expresses CXCR4. This lack of CXCR4 expression in cell lines might 
result from the fact that cultivation of these for a long time might have left cells 
altered in their expression of several surface markers and ES/PNET cell lines 
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have become less dependent on signals from their normal microenvironment 
(here CXCL12). The role of CXCR4 expression as a prognostic biomarker that 
predicts a metastatic phenotype would then need to be explored and confirmed in 
a prospective clinical study. 
Concluding, it could be demonstrated that the constructed vector pEPI-EGFP 
with the pol III promoter H1 can be used in ES/PNET cells as a tool for 
knockdown of different target genes as well. The pEPI-EGFP vector with the pol 
II promoter H1 will be a useful tool to analyse candidate genes for ES/PNET 
metastasis. 
 
To be able to perform research focused on the interaction of ES/PNET cells in 
the “natural” microenvironment an orthotopic model was developed by injecting 
tumour cells directly into the easily assessable femur of mice. The significance 
and great importance of orthotopic transplantation becomes obvious through the 
proof that the whole process of metastasis is more efficient, closely mimics 
human metastasis and metastases manifest in clinically relevant sites (Bibby, 
2004).  
The primary tumours developed in this orthotopic i. f. model for ES/PNET and 
OS mirror to a great extent the clinical situation of primary bone tumours and 
their interaction with the bone tissue in patients. CT images showed the influence 
transplanted cells had on remodelling murine femur. In ES/PNET transplanted 
mice bones reacted with formation of new bone material that appeared in form of 
sunray spicules and lifting of the periosteum. In OS transplanted mice the 
formation of reactive bone was visible as well. In addition to this malignant bone 
formation within the tumour mass was visible. Further studies with improved 
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imaging techniques that visualise metastatic disease reliably will have to be 
carried out to be able to also focus on metastatic progression in the experimental 
mice.  
The proposed model of i. f. transplantation in combination with NanoCT 
imaging, MRI and histology promises to be a valuable and reliable tool for future 
experiments on the interaction between tumour cells and the bone 
microenvironment. It will be possible to directly investigate the influence of 
tumour cells on the different cell types within this microenvironment. As the cell 
of origin for ES/PNET is most probably a mesenchymal stem cell, a model 
employing transplantation into the bone marrow cavity can be postulated to be 
very likely orthotopic. However, this remains speculative as long as the cell of 
orgin is open to debate. As ES/PNET metastasis is considered to be via 
haematogenic spread and ES/PNET cells can be found in the bone marrow, this 
model is likely to represent a model reflecting bone marrow and bone metastasis. 
However, it has to be kept in mind that the “resolution” is very different with 
5x106 cells being transplanted where usually one cell turns malignant. And thus 
interaction between injected tumour cells and the microenvironment has to be 
understood as different in comparison to the interaction between a single 
malignant cell of origin and its “natural” microenvironment (always bearing in 
mind that there is also the difference between human and murine cells in the 
microenvironment of the bone marrow). Further experiments should thus also be 
carried out with down-scalled numbers of human ES/PNET cells transplanted 
onto experimental mice. 
Furthermore, studies on novel treatments will benefit from this model as it is 
highly reproducible and easy to handle and could thus be used in addition to s. c. 
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models that are routinely used in drug development. Results of studies will have 
high significance against the background of the employment of an orthotopic 
model, particularly when using primary tumour cells that will be more 
micronenvironment-dependent as compared with cell lines.  
In conclusion, this model will provide an excellent tool for functional studies of 
the metastatic phenotype using an RNAi approach; in particular to dissect the 
role of CXCR4 and other candiate genes identified here through gene expression 
studies.  
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7.2 Future Directions 
Metastatic disease is the clinically most important adverse risk factor and 
associated with a dismal outcome. Therefore, there is a great need of 
understanding the biology of metastasis in ES/PNET. A mechanistic 
understanding will be fundamental for the identification of new targets against 
which drugs could be developed that are specifically active in metastatic disease.  
One candidate mechanism that was studied in the thesis was CXCR4. CXCR4 is 
expressed in a variety of cancer types and has been shown to play a role in 
metastasis of these cancers. As CXCR4 is up-regulated by the EWS/FLI1 fusion 
gene the key molecular event in ES/PNET and as CXCR4 is expressed on the 
cell surface it is likely to play a role in migration and homing of ES/PNET cells. 
A vector-based knockdown-system has been developed to study the role of 
CXCR4 in vitro and in vivo. With this tool it will be possible to further 
investigate the role of CXCR4 in migration, adhesion and invasion of ES/PNET 
cells in vitro and on the metastatic phenotype in preclinical in vivo models. 
CXCR4 might constitute a potential target for treatment and CXCR4 antagonists 
that can disrupt CXCR4-mediated tumour cell adhesion to stromal cells and 
sensitise cancer cells to chemotherapy are already in clinical development.  
One key focus of this thesis has been a detailed investigation of the interactions 
between human ES/PNET, OS and CaP cells and the murine bone and bone 
marrow microenvironment in an orthotopic xenograft model. The human cancer 
cells induce re-modelling of the murine bone in a fashion similar to that seen in 
patients, including induction of reactive bone growth (spiculae fomation) and 
osteolysis; and also formation of malignant bone within OS. Thus, this model 
provides a good basis for future research in this field and will be a reliable tool 
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for investigations on the biology of these cancers as well as an addition to s. c. 
models applied in investigations on new pharmaceuticals. 
Beyond this, identification of the cell of origin still remains a goal that has to be 
achieved. This is of specific interest as the knowledge about the cell of origin or 
cells of origin for different types of ES/PNET will greatly influence our 
understanding of the biology and thus the clinical behaviour of ES/PNET. 
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9.1 Abstracts and posters for scientific meetings 
 
Abstract for the XXth Annual Research Meeting of the Kind-Philipp 
Foundation for Leukemia Research, June 6th-9th, 2007 (Wilsede, Germany). 
(Klin Padiatr. 2007 May-Jun;219(3):181-96):  
Oral presentation 
 
Identifying Cellular Mechanisms of Organ-Specific Metastasis of Ewing 
Tumours 
 
H Knizia1, M Hotfilder1, J Vormoor2 
Dep. of Paediatric Haematology/Oncology, U of Muenster1, and NICR2, 
Newcastle, UK 
 
The most important factor in the prognosis of Ewing sarcomas is the presentation 
of primary metastasis. The 5-year-outcome of patients with lung metastases and 
with bone tumours or involvement of bone marrow it is 36% resp. only 20%. 
Patients with a localised tumour can be cured in 50% of the cases. The metastasis 
model for Ewing sarcoma in NOD/scid-mice shows a metastasis pattern equal to 
patients. So the conservation of interaction between human tumour cells and the 
microenvironment of the different mouse organs can be assumed. After 
intravenous application of Ewing tumour cells, tumour clones are isolated, 
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preferentially from lung, bone and bone marrow. These tumour clones are 
analysed in vitro, and re-transplanted into mice. Global gene expression analysis 
will identify genes, whose expression is correlated to organ specific metastasis. 
Functional analysis of these genes will be done with the NOD/scid-mouse model. 
(e.g. by siRNA technology). Intention of our work is the identification of genes, 
which are involved in organ-specific metastasis and may function as new targets 
for molecular therapies and diagnostic. 
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Abstract for XXIth Annual Research Meeting of the Kind-Philipp 
Foundation for Leukemia Research, June 11th-14th, 2008 (Wilsede, 
Germany):  
Oral presentation 
 
Identifying Cellular Mechanisms of Organ-Specific Metastasis of Ewing’s 
Sarcoma 
 
H Knizia1, R Unland1, M Hotfilder1, E Korsching2, U Dirksen1, H Jürgens1, J 
Vormoor3  
Dep. of Paediatric Haematology/Oncology1, Dep. of Pathology2, University of 
Münster, and NICR3, Newcastle, UK 
 
Prognosis of Ewing sarcomas is mainly influenced by the occurrence of primary 
metastasis. While 2/3 of patients with localized disease can be cured, the 3-year 
ETS in patients with lung metastases only is ~50% and the prognosis of patients 
with bony metastases is <20%. The metastasis model for Ewing sarcoma in 
NOD/scid-mice shows a metastasis pattern equal to patients. So the conservation 
of interaction between human tumour cells and the microenvironment of the 
different mouse organs can be assumed.  
Via transplantation of cell lines TC-71 and VH-64 onto NOD/scid-mice 14 
subclones preferentially from lung, bone and bone marrow could be generated. 
The tumour clones where analysed in vitro and re-transplanted into mice. First 
global gene expression analysis identified 247 genes with different expression 
levels in bone metastases resp. lung metastases. These genes may be correlated to 
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organ specific metastasis. Functional analysis of these genes will be done with 
the NOD/scid-mouse model. (e.g. by shRNA technology).  
Intention of our work is the identification of genes, which are involved in organ-
specific metastasis and may function as new targets for molecular therapies and 
diagnostic. 
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Abstract for BACR/RSM Oncology Section/APS Joint Meeting: “Preclinical 
models, biomarkers and targeted therapy”, November 27th, 2008 (London, 
UK):  
Selected for poster presentation and oral presentation (poster talk) 
 
Identifying Cellular Mechanisms of Organ-Specific Metastasis of Ewing’s 
Sarcoma 
 
Knizia1,2 H, Batey1 M, Unland2 R, Korsching3 E, Dirksen2 U, Jürgens2 H, 
Heidenreich1 O, Hotfilder2 M, Hempel2 G, Vormoor1 J 
Northern Institute for Cancer Research1, Newcastle University, UK and Dep. of 
Paediatric Haematology/Oncology2, Dep. of Pathology3, University of Münster, 
Germany 
 
Ewing's sarcoma is the second most common bone tumour in children and 
adolescents. The prognosis of Ewing’s sarcomas is mainly influenced by the 
occurrence of primary metastasis. While 2/3 of patients with localized disease 
can be cured, the 3-year event free survival in patients with lung metastases is 
only ~50% and <20% in patients with bony metastases. Metastatic models of 
Ewing’s sarcoma in Rag2-/-c-/-and Nod/Scid mice show a pattern of disease 
spread similar to that found in patients, providing us with a suitable system for 
studying this disease. 
Transplantation of the TC-71 and VH-64 Ewing’s sarcoma cell lines into 
NOD/scid-mice leads to the development of metastases in lung, bone and bone 
marrow. Following aseptic removal and disaggregation of tumour cells from 
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each of these sites, these cells were analysed in vitro and re-transplanted into 
mice. Global gene expression analysis of clones and subclones identified several 
genes with differential expression levels in bone metastases compared to lung 
metastases. Functional analysis of these genes will be carried out in our 
immunocompromised animal models. 
Transplanted mice are imaged using PET and MRI to detect and monitor 
growing metastases from early stages of development. We are utilising bone 
density assessment software to interpret some of the MRI data. With this analysis 
the correlation between possible bone metastases and a loss of bone density will 
be determined.  
Understanding the molecular mechanisms that underlie metastatic spread in 
Ewing’s sarcoma, will allow us to develop more specific therapies for patients 
with advanced stage Ewing's sarcoma in the future. 
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Abstract for AACR 101st Annual Meeting 2010, April 17th-21st, 2010 
(Washington D.C., USA): Selected for poster presentation 
 
Development of an orthotopic model for human malignant bone diseases in 
immunocompromised NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG) mice  
 
Knizia H, Batey MA, Almeida GS, Wilson I, Maxwell RJ, Dildey P, Hide IG, 
Bacon CM, Vormoor J 
Northern Institute for Cancer Research, Newcastle University, UK  
 
Bone is the third most common site for metastatic disease in cancer. The 
continuity of bone tissue relies on the delicate balance between osteoblasts and 
osteoclasts and the formation and resorbtion of new bone tissue. The presence of 
cancer cells disturbs this equilibrium and can lead to aberrant new bone 
formation or destruction. In Ewing’s Sarcoma (ES) the 3-year event free survival 
in patients with osseous metastases or bone marrow infiltration is less than 20%, 
which accounts for 10% of patients. Clinically, the morphological changes to 
bone caused by ES differ from those of other cancer types such as prostate cancer 
(CaP). 
To better address the interaction between ES and bone, we have developed a 
preclinical orthotopic bone model. Intrafemoral (i. f.) transplantation is a 
technically feasible and convenient method for the study of cancer types 
associated with bone or bone marrow. Cells are injected directly into the bone 
marrow cavity of the femur via the knee. ES cell lines TC-71 and VH-64 and the 
CaP cell line PC3M were injected into the right femur of NSG mice at varying 
Chapter 10 – Appendix  
I 
cell doses. The course of the disease was tracked using Computed Tomography 
(CT) and 2-[18F]fluoro-2-deoxy-D-glucose-Positron Emission Tomography 
(FDG-PET); a final MR documented the tumor before dissection. Areas of 
interest, identified by imaging, were taken for immunohistochemistry (IHC) and 
compared to patient images and IHC.  
Seven weeks post injection, CT images of mice transplanted with the ES cell line 
VH-64 showed development of structures identified as sunray spicules. The ES 
cell line TC-71 did not initiate the development of such structures, but appeared 
mottled and thickened compared to the left femur in the same mouse matching 
the permeative growth of Ewing sarcoma in human patients. Conversely, 66% of 
PC3M transplanted mice developed a pathological fracture of the right femur. In 
addition to palpable tumors in the thigh, all experimental mice had developed 
metastases at distant sites including liver and lungs. IHC analysis of the right 
femurs confirmed the findings of CT, and both ES cell lines were shown to have 
induced new bone formation. A review of ES patient images and IHC shows that 
a considerable number of patients present with new bone formation 
demonstrating the good concordance and clinical relevance of our proposed 
model. 
As 20% of ES arise in the diaphysis region of the femur and patients develop 
lung or bone metastases, this i. f. model better reflects the situation in patients 
than s. c. or i. v. models. All ES implanted animals developed bone tumors, 
suggesting that this model may be useful in preclinical studies. I. f. injection is a 
minimally invasive and non-traumatic procedure, which provides us with a 
preclinical orthotopic model for ES and a model of primary metastasis in CaP. In 
addition to examining the biology of bone malignancies to the model can be used 
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study new drugs disturbing the interaction between cancer cells and bone 
microenvironment. 
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Abstract for the BACR 50th Anniversary Celebration meeting 'Hallmarks 
of Cancer: from Mechanisms to Therapies', June 13th-15th, 2010 
(Edinburgh, UK):  
Selected for poster presentation 
 
Development of an orthotopic model for human malignant bone diseases in 
immunocompromised NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG) mice  
 
Knizia H1, Batey MA1, Almeida GS1, Wilson I1, Maxwell RJ1, Dildey P2, Hide 
IG2, Bacon C1, Vormoor J1,2  
 
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon 
Tyne, NE2 4HH, Newcastle upon Tyne, UK and  
2Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, 
UK 
 
The continuity of bone tissue relies on the delicate balance between osteoblasts 
and osteoclasts and the formation and resorption of new bone tissue. The 
presence of cancer cells disturbs this equilibrium. Ewing’s sarcoma (ES) and 
osteosarcoma (OS) are the two most frequent primary osseous sarcomas in 
childhood and adolescence and primary osseous metastasis is the main adverse 
prognostic factor in patients. Clinically, the morphological changes to bone 
caused by ES differ from those of other cancer types metastasizing to the bone, 
such as prostate cancer (CaP). 
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We developed a preclinical orthotopic intrafemoral (i. f.) model addressing the 
interaction between tumour and bone directly. For this, ES cell lines TC-71 and 
VH-64, OS cell line SaOS-2 and CaP cell line PC3M were injected into the right 
femur of NSG mice via the knee. The course of the disease was tracked using 
Computed Tomography (CT) and 2-[18F]fluoro-2-deoxy-D-glucose-Positron 
Emission Tomography (FDG-PET); a final MR documented the tumour. Areas 
of interest, identified by imaging, were taken for histopathology.  
Post injection CT images of femurs injected with the ES cell line VH-64 showed 
induction of sunray spicules, while femurs of TC-71 transplanted mice appeared 
mottled. CT images of SaOS-2 transplanted mice showed, that the tumour cells 
appear to be able to mature and form new malignant bone. Conversely, 66% of 
PC3M transplanted mice developed a pathological fracture of the injected femur. 
Histopathological analysis of the right femurs confirmed the findings of CT and 
a review of patient images and pathology shows that a considerable number of 
patients present with different forms of new bone formation. This demonstrates 
the good concordance and clinical relevance of the proposed model and as all 
implanted animals developed bone tumours, this model may be useful for 
examining the biology of bone malignancies and in preclinical studies. 
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Abstract for the NCRI Cancer Conference 2010, November 7th-10th 2010 
(Liverpool, UK): Selected for poster presentation 
 
Establishment of a preclinical orthotopic model for human malignant bone 
disease in immunocompromised NSG mice using small animal PET, CT and 
MRI imaging 
 
Knizia H1, Batey MA1, Almeida GS1, Wilson I1, Maxwell RJ1, Dildey P2, 
Hide IG2, Bacon CM1, Vormoor HJ1,2  
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon 
Tyne, NE2 4HH, UK and  
2Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 
NE2 4HH, UK 
Background: Ewing sarcoma (ES) and osteosarcoma (OS) are the two most 
frequent primary osseous sarcomas in childhood and adolescence. In both 
primary bone tumours and other cancers, bone metastases are the main adverse 
prognostic factor. Through complex interactions with cells such as osteoblasts 
and osteoclasts, cancer cells disturb the delicately balanced bone 
microenvironment causing different patterns of bone remodelling. Orthotopic 
models are needed both to study the biology of the interaction between tumour 
cells and bone and as preclinical models for drug development. 
Methods: To develop a preclinical orthotopic intrafemoral model addressing 
interaction between tumour and bone, ES cell lines VH-64 and TC-71, OS cell 
line SaOS-2 and prostate cancer (CaP) cell line PC3M were injected into the 
right femurs of NSG mice. The disease was tracked using Computed 
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Tomography (CT) and 2-[18F]fluoro-2-deoxy-D-glucose-Positron Emission 
Tomography (FDG-PET); final Magnetic Resonance Imaging (MRI) 
documented tumours. Areas of interest identified by imaging were taken for 
histopathology. 
Results: CT images of femurs injected with ES and OS cell lines showed 
remodelling of the murine bone with induction of pathological new bone 
formation. Additionally, OS transplanted mice showed formation of new 
malignant bone within the tumour mass itself. However, CaP cells caused 
osteolytic lesions and 28% of transplanted mice developed pathological fractures 
of the injected femur. 
Histopathological analysis of the femurs confirmed the findings of CT imaging. 
Comparison of the model with images and pathology from patients with bone 
tumours showed a considerable similarity, demonstrating the clinical and 
biological relevance of the model. Finally, small animal MRI proved to be a 
good tool to quantify tumour volumes. 
Conclusions: We have established a consistent orthotopic xenograft mouse 
model to study remodelling of the bone microenvironment by malignant cells. 
Moreover, this model can be used as a quantitative assay for preclinical drug 
testing. 
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9.2 Internal Presentations 
Research days of the Pediatric Oncology, University Hospital Münster, 
Mittelberg, Kleinwalsertal, Austria: 
March 2007 
February 2008 
March 2009 
 
Friday Research Forum, Northern Institute for Cancer Research, Newcastle upon 
Tyne, UK: 
May 22nd 2009 
March 12th 2010 
 
Diverse Journal-Club presentations in the working groups in Münster and 
Newcastle upon Tyne. 
 
9.3 External Presentations 
Cellular Tumour Immune-Therapy Meeting, University Hospital Münster, 
Münster, Germany (invited):  
September 2007 
April 2008 
 
Newcastle Cancer Centre Drug Discovery and Imaging Group Meeting, General 
Hospital, Newcastle upon Tyne, UK (invited): 
September 29th 2009  
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9.4 Publications 
Prepared manuscript which will be submitted to Neoplasia: 
Knizia, H. K., Batey, M. A., Almeida, G. S., Wilson, I., O’Toole, K., Dildey, P., 
Hide, G. I., Maxwell, R. J., Bacon, C. M., Vormoor, H. J. 
Development of an orthotopic model for human malignant bone diseases in 
immunocompromised NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG) mice using in vivo 
imaging techniques.  
 
 
Manuscript in preparation:  
Gene expression patterns in organ-specific metastases of Ewing’s sarcoma in an 
in vivo model of NOD/Scid mice.  
